COMPOSITIONS COMPRISING 2,2,4-TRIMETHYL-N-PHENYL-1,2-DIHYDROQUINOLIN-6-AMINE

Abstract

The present disclosure provides compounds and compositions with antidegradant, e.g., antiozonant, antioxidant and / or antifatigue, properties that are useful additives for vulcanized rubber articles. In some embodiments, the compositions comprise 2,2,4-trimethyl-N-phenyl-1,2-dihydroquinolin-6-amine.

Description

"COMPOSITIONS COMPRISING 2,2,4-TRIMETHYL-N-PHENYL-1,2-DIHYDROQUINOLIN-6-AMINE" BACKGROUND FIELD

[001] This disclosure provides compounds and compositions with antidegradant properties, for example, antiozonants, antioxidants and / or antifatigue agents, which are useful additives for vulcanized rubber articles. In some embodiments, the compositions comprise 2,2,4-trimethyl-N-phenyl-1,2-dihydroquinolin-6-amine. BACKGROUND

[002] Many materials, such as plastics, elastomers, elastomeric products (tires, belts, hoses, bushings, supports, vibration isolators, etc.), lubricants, and petroleum-derived products (such as hydraulic fluids, oils, fuels, and oil / fuel additives for automotive and aviation applications) are prone to degradation after prolonged exposure to light, heat, oxygen, ozone, repetitive mechanical actions, and the like. Consequently, compounds and compositions that demonstrate anti-degradation efficacy are well known in the art. For example, U.S. Patent No. 8,987,515 discloses an aromatic polyamine useful in inhibiting oxidative degradation, particularly in lubricating compositions. U.S. Patent Application Publication No. 2014 / 0316163 discloses antioxidant macromolecules with purported improved solubility in many commercially available oils and lubricants.

[003] Antidegradants useful in the manufacture of articles made of elastomers, plastics and the like require a very specific combination of qualities that can be difficult to achieve. While antidegradants must obviously have commercially acceptable efficacy, they must also exhibit this efficacy over extended periods of time associated with the use of the article, particularly on exposed surfaces of the article where degradation primarily occurs due to environmental factors such as light, oxygen and ozone. Just as important as protecting exposed surface components is the effectiveness in protecting embedded components of composite materials against the effects of Petition 870250102374, dated 07 / 11 / 2025, page 6 / 187 2 / 159 Oxidative aging and repetitive mechanical action are extremely important. Antidegradants must achieve these results without negatively impacting the effectiveness of other additives or the desirable characteristics of the final article. Furthermore, antidegradants that provide or improve mechanical fatigue life after an article has been put into service, aged by oxidation, or by ozone exposure are highly valued, as this inherently improves the mechanical life of the article. Consequently, elastomeric articles that undergo repeated bending, extension, or mechanical compression during service would greatly benefit from such a discovery.

[004] Articles made of general-purpose elastomers, such as natural rubber, particularly tires, are especially prone to degradation by oxygen and ozone. As discussed in U.S. Patent No. 2,905,654, the effect of oxygen degradation on rubber is different from the effect of ozone degradation; however, both effects can be detrimental to tire performance, appearance, and life expectancy. Fatigue and crack propagation are also matters of particular concern, particularly for steel belt edge areas and tire sidewalls, which are subject to significant stress and tensile forces while flexed, inflated, partially inflated, uninflated, and throughout the tire's lifespan. U.S. Patent No. 8,833,417 describes an antioxidant system that purports to increase long-term resistance to fatigue and crack propagation relative to known antioxidants discussed immediately below.

[005] Materials with anti-degradation efficacy are well known in the art for use in tire applications and are commercially available. For example, disubstituted N,N'-paraphenylenediamines, such as those sold under the trademark Santoflex™, are generally preferred by many tire manufacturers for this purpose. Document EP 3147321 A1 discloses rubber compositions, tires, amine compounds and anti-aging agents and, in particular, a rubber composition that is considered suitable for use in tire tread rubber or sidewall rubber. U.S. Patent No. 3,362,930 discloses 6-anilino-2,2,4-trimethyl-1,2-dihydroquinoline and its use as an antiozonant in a rubber composition. U.S. Patent No. 5,117,063 discloses a method for Petition 870250102374, dated 07 / 11 / 2025, page 7 / 187 3 / 159 to produce 4-aminodiphenylamine (“4-adpa”), and 4-adpa can be used to produce 6-anilino-2,2,4-trimethyl-1,2-dihydroquinoline. There is a need for compositions comprising 6-anilino-2,2,4-trimethyl-1,2-dihydroquinoline (also known as 2,2,4-trimethyl-n-phenyl-1,2-dihydroquinoline-6-amine) and other antidegradants for use in vulcanized rubber articles. BRIEF SUMMARY

[006] This disclosure provides compounds and compositions that are useful as antidegradants, for example, antiozonants and / or antioxidants, and / or as additives in vulcanized rubber articles, lubricants or fuels.

[007] In one aspect, the present disclosure provides a compound of Formula (I): (I), or a salt or solvate thereof, where = represents a single or double bond.

[008] In another aspect, the present disclosure provides a compound of Formula (II): (II), or a salt or solvate thereof, where = represents a single or double bond.

[009] In another aspect, the present disclosure provides a compound of Formula (III): Petition 870250102374, dated 07 / 11 / 2025, p. 8 / 187 4 / 159 (III), or a salt or solvate thereof, where = represents a single or double bond.

[010] In another aspect, the present disclosure provides Compound (21): HN NH (21), or a salt or solvate thereof.

[011] In another aspect, the present disclosure provides Compound (22): \ OH cüH(22), or a salt or solvate thereof.

[012] In another aspect, the present disclosure provides Compound (23): or a salt or solvate of it.

[013] In another aspect, the present disclosure provides Compound (24): (24), or a salt or solvate thereof.

[014] In another embodiment, the present disclosure provides Compound (25): Petition 870250102374, dated 07 / 11 / 2025, p. 9 / 187 5 / 159 (25). or a salt or solvate of it.

[015] In another aspect, the present disclosure provides a composition comprising a compound of Formula (IV): (IV), or a salt or solvate thereof, where = represents a single or double bond.

[016] In another aspect, the present disclosure provides a process for preparing a composition comprising Formula (IV), or a salt or solvate thereof, the process comprising reacting 4-aminodiphenylamine with acetone, 2,2-dimethoxypropane or mesityl oxide in the presence of a strong acid, for example, hydrochloric acid.

[017] Other modalities and advantages of disclosure will be presented, in part, in the following description and will flow from the description or can be learned through the practice of disclosure. The modalities and advantages of disclosure will be realized and achieved through the elements and combinations particularly pointed out in the appended claims.

[018] It should be understood that both the preceding summary and the detailed description below are merely illustrative and explanatory and are not limited to the invention as claimed. BRIEF DESCRIPTION OF THE DRAWINGS

[019] Figure 1 is a high-performance liquid chromatography (HPLC) chromatograph of a representative Disclosure Composition that has been annotated to include the peak positions of certain Disclosure Compounds.

[020] Figure 2 shows two chromatograms illustrating the chromatographic detection of Compound (2) in the mixture with Compound (10) (above) and the Petition 870250102374, dated 07 / 11 / 2025, page 10 / 187 6 / 159 chromatogram of the (2) authentic (below) using Method 3.

[021] Figure 3 shows two chromatograms illustrating the chromatographic detection of Compound (21) in the mixture with Compound (10) (above) and the chromatogram of authentic (21) (below) using Method 3.

[022] Figure 4 shows two chromatograms illustrating the chromatographic detection of Compound (23) in the mixture with Compound (10) (above) and the chromatogram of authentic (23) (below) using Method 3.

[023] Figure 5 shows two chromatograms illustrating the chromatographic detection of Compound (25) in the mixture with Compound (10) (above) and the chromatograms of genuine (25) (below) using Method 3.

[024] Figure 6 shows two chromatograms illustrating the chromatographic detection of Compound (21) in the mixture with Compound (10) (above) and the chromatogram of authentic (21) (below) using Method 2.

[025] Figure 7 shows two chromatograms illustrating the chromatographic detection of Compound (25) in the mixture with Compound (10) (above) and (below) the chromatogram of authentic (25) using Method 2.

[026] Figure 8 is an NMR spectrum of Compound (4).

[027] Figure 9 is an HPLC chromatogram of Compound (4).

[028] Figure 10 is a 13 APT NMR spectrum of Compound (2).

[029] Figure 11 is an HPLC chromatogram of Compound (2).

[030] Figure 12 is a 13 APT NMR spectrum of Compound (21).

[031] Figure 13 is an HPLC chromatogram of Compound (21).

[032] Figure 14 is a 13 APT NMR spectrum of Compound (24).

[033] Figure 15 is an HPLC chromatogram of Compound (24).

[034] Figure 16 is a 13 APT NMR spectrum of Compound (23).

[035] Figure 17 is an HPLC chromatogram of Compound (23).

[036] Figure 18 is a 13 APT NMR spectrum of Compound (7).

[037] Figure 19 is an HPLC chromatogram of Compound (7).

[038] Figure 20 is a proton NMR spectrum of Compound (25)

[039] Figure 21 is a 13 APT NMR spectrum of Compound (25).

[040] Figure 22 is an HPLC chromatogram of Compound (25).

[041] Figure 23 shows two chromatograms that illustrate the detection Petition 870250102374, dated 07 / 11 / 2025, p. 11 / 187 7 / 159 chromatographic of Compound (37) in the mixture with Compound (10) (above) and the chromatograms of the authentic (37) (below) using Method 3. DETAILED DESCRIPTION I. COMPOUNDS OF DISCLOSURE

[042] In one embodiment, the present disclosure provides a composite of Formula (I), or a salt or solvate thereof: (I), where = represents a single or double bond.

[043] In another embodiment, the present disclosure provides a compound of Formula (I), where = represents a single bond, i.e., Compound (1), or a salt or solvate thereof: (1).

[044] In another embodiment, the present disclosure provides a compound of Formula (I), where = represents a double bond, i.e., Compound (2), or a salt or solvate thereof: (2).

[045] In another embodiment, the present disclosure provides a compound of Petition 870250102374, dated 07 / 11 / 2025, p. 12 / 187 8 / 159 Formula (II): oxXN\ (II), or a salt or solvate thereof, where = represents a single or double bond.

[046] In another embodiment, the present disclosure provides a compound of Formula (II), where = represents a single bond, that is, Compound (3), or a salt or solvate thereof: αχχχN\ (3).

[047] In another embodiment, the present disclosure provides a compound of Formula (II), where = represents a double bond, that is, Compound (4), or a salt or solvate thereof: oxXN\ (4).

[048] In another embodiment, the present disclosure provides a compound of Formula (III): ΓΥχ llN 3σN (III), or a salt or solvate thereof, where = represents a single or double bond.

[049] In another embodiment, the present disclosure provides a compound of Formula (III), where = represents a single bond, i.e., Compound (5), or Petition 870250102374, dated 07 / 11 / 2025, p. 13 / 187 9 / 159 a salt or solvate of the same: (5).

[050] In another embodiment, the present disclosure provides a compound of Formula (III), where = represents a double bond, i.e., Compound (6), or a salt or solvate thereof: (6).

[051] In another embodiment, the present disclosure provides Compound (21): (21), or a salt or solvate thereof.

[052] In another embodiment, the present disclosure provides Compound (22): (22), or a salt or solvate thereof.

[053] In another embodiment, the present disclosure provides Compound (23): Petition 870250102374, dated 07 / 11 / 2025, p. 14 / 187 10 / 159 or a salt or solvate thereof.

[054] In another embodiment, the present disclosure provides Compound (24): or a salt or solvate of it.

[055] In another embodiment, the present disclosure provides Compound (25): (25), or a salt or solvate thereof.

[056] In another embodiment, the present disclosure provides a compound from Table 1, or a salt or solvate thereof. TABLE 1 Compound Structure (1) OCX 1 H xu (2) OXu 1 H x (Ύ (3) . Petition 870250102374, dated 07 / 11 / 2025, p. 15 / 187 11 / 159 (4) (5) ΟΧΙ ,Ν ex (6) CCl Y^nv γγ,Ν ex (7) H (8) γΥ^ n Co (9) , (10) Petition 870250102374, dated 07 / 11 / 2025, p. 16 / 187 12 / 159 (11 A) ςά Μ (11B) KH Qí (12) H , N / h Ó Of (13) H , NY Ò Of (14) xV YYíNH Petition 870250102374, dated 07 / 11 / 2025, p. 17 / 187 13 / 159 (15) N^ / ό α (16) A 0' ò (17) HIN (J L1 O (18) HI í JTT Ί (19) vais LJ (20A) ok^r (20B) oAá H Petition 870250102374, dated 07 / 11 / 2025, p. 18 / 187 14 / 159 (21) H \ / N ~V CQj H 7=7 (22) HV°HH (23) / V / N. / x J. (Ύ TXX 1 (24) 1 I / V / N\ í J XXX 1 (25) / N \ / Lx Cj XIX vN / \ H x (26) jX (27a) wvX (27b) O Petition 870250102374, dated 07 / 11 / 2025, p. 19 / 187 15 / 159 (28) / H (29) (30) ^=N__HN- (31) HN''^--- (32) H2N HN---ά / > t) (33) (34) O .-------. Petition 870250102374, dated 07 / 11 / 2025, p. 20 / 187 16 / 159 (35) 1 I (36) H (37) \ J (38) | 1 ,nh2 (39) 0 H | H YN\ (40) 0 H / N\ 0 X\ ήη2 (41) H LJ XX XH x (42) \ / H / XX / N \ / CX XXX H Petition 870250102374, dated 07 / 11 / 2025, p. 21 / 187 17 / 159 (43) / N—C / 1— (44) 5 . H / / N\ / Cl XIX H (45) / XH / O XIX ó (46) ^1-- Petition 870250102374, dated 07 / 11 / 2025, p. 22 / 187 18 / 159

[057] The compounds in this Section I are collectively referred to as “Disclosure Compounds” and individually as “Disclosure Compound”. II. COMPOSITIONS OF THE DISCLOSURE

[058] In another embodiment, the present disclosure provides a composition comprising a Disclosure Compound.

[059] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (I). In another embodiment, the composition Petition 870250102374, dated 07 / 11 / 2025, page 23 / 187 19 / 159 comprises 0.0001% to 99.9% of Formula (I), as measured by high-performance liquid chromatography (HPLC) analysis, gas chromatography (GC) analysis and / or a combination of HPLC and GC analysis.

[060] In another embodiment, the present disclosure provides a composition comprising Compound (1). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (1), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (1), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (1).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (1), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (1). The compositions comprising Compound (1) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (1) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[061] In another embodiment, the present disclosure provides a composition comprising Compound (2). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (2), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (2), as measured by HPLC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (2). In another embodiment, the composition comprises Petition 870250102374, dated 07 / 11 / 2025, p. 24 / 187 20 / 159 about 0.000001% to about 15% of Compound (2), as measured by HPLC and / or GC analysis, e.g., about 0.000001% to about 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about 0.00001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% to about 3% or about 0.001% to about 1% of Compound (2). The compositions comprising Compound (2) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (2) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[062] In another embodiment, the present disclosure provides a compound of Formula (II), or a salt or solvate thereof: 0'XàN\ (II), where = represents a single or double bond.

[063] In another embodiment, the disclosure provides a compound of Formula (II), where = represents a single bond, i.e., Compound (3), or a salt or solvate thereof: N\ (3).

[064] In another embodiment, the present disclosure provides a compound of Formula (II), where = represents a double bond, i.e., Compound (4), or a salt or solvate thereof: N\ (4).

[065] In another form, the present disclosure provides a composition Petition 870250102374, dated 07 / 11 / 2025, p. 25 / 187 21 / 159 comprising a compound of Formula (II), or a salt or solvate thereof. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Formula (II), as measured by HPLC analysis.

[066] In another embodiment, the present disclosure provides a composition comprising Compound (3). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (3), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (3), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from 50% to 99.9%, from about 75% to 99.9%, from 90% to 99.9% or from 95% to 99.9% of Compound (3).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (3), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (3). The compositions comprising Compound (3) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (3) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[067] In another embodiment, the present disclosure provides a composition comprising Compound (4). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (4), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (4), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (4). In another embodiment, the composition Petition 870250102374, dated 07 / 11 / 2025, p. 26 / 187 22 / 159 comprises about 0.000001% to about 15% of Compound (4), as measured by HPLC and / or GC analysis, for example, about 0.000001% to about 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about 0.00001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% to about 3%, or about 0.001% to about 1% of Compound (4). The compositions comprising Compound (4) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (4) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[068] In another embodiment, the present disclosure provides a composition comprising Compound (4) and Compound (10). In another embodiment, the composition comprises about 50% to 99.9% of Compound (4), as measured by HPLC analysis, for example, about 75% to 99.9%, about 90% to 99.9% or about 95% to 99.9% of Compound (4).

[069] In another embodiment, the present disclosure provides a compound of Formula (III), or a salt or solvate thereof: (III) where = represents a single or double bond.

[070] In another embodiment, the present disclosure provides a compound of Formula (III), where = represents a single bond, i.e., Compound (5), or a salt or solvate thereof: Petition 870250102374, dated 07 / 11 / 2025, p. 27 / 187 23 / 159 (5).

[071] In another embodiment, the present disclosure provides a compound of Formula (III), where = represents a double bond, i.e., Compound (6), or a salt or solvate thereof: (6).

[072] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (III), or a salt or solvate thereof. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Formula (III), as measured by HPLC analysis.

[073] In another embodiment, the present disclosure provides a composition comprising Compound (5). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (5), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (5), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (5). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (5), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.00001% to Petition 870250102374, dated 07 / 11 / 2025, p. 28 / 187 24 / 159 approximately 1%, approximately 0.0001% to approximately 3%, approximately 0.0001% to approximately 1%, approximately 0.001% to approximately 3%, or approximately 0.001% to approximately 1% of Compound (5). Compositions comprising Compound (5) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, compositions comprising Compound (5) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[074] In another embodiment, the present disclosure provides a composition comprising Compound (6). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (6), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (6), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (6).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (6), as measured by HPLC and / or GC analysis, for example, about 0.000001% to about 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about 0.00001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% to about 3% or about from 0.001% to about 1% of Compound (6). Compositions comprising Compound (6) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, compositions comprising Compound (6) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[075] In another embodiment, the present disclosure provides a composition comprising Compound (7). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (7), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to Petition 870250102374, dated 07 / 11 / 2025, page 29 / 187 25 / 159 99.9% of Compound (7) as measured by HPLC and / or GC analysis, e.g., about 0.0001% to about 50%, about 0.0001% to about 25%, about 0.0001% to about 10%, about 0.0001% to about 5%, about 0.0001% to about 1%, about 50% to 99.9%, about 75% to 99.9%, about 90% to 99.9% or about 95% to 99.9% of Compound (7). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (7), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (7). Compositions comprising Compound (7) may optionally contain one or more of the other Disclosure Compounds listed in Table 1.In one embodiment, the compositions comprising Compound (7) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[076] In another embodiment, the present disclosure provides a composition comprising Compound (8). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (8), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (8), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (8).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (8), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (8). Compositions comprising Compound (8) may optionally contain a. Petition 870250102374, dated 07 / 11 / 2025, p. 30 / 187 26 / 159 or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (8) also comprise Compound (10) and, optionally, any one or more of the others. Disclosure components listed in Table 1.

[077] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV): (IV),

[078] or a salt or solvate thereof, where = represents a single or double bond. In another embodiment, the composition comprises about 50% to 99.9% of Formula (IV), as measured by HPLC analysis, for example, approximately 75% to 99.9%, approximately 80% to 99.9%, approximately 85% to 99.9%, approximately 90% to 99.9% or approximately 95% to 99.9% of Formula (IV).

[079] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), where = represents a single bond, i.e., Compound (9), or a salt or solvate thereof: (9).

[080] In another embodiment, the composition comprises about 25% to 99.9% of Compound (9), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises about 50% to 99.9% of Compound (9), as measured by HPLC and / or GC analysis, for example, about 75% to 99.9%, about 80% to 99.9%, about 85% to 99.9%, about 90% to 99.9% or about 95% to 99.9% of Compound (9).

[081] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), where = represents a double bond, i.e., Compound (10), or a salt or solvate thereof: Petition 870250102374, dated 07 / 11 / 2025, p. 31 / 187 27 / 159 (10).

[082] In another embodiment, the composition comprises about 25% to 99.9% of Compound (10), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises about 50% to 99.9% of Compound (10), as measured by HPLC and / or analysis, for example, about 75% to 99.9%, about 80% to 99.9%, about 85% to 99.9%, about 90% to 99.9% or about 55% to 99.9% of Compound (10). In another embodiment, the composition comprises about 25%, about 30%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% of Compound (10). Compositions comprising Compound (10) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1.Such compositions may comprise from about 0.000001% to about 15% of one or more other Disclosure Compounds, as measured by HPLC and / or GC analysis, for example, about 0.000001% to about 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about 0.0001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% about 3% or about 0.001% to about 1% of one or more other Disclosure Compounds.

[083] In another embodiment, the present disclosure provides a composition comprising Compound (11A). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (11A), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (11A), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, about 90% Petition 870250102374, dated 07 / 11 / 2025, p. 32 / 187 28 / 159 at 99.9% or approximately 95% to 99.9% of the Compound (11A). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (11A), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (11A). The compositions comprising Compound (11A) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (11A) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[084] In another embodiment, the present disclosure provides a composition comprising Compound (11B). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (11B), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (11B), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (11B).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (11B), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.00001% to about 1%, from about 0.0001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (11B). Compositions comprising Compound (11B) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, compositions comprising Compound (11B) also comprise Compound (10) and, optionally, any one or more of the others. Petition 870250102374, dated 07 / 11 / 2025, p. 33 / 187 29 / 159 Disclosure components listed in Table 1.

[085] In another embodiment, the present disclosure provides a composition comprising Compound (12). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (12), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (12), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (12).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (12), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 3%, or from about 0.001% to about 1% of Compound (12). The compositions comprising Compound (12) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (12) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[086] In another embodiment, the present disclosure provides a composition comprising Compound (13). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (13), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (13), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (13). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (13), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about Petition 870250102374, dated 07 / 11 / 2025, p. 34 / 187 30 / 159 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about 0.00001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% to about 3%, or about 0.001% to about 1% of Compound (13). The compositions comprising Compound (13) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (13) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[087] In another embodiment, the present disclosure provides a composition comprising Compound (14). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (14), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (14), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (14).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (14), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 3%, or from about 0.001% to about 1% of Compound (14). The compositions comprising Compound (14) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (14) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[088] In another embodiment, the present disclosure provides a composition comprising Compound (15). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (15), as measured by analysis of Petition 870250102374, dated 07 / 11 / 2025, page 35 / 187 31 / 159 HPLC and / or GC. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (15), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (15). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (15), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (15).The compositions comprising Compound (15) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (15) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[089] In another embodiment, the present disclosure provides a composition comprising Compound (16). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (16), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (16), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (16).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (16), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 1% of Compound (16). Petition 870250102374, dated 07 / 11 / 2025, p. 36 / 187 32 / 159 The compositions comprising Compound (16) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (16) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[090] In another embodiment, the present disclosure provides a composition comprising Compound (17). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (17), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (17), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (17).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (17), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (17). The compositions comprising Compound (17) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (17) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[091] In another embodiment, the present disclosure provides a composition comprising Compound (18). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (18), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (18), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to Petition 870250102374, dated 07 / 11 / 2025, p. 37 / 187 33 / 159 about 1%, about 50% to 99.9%, about 75% to 99.9%, about 90% to 99.9% or about 95% to 99.9% of Compound (118). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (18), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (18). The compositions comprising Compound (18) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (18) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[092] In another embodiment, the present disclosure provides a composition comprising Compound (19). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (19), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (19), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (19).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (19), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (19). The compositions comprising Compound (19) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (19) also comprise Compound (10) and, optionally, any one or more of the others. Petition 870250102374, dated 07 / 11 / 2025, p. 38 / 187 34 / 159 Disclosure components listed in Table 1.

[093] In another embodiment, the present disclosure provides a composition comprising Compound (20A). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (20A), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (20A), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (20A).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (20A), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (20A). The compositions comprising Compound (20A) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, compositions comprising Compound (20A) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[094] In another embodiment, the present disclosure provides a composition comprising Compound (20B). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (20B), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (20B), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (20B). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (20B), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to Petition 870250102374, dated 07 / 11 / 2025, p. 39 / 187 35 / 159 about 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about 0.00001% to about 1%, about 0.0001 % to about 3%, about 0.0001% to about 1%, about 0.001% to about 3% or about 0.001% to about 1% of Compound (20B). The compositions comprising Compound (20B) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (20B) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[095] In another embodiment, the present disclosure provides a composition comprising Compound (21). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (21), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (21), as measured by HPLC and / or analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (21).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (21), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (21). The compositions comprising Compound (21) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (21) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[096] In another embodiment, the present disclosure provides a composition comprising Compound (22). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (22), as measured by analysis of Petition 870250102374, dated 07 / 11 / 2025, page 40 / 187 36 / 159 HPLC and / or GC. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (22), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (22). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (22), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (22).The compositions comprising Compound (22) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (22) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[097] In another embodiment, the present disclosure provides a composition comprising Compound (23). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (23), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 50% to 99.9% of Compound (23), as measured by HPLC and / or GC analysis, for example, from about 75% to 99.9%, from about 80% to 99.9%, from about 85% to 99.9%, from about 90% to 99.9% or from about 55% to 99.9% of Compound (23).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (23), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 3%, or from about 0.001% to about 1% of Compound (23). The compositions comprising Compound (23) may optionally contain any one or more of the other Compounds in the Disclosure. Petition 870250102374, dated 07 / 11 / 2025, p. 41 / 187 37 / 159 listed in Table 1. In one embodiment, the compositions comprising Compound (23) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[098] In another embodiment, the present disclosure provides a composition comprising Compound (24). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (24), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 50% to 99.9% of Compound (24), as measured by HPLC analysis, for example, from about 75% to 99.9%, from about 80% to 99.9%, from about 85% to 99.9%, from about 90% to 99.9% or from about 55% to 99.9% of Compound (24).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (24), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 3%, or from about 0.001% to about 1% of Compound (24). The compositions comprising Compound (24) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (24) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[099] In another embodiment, the present disclosure provides a composition comprising Compound (25). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (25), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (25), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (25). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (25), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about Petition 870250102374, dated 07 / 11 / 2025, p. 42 / 187 38 / 159 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about 0.00001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% to about 3% or about 0.001% to about 1% of Compound (25). The compositions comprising Compound (25) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (25) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0100] In another embodiment, the present disclosure provides a composition comprising Compound (26). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (26), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (26), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (26).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (26), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (26). The compositions comprising Compound (26) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (26) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0101] In another embodiment, the present disclosure provides a composition comprising Compound (27A). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (27A), as measured by Petition 870250102374, dated 07 / 11 / 2025, page 43 / 187 39 / 159 HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (27A), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from 90% to 99.9% or from about 95% to 99.9% of Compound (27A). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (27A), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (27A).The compositions comprising Compound (27A) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, compositions comprising Compound (27A) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0102] In another embodiment, the present disclosure provides a composition comprising Compound (27B). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (27B), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (27B), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (27B).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (27B), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.00001% to about 1%, from about 0.0001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.0001% to about 1%, about. Petition 870250102374, dated 07 / 11 / 2025, page 44 / 187 40 / 159 0.001% to about 3% or about 0.001% to about 1% of Compound (27B). Compositions comprising Compound (27B) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, compositions comprising Compound (27B) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0103] In another embodiment, the present disclosure provides a composition comprising Compound (28). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (28), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (28), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (28).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (28), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (28). The compositions comprising Compound (28) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (28) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0104] In another embodiment, the present disclosure provides a composition comprising Compound (29). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (29), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (29), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, about Petition 870250102374, dated 07 / 11 / 2025, p. 45 / 187 41 / 159 from 0.0001% to about 10%, about 0.0001% to about 5%, about 0.0001% to about 1%, about 50% to 99.9%, about 75% to 99.9%, about 90% to 99.9% or about 95% to 99.9% of the Compound (29). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (29), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (29). The compositions comprising Compound (29) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1.In one embodiment, the compositions comprising Compound (29) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0105] In another embodiment, the present disclosure provides a composition comprising Compound (30). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (30), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (30), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (30).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (30), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (30). The compositions comprising Compound (30) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (30) also. Petition 870250102374, dated 07 / 11 / 2025, p. 46 / 187 42 / 159 comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0106] In another embodiment, the present disclosure provides a composition comprising Compound (31). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (31), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (31), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (31).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (31), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (31). The compositions comprising Compound (31) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (31) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0107] In another embodiment, the present disclosure provides a composition comprising Compound (32). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (32), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (32), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (32). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (32), as measured by HPLC and / or GC analysis. Petition 870250102374, dated 07 / 11 / 2025, p. 47 / 187 43 / 159 measured by HPLC and / or GC analysis, for example, about 0.000001% to about 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about from 0.00001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% to about 3% or about 0.001% to about 1% of Compound (32). The compositions comprising Compound (32) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (32) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0108] In another embodiment, the present disclosure provides a composition comprising Compound (33). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (33), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (33), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (33).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (33), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (33). The compositions comprising Compound (33) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (33) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0109] In another embodiment, the present disclosure provides a composition comprising Compound (34). In another embodiment, the composition comprises Petition 870250102374, dated 07 / 11 / 2025, page 48 / 187 44 / 159 from about 0.000001% to 99.9% of Compound (34), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (34), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from 90% to 99.9% or from about 95% to 99.9% of Compound (34).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (34), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (34). The compositions comprising Compound (34) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (34) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0110] In another embodiment, the present disclosure provides a composition comprising Compound (35). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (35), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (35), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (35).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (35), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.00001% to about 1%, from about 0.0001% to about 3%, from about 0.0001% to about 1%. Petition 870250102374, dated 07 / 11 / 2025, p. 49 / 187 45 / 159 from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (35). The compositions comprising Compound (35) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (35) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0111] In another embodiment, the present disclosure provides a composition comprising Compound (36). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (36), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (36), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (36).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (36), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (36). The compositions comprising Compound (36) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (36) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0112] In another embodiment, the present disclosure provides a composition comprising Compound (37). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (37), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (37), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, about Petition 870250102374, dated 07 / 11 / 2025, p. 50 / 187 46 / 159 from 0.0001% to about 10%, about 0.0001% to about 5%, about 0.0001% to about 1%, about 50% to 99.9%, about 75% to 99.9%, about 90% to 99.9% or about 95% to 99.9% of the Compound (37). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (37), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (37). The compositions comprising Compound (37) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1.In one embodiment, the compositions comprising Compound (37) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0113] In another embodiment, the present disclosure provides a composition comprising Compound (38). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (38), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (38), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (38).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (38), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (38). The compositions comprising Compound (38) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (38) also. Petition 870250102374, dated 07 / 11 / 2025, p. 51 / 187 47 / 159 comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0114] In another embodiment, the present disclosure provides a composition comprising Compound (39). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (39), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (39), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (39).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (39), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.0001% to about 3%, from about 0.001% to about 3%, or from about 0.001% to about 1% of Compound (39). The compositions comprising Compound (39) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (39) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0115] In another embodiment, the present disclosure provides a composition comprising Compound (40). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (40), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (40), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (40). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (40), as measured by HPLC and / or GC analysis. Petition 870250102374, dated 07 / 11 / 2025, p. 52 / 187 48 / 159 measured by HPLC and / or GC analysis, for example, about 0.000001% to about 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about from 0.00001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% to about 3% or about 0.001% to about 1% of Compound (40). The compositions comprising Compound (0) may optionally contain one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (40) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0116] In another embodiment, the present disclosure provides a composition comprising Compound (41). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (41), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (41), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (41).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (41), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 1% of Compound (41). The compositions comprising Compound (41) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (41) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0117] In another embodiment, the present disclosure provides a composition comprising Compound (42). In another embodiment, the composition comprises Petition 870250102374, dated 07 / 11 / 2025, page 53 / 187 49 / 159 from about 0.000001% to 99.9% of Compound (42), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (42), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from 90% to 99.9% or from about 95% to 99.9% of Compound (42).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (42), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 1% of Compound (42). The compositions comprising Compound (42) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (42) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0118] In another embodiment, the present disclosure provides a composition comprising Compound (43). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (43), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (43), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (43).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (43), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.00001% to about 1%, from about 0.0001% to about 3%, from about 0.0001% to about 1%. Petition 870250102374, dated 07 / 11 / 2025, p. 54 / 187 50 / 159 from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (43). Compositions comprising Compound (43) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, compositions comprising Compound (43) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0119] In another embodiment, the present disclosure provides a composition comprising Compound (44). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (44), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (44), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (44).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (44), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 3%, or from about 0.001% to about 1% of Compound (44). The compositions comprising Compound (44) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (44) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0120] In another embodiment, the present disclosure provides a composition comprising Compound (45). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (45), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (45), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, about Petition 870250102374, dated 07 / 11 / 2025, p. 55 / 187 51 / 159 from 0.0001% to about 10%, about 0.0001% to about 5%, about 0.0001% to about 1%, about 50% to 99.9%, about 75% to 99.9%, about 90% to 99.9% or about 95% to 99.9% of the Compound (45). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (45), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (45). The compositions comprising Compound (45) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1.In one embodiment, the compositions comprising Compound (45) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0121] In another embodiment, the present disclosure provides a composition comprising Compound (46). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (46), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (46), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (46).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (46), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 3%, or from about 0.001% to about 1% of Compound (46). The compositions comprising Compound (46) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (46) also. Petition 870250102374, dated 07 / 11 / 2025, p. 56 / 187 52 / 159 comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0122] In another embodiment, the present disclosure provides a composition comprising Compound (47). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (47), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (47), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (47).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (47), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (47). The compositions comprising Compound (47) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (47) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0123] In another embodiment, the present disclosure provides a composition comprising Compound (48). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (48), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (48), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (48). In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (48), as measured by HPLC and / or GC analysis. Petition 870250102374, dated 07 / 11 / 2025, p. 57 / 187 53 / 159 measured by HPLC and / or GC analysis, for example, about 0.000001% to about 10%, about 0.000001% to about 5%, about 0.000001% to about 3%, about 0.000001% to about 1%, about 0.00001% to about 3%, about from 0.00001% to about 1%, about 0.0001% to about 3%, about 0.0001% to about 1%, about 0.001% to about 3% or about 0.001% to about 1% of Compound (48). The compositions comprising Compound (48) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (48) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0124] In another embodiment, the present disclosure provides a composition comprising Compound (49). In another embodiment, the composition comprises from about 0.000001% to 99.9% of Compound (49), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (49), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from about 90% to 99.9% or from about 95% to 99.9% of Compound (49).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (49), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 1%, from about 0.001% to about 3% or from about 0.001% to about 1% of Compound (49). The compositions comprising Compound (49) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (49) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0125] In another embodiment, the present disclosure provides a composition comprising Compound (50). In another embodiment, the composition comprises Petition 870250102374, dated 07 / 11 / 2025, page 58 / 187 54 / 159 from about 0.000001% to 99.9% of Compound (50), as measured by HPLC and / or GC analysis. In another embodiment, the composition comprises from about 0.0001% to 99.9% of Compound (50), as measured by HPLC and / or GC analysis, for example, from about 0.0001% to about 50%, from about 0.0001% to about 25%, from about 0.0001% to about 10%, from about 0.0001% to about 5%, from about 0.0001% to about 1%, from about 50% to 99.9%, from about 75% to 99.9%, from 90% to 99.9% or from about 95% to 99.9% of Compound (50).In another embodiment, the composition comprises from about 0.000001% to about 15% of Compound (50), as measured by HPLC and / or GC analysis, for example, from about 0.000001% to about 10%, from about 0.000001% to about 5%, from about 0.000001% to about 3%, from about 0.000001% to about 1%, from about 0.00001% to about 3%, from about 0.0001% to about 1%, from about 0.001% to about 3%, from about 0.001% to about 3%, or from about 0.001% to about 1% of Compound (50). The compositions comprising Compound (50) may optionally contain any one or more of the other Disclosure Compounds listed in Table 1. In one embodiment, the compositions comprising Compound (50) also comprise Compound (10) and, optionally, any one or more of the other Disclosure Compounds listed in Table 1.

[0126] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), for example, Compound (9) or Compound (10), or a salt or solvate thereof; and: (a) a compound of Formula (I), for example, Compound (1) or Compound (2), or a salt or solvate thereof: (I); or (b) a compound of Formula (II), for example, Compound (3) or Compound (4), or a salt or solvate thereof: Petition 870250102374, dated 07 / 11 / 2025, p. 59 / 187 55 / 159 (II); or (c) a compound of Formula (III), for example, Compound (5) or Compound (6), or a salt or solvate thereof: (III); or (d) Compound (7), or a salt or solvate thereof: (7); or (e) Compound (8), or a salt or solvate thereof: (8); or (f) Compound (11A), or a salt or solvate thereof: (11A); or (g) Compound (11B), or a salt or solvate thereof: Petition 870250102374, dated 07 / 11 / 2025, p. 60 / 187 56 / 159 (11B); or (h) Compound (20A), or a salt or solvate thereof: (20A); or (i) Compound (20B), or a salt or solvate thereof: h (20B); or (j) Compound (21), or a salt or solvate thereof: (k) Compound (22), or a salt or solvate thereof: H π ; or (I) Compound (23), or a salt or solvate thereof: (m) Compound (24), or a salt or solvate thereof: Petition 870250102374, dated 07 / 11 / 2025, p. 61 / 187 57 / 159 (n) Compound (25), or a salt or solvate thereof: (o) Compound (37), or a salt or solvate thereof: ; or (p) a combination of Formula (I), or a salt or solvate thereof; Formula (II), or a salt or solvate thereof; Formula (III), or a salt or solvate thereof; Compound (7), or a salt or solvate thereof, Compound (8), or a salt or solvate thereof, Compound (11A), or a salt or solvate thereof, Compound (11B), or a salt or solvate thereof, Compound (20A), or a salt or solvate thereof, Compound (20B), or a salt or solvate thereof, Compound (21), or a salt or solvate thereof, Compound (22), or a salt or solvate thereof, Compound (23), or a salt or solvate thereof, Compound (24), or a salt or solvate thereof, Compound (25), or a salt or solvate thereof, and / or Compound (37), or a salt or solvate thereof, where = represents a single or double bond.

[0127] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and a compound of Formula (I), or a salt or solvate thereof. In another embodiment, the composition comprises Formula (IV) and about 0.001% to about 10% of Formula (I), as measured by HPLC analysis, for example, about 0.01% to about 10%, about 0.1% to about 10%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5% or about Petition 870250102374, dated 07 / 11 / 2025, p. 62 / 187 58 / 159 0.05% to approximately 0.5% of Formula (I). In another embodiment, the composition comprises Formula (IV) and approximately 0.01%, approximately 0.02%, approximately 0.03%, approximately 0.04%, approximately 0.05%, approximately 0.06%, approximately 0.07%, approximately 0.08%, approximately 0.09%, approximately 0.1%, approximately 0.11%, approximately 0.12%, approximately 0.13%, approximately 0.14%, approximately 0.15%, approximately 0.16%, approximately 0.17%, approximately 0.18%, approximately 0.19%, approximately 0.2%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9% or about 1% of Formula (I). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10). In another embodiment, the compound of Formula (I) is Compound (1). In another embodiment, the compound of Formula (I) is Compound (2).

[0128] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and a compound of Formula (I), or a salt or solvate thereof, wherein the weight ratio of Formula (I) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Formula (I) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (10). In another embodiment, the compound of Formula (I) is Compound (1). In another embodiment, the compound of Formula (I) is Compound (2).

[0129] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and a compound of Formula (II), or a salt or solvate thereof. In another embodiment, the composition comprises Formula (IV) and about 0.001% to about 10% of Formula (II), as measured by HPLC analysis, for example, about 0.01% to about 10%, about 0.1% to about 10%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to 0.5% of Formula (II).In another embodiment, the composition comprises Formula (IV) and approximately 0.01%, approximately 0.2%, approximately 0.21%, approximately 0.22%, approximately 0.23%, approximately 0.24%, approximately 0.25%, approximately 0.26%, approximately 0.27%, approximately 0.28%, approximately 0.29%, approximately 0.3%, approximately 0.31%, approximately 0.32%, approximately 0.33%, approximately 0.34%, approximately 0.35%, approximately. Petition 870250102374, dated 07 / 11 / 2025, page 63 / 187 59 / 159 0.36%, approximately 0.37%, approximately 0.38%, approximately 0.39%, approximately 0.4%, approximately 0.41%, approximately 0.42%, approximately 0.43%, approximately 0.44%, approximately 0.45%, approximately 0.46%, approximately 0.47%, approximately 0.48%, approximately 0.49%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9% or approximately 1% of Formula (II). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10). In another embodiment, the compound of Formula (II) is Compound (3). In another embodiment, the compound of Formula (II) is Compound (4).

[0130] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and a compound of Formula (II), or a salt or solvate thereof, wherein the weight ratio of Formula (II) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Formula (II) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10). In another embodiment, the compound of Formula (II) is Compound (3). In another embodiment, the compound of Formula (II) is Compound (4).

[0131] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and a compound of Formula (III), or a salt or solvate thereof. In another embodiment, the composition comprises Formula (IV) and from about 0.001% to about 10% of Formula (III), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5% or from about 0.1% to about 5% of Formula (III). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10). In another embodiment, the compound of Formula (III) is Compound (5). In another embodiment, the compound of Formula (III) is Compound (6).

[0132] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and a compound of Formula (III), or a salt or solvate thereof, wherein the weight ratio of Formula (III) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, Petition 870250102374, dated 07 / 11 / 2025, p. 64 / 187 60 / 159 0.001 to 0.01 or 0.001 to 0.005 of Formula (III) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10). In another embodiment, the compound of Formula (III) is Compound (5). In another embodiment, the compound of Formula (III) is Compound (6).

[0133] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (7), or a salt or solvate thereof. In another embodiment, the composition comprises Formula (IV) and about 0.001% to about 10% of Compound (7), as measured by HPLC analysis, for example, about 0.01% to about 10%, about 0.1% to about 10%, about 0.001% to about 5%, about 0.01% to about 5% or about 0.1% to about 5% of Compound (7). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0134] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (7), or a salt or solvate thereof, wherein the weight ratio of Compound (7) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (7) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0135] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (8), or a salt or solvate thereof. In another embodiment, the composition comprises Formula (IV) and about 0.001% to about 10% of Compound (8), as measured by HPLC analysis, for example, about 0.01% to about 10%, about 0.1% to about 10%, about 0.001% to about 5%, about 0.01% to about 5% or about 0.1% to about 5% of Compound (8). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0136] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and the Petition 870250102374, dated 07 / 11 / 2025, p. 65 / 187 61 / 159 Compound (8), or a salt or solvate thereof, wherein the weight ratio of Compound (8) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (8) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0137] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (11), or a salt or solvate thereof. In another embodiment, the composition comprises Formula (IV) and from about 0.001% to about 10% of Compound (11), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5% or from about 0.1% to about 5% of Compound (11).In another modality, the composition comprises approximately 0.01%, approximately 0.02%, approximately 0.03%, approximately 0.04%, approximately 0.05%, approximately 0.06%, approximately 0.07%, approximately 0.08%, approximately 0.09%, approximately 0.1%, approximately 0.11%, approximately 0.12%, approximately 0.13%, approximately 0.14%, approximately 0.15%, approximately 0.16%, approximately 0.17%, approximately 0.18%, approximately 0.19%, approximately 0.2%, approximately 0.21%, approximately 0.22%, approximately 0.23%, approximately 0.24%, approximately 0.25%, approximately 0.26%, approximately 0.27%, approximately 0.28%, approximately 0.29%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9% or approximately 1% of Compound (11). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0138] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (11A), or a salt or solvate thereof, wherein the weight ratio of Compound (11A) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (11A) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0139] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (11B), or a salt or solvate thereof, wherein the weight ratio of Petition 870250102374, dated 07 / 11 / 2025, p. 66 / 187 62 / 159 Compound (11B) for Formula (IV) is from 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (11B) for Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0140] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (20A), or a salt or solvate thereof, wherein the weight ratio of Compound (20A) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (20A) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0141] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (20B), or a salt or solvate thereof, wherein the weight ratio of Compound (20B) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (20B) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0142] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (21), or a salt or solvate thereof, wherein the weight ratio of Compound (21) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (21) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0143] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (2), or a salt or solvate thereof.

[0144] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (2), or a salt or solvate thereof, wherein the weight ratio of Compound (2) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 Petition 870250102374, dated 07 / 11 / 2025, p. 67 / 187 63 / 159 or 0.001 to 0.005 from Compound (2) to Compound (10).

[0145] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (21), or a salt or solvate thereof.

[0146] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (21), or a salt or solvate thereof, wherein the weight ratio of Compound (21) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (21) to Compound (10).

[0147] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, Compound (2), or a salt or solvate thereof, and Compound (21), or a salt or solvate thereof.

[0148] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, Compound (2), or a salt or solvate thereof, and Compound (21), or a salt or solvate thereof, wherein the weight ratio of Compound (2) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01, or 0.001 to 0.005 of Compound (2) to Compound (10), and the weight ratio of Compound (21) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01, or 0.001 to 0.005 of Compound (21) for Compound (10).

[0149] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (22), or a salt or solvate thereof, wherein the weight ratio of Compound (22) to Formula (IV) is 0.001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (22) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0150] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (22), or a salt or solvate thereof.

[0151] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound Petition 870250102374, dated 07 / 11 / 2025, p. 68 / 187 64 / 159 (22), or a salt or solvate thereof, wherein the weight ratio of Compound (22) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (22) to Compound (10).

[0152] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, Compound (2), or a salt or solvate thereof, and Compound (22), or a salt or solvate thereof.

[0153] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, Compound (2), or a salt or solvate thereof, and Compound (22), or a salt or solvate thereof, wherein the weight ratio of Compound (2) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01, or 0.001 to 0.005 of Compound (2) to Compound (10), and the weight ratio of Compound (22) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01, or 0.001 to 0.005 of Compound (22) for Compound (10).

[0154] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (23), or a salt or solvate thereof, wherein the weight ratio of Compound (23) to Formula (IV) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (23) to Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0155] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (23), or a salt or solvate thereof.

[0156] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (23), or a salt or solvate thereof, wherein the weight ratio of Compound (23) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (23) to Compound (10).

[0157] In another embodiment, the present disclosure provides a composition comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (24), or a salt or solvate thereof, wherein the weight ratio of Petition 870250102374, dated 07 / 11 / 2025, p. 69 / 187 65 / 159 Compound (24) for Formula (IV) is from 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (24) for Formula (IV). In another embodiment, the compound of Formula (IV) is Compound (9). In another embodiment, the compound of Formula (IV) is Compound (10).

[0158] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (24), or a salt or solvate thereof.

[0159] In another embodiment, the present disclosure provides a composition comprising Compound (10), or a salt or solvate thereof, and Compound (24), or a salt or solvate thereof, wherein the weight ratio of Compound (24) to Compound (10) is 0.0001 to 0.1, for example, 0.001 to 0.05, 0.001 to 0.01 or 0.001 to 0.005 of Compound (24) to Compound (10).

[0160] In another embodiment, the present disclosure provides a composition comprising a compound from Table 1.

[0161] In another embodiment, the present disclosure provides a composition comprising Compound (10) and at least one other compound from Table 1.

[0162] In another embodiment, the present disclosure provides a composition comprising about 80% to about 99% of Compound (10), for example, about 85% to about 99%, about 90% to about 99% or about 95% to about 99% of Compound (10) and 0.0001% to 5%, for example, 0.001% to 3%, 0.001% to 1%, 0.01% to 1% or 0.1% to 1% of at least one other compound from Table 1.

[0163] In another embodiment, the present disclosure provides a composition comprising about 80% to about 99% of Compound (10), for example, about 85% to about 99%, about 90% to about 99% or about 95% to about 99% of Compound (10) and 0.0001% to 5% of Compound (2), for example, 0.001% to 3%, 0.001% to 1%, 0.01% to 1% or 0.1% to 1% of Compound (2).

[0164] In another embodiment, the present disclosure provides a composition comprising about 80% to about 99% of Compound (10), for example, about 85% to about 99%, about 90% to about 99% or about 95% to about 99% of Compound (10) and 0.0001% to 5% of Compound (21), for example, 0.001% to 3%, 0.001% to 1%, 0.01% to 1% or 0.1% to 1% of Compound (21).

[0165] In another form, the present disclosure provides a composition Petition 870250102374, dated 07 / 11 / 2025, p. 70 / 187 66 / 159 comprising about 80% to about 99% of Compound (10), for example, about 85% to about 99%, about 90% to about 99% or about 95% to about 99% of Compound (10) and 0.0001% to 5% of Compound (2), for example, 0.001% to 3%, 0.001% to 1%, 0.01% to 1% or 0.1% to 1% of Compound (2) and 0.0001% to 5% of Compound (21), for example, 0.001% to 3%, 0.001% to 1%, 0.01% to 1% or 0.1% to 1% of Compound (21).

[0166] In another embodiment, the present disclosure provides a composition comprising about 80% to about 99% of Compound (10), for example, about 85% to about 99%, about 90% to about 99% or about 95% to about 99% of Compound (10) and 0.0001% to 5% of Compound (22), for example, 0.001% to 3%, 0.001% to 1%, 0.01% to 1% or 0.1% to 1% of Compound (22).

[0167] In another embodiment, the present disclosure provides a composition comprising about 80% to about 99% of Compound (10), for example, about 85% to about 99%, about 90% to about 99% or about 95% to about 99% of Compound (10) and 0.0001% to 5% of Compound (23), for example, 0.001% to 3%, 0.001% to 1%, 0.01% to 1% or 0.1% to 1% of Compound (23).

[0168] In another embodiment, the present disclosure provides a composition comprising about 80% to about 99% of Compound (10), for example, about 85% to about 99%, about 90% to about 99% or about 95% to about 99% of Compound (10) and 0.0001% to 5% of Compound (24), for example, 0.001% to 3%, 0.001% to 1%, 0.01% to 1% or 0.1% to 1% of Compound (24).

[0169] This disclosure provides the following specific compositional arrangements with respect to the compositions comprising Compound (10).

[0170] Composition Modality 1. A composition comprising: (i) Compound (10), or a salt or solvate thereof; and (ii) one or more molecules, or a salt or solvate thereof, wherein one or more molecules are selected from the group consisting of Compounds (1)-(9), (11A), (11B), (12)-(19), (20A), (20B), (21)-(26), (27A), (27B) and (28)-(50) of Table 1, or a combination thereof.

[0171] Composition Modality 2. The composition of Composition Modality 1, in which the composition comprises Compound (1) as a Petition 870250102374, dated 07 / 11 / 2025, page 71 / 187 67 / 159 molecule.

[0172] Composition Modality 3. The composition of Composition Modalities 1 or 2, wherein the composition comprises Compound (2) as a molecule.

[0173] Composition Modality 4. The composition of any of the Composition Modalities 1-3, wherein the composition comprises Compound (3) as a molecule.

[0174] Composition Modality 5. The composition of any of the Composition Modalities 1-4, wherein the composition comprises Compound (4) as a molecule.

[0175] Composition Modality 6. The composition of any of the Composition Modalities 1-5, wherein the composition comprises Compound (5) as a molecule.

[0176] Composition Modality 7. The composition of any of the Composition Modalities 1-6, wherein the composition comprises Compound (6) as a molecule.

[0177] Composition Modality 8. The composition of any of the Composition Modalities 1-7, wherein the composition comprises Compound (7) as a molecule.

[0178] Composition Modality 9. The composition of any of the Composition Modalities 1-8, wherein the composition comprises Compound (8) as a molecule.

[0179] Composition Modality 10. The composition of any of the Composition Modalities 1-9, wherein the composition comprises Compound (9) as a molecule.

[0180] Composition Modality 11. The composition of any of the Composition Modalities 1-10, wherein the composition comprises Compound (11A) as a molecule.

[0181] Composition Modality 12. The composition of any of the Composition Modalities 1-11, wherein the composition comprises Compound (11B) as a molecule.

[0182] Composition Modality 13. The composition of any of the Petition 870250102374, dated 07 / 11 / 2025, page 72 / 187 68 / 159 Composition 1-12 modalities, wherein the composition comprises Compound (12) as a molecule.

[0183] Composition Modality 14. The composition of any of the Composition Modalities 1-12, wherein the composition comprises Compound (13) as a molecule.

[0184] Composition Modality 15. The composition of any of the Composition Modalities 1-14, wherein the composition comprises Compound (14) as a molecule.

[0185] Composition Modality 16. The composition of any of the Composition Modalities 1-15, wherein the composition comprises Compound (15) as a molecule.

[0186] Composition Modality 17. The composition of any of the Composition Modalities 1-16, wherein the composition comprises Compound (16) as a molecule.

[0187] Composition Modality 18. The composition of any of the Composition Modalities 1-17, wherein the composition comprises Compound (17) as a molecule.

[0188] Composition Modality 19. The composition of any of the Composition Modalities 1-18, wherein the composition comprises Compound (18) as a molecule.

[0189] Composition Modality 20. The composition of any of the Composition Modalities 1-19, wherein the composition comprises Compound (19) as a molecule.

[0190] Composition Modality 21. The composition of any of the Composition Modalities 1-20, wherein the composition comprises Compound (20A) as a molecule.

[0191] Composition Modality 22. The composition of any of the Composition Modalities 1-21, wherein the composition comprises Compound (20B) as a molecule.

[0192] Composition Modality 23. The composition of any of the Composition Modalities 1-22, wherein the composition comprises Compound (21) as a molecule. Petition 870250102374, dated 07 / 11 / 2025, page 73 / 187 69 / 159

[0193] Composition Modality 24. The composition of any of the Composition Modalities 1-23, wherein the composition comprises Compound (22) as a molecule.

[0194] Composition Modality 25. The composition of any of the Composition Modalities 1-24, wherein the composition comprises Compound (23) as a molecule.

[0195] Composition Modality 26. The composition of any of the Composition Modalities 1-25, wherein the composition comprises Compound (24) as a molecule.

[0196] Composition Modality 27. The composition of any of the Composition Modalities 1-26, wherein the composition comprises Compound (25) as a molecule.

[0197] Composition Modality 28. The composition of any of the Composition Modalities 1-27, wherein the composition comprises Compound (26) as a molecule.

[0198] Composition Modality 29. The composition of any of the Composition Modalities 1-28, wherein the composition comprises Compound (27A) as a molecule.

[0199] Composition Modality 30. The composition of any of the Composition Modalities 1-29, wherein the composition comprises Compound (27B) as a molecule.

[0200] Composition Modality 31. The composition of any of the Composition Modalities 1-30, wherein the composition comprises Compound (28) as a molecule.

[0201] Composition Modality 32. The composition of any of the Composition Modalities 1-31, wherein the composition comprises Compound (29) as a molecule.

[0202] Composition Modality 33. The composition of any of the Composition Modalities 1-32, wherein the composition comprises Compound (30) as a molecule.

[0203] Composition Modality 34. The composition of any of the Composition Modalities 1-33, wherein the composition comprises the Compound Petition 870250102374, dated 07 / 11 / 2025, page 74 / 187 70 / 159 (31) as a molecule.

[0204] Composition Modality 35. The composition of any of the Composition Modalities 1-34, wherein the composition comprises Compound (32) as a molecule.

[0205] Composition Modality 36. The composition of any of the Composition Modalities 1-35, wherein the composition comprises Compound (33) as a molecule.

[0206] Composition Modality 37. The composition of any of the Composition Modalities 1-36, wherein the composition comprises Compound (34) as a molecule.

[0207] Composition Modality 38. The composition of any of the Composition Modalities 1-37, wherein the composition comprises Compound (35) as a molecule.

[0208] Composition Modality 39. The composition of any of the Composition Modalities 1-38, wherein the composition comprises Compound (36) as a molecule.

[0209] Composition Modality 40. The composition of any of the Composition Modalities 1-39, wherein the composition comprises Compound (37) as a molecule.

[0210] Composition Modality 41. The composition of any of the Composition Modalities 1-40, wherein the composition comprises Compound (38) as a molecule.

[0211] Composition Modality 42. The composition of any of the Composition Modalities 1-41, wherein the composition comprises Compound (39) as a molecule.

[0212] Composition Modality 43. The composition of any of the Composition Modalities 1-2, wherein the composition comprises Compound (40) as a molecule.

[0213] Composition Modality 44. The composition of any of the Composition Modalities 1-43, wherein the composition comprises Compound (41) as a molecule.

[0214] Composition Modality 45. The composition of any of the Petition 870250102374, dated 07 / 11 / 2025, page 75 / 187 71 / 159 Composition Modalities 1-44, wherein the composition comprises Compound (42) as a molecule.

[0215] Composition Modality 46. The composition of any of the Composition Modalities 1-45, wherein the composition comprises Compound (43) as a molecule.

[0216] Composition Modality 47. The composition of any of the Composition Modalities 1-46, wherein the composition comprises Compound (44) as a molecule.

[0217] Composition Modality 48. The composition of any of the Composition Modalities 1-47, wherein the composition comprises Compound (45) as a molecule.

[0218] Composition Modality 49. The composition of any of the Composition Modalities 1-48, wherein the composition comprises Compound (46) as a molecule.

[0219] Composition Modality 50. The composition of any of the Composition Modalities 1-49, wherein the composition comprises Compound (47) as a molecule.

[0220] Composition Modality 51. The composition of any of the Composition Modalities 1-50, wherein the composition comprises Compound (48) as a molecule.

[0221] Composition Modality 52. ​​The composition of any of the Composition Modalities 1-51, wherein the composition comprises Compound (49) as a molecule.

[0222] Composition Modality 53. The composition of any of the Composition Modalities 1-52, wherein the composition comprises Compound (50) as a molecule

[0223] Composition Modality 54. The composition of Composition Modality 1, in which the composition comprises Compound (2) and Compound (21) as molecules.

[0224] Composition Modality 55. The composition of Composition Modality 1, in which the composition comprises Compound (2) and Compound (25) as molecules. Petition 870250102374, dated 07 / 11 / 2025, page 76 / 187 72 / 159

[0225] Composition Modality 56. The composition of Composition Modality 1, in which the composition comprises Compound (2) and Compound (37) as molecules.

[0226] Composition Modality 57. The composition of Composition Modality 1, in which the composition comprises Compound (21) and Compound (25) as molecules.

[0227] Composition Modality 58. The composition of Composition Modality 1, in which the composition comprises Compound (21) and Compound (37) as molecules.

[0228] Composition Modality 59. The composition of Composition Modality 1, in which the composition comprises Compound (25) and Compound (37) as molecules.

[0229] Composition Modality 60. The composition of Composition Modality 1, in which the composition comprises Compound (2), Compound (21) and Compound (25) as molecules.

[0230] Composition Modality 61. The composition of Composition Modality 1, in which the composition comprises Compound (2), Compound (21) and Compound (37) as molecules.

[0231] Composition Modality 62. The composition of Composition Modality 1, in which the composition comprises Compound (2), Compound (25) and Compound (37) as molecules.

[0232] Composition Modality 63. The composition of Composition Modality 1, in which the composition comprises Compound (21), Compound (25) and Compound (37) as molecules.

[0233] Composition Modality 64. The composition of Composition Modality 1, in which the composition comprises Compound (2), Compound (21), Compound (25) and Compound (37) as molecules.

[0234] Composition Modality 65. The composition of any of the Composition Modalities 5-66 comprising from about 25% to about 99% of Compound (10), as measured by HPLC and / or GC analysis.

[0235] Composition Modality 66. The composition of Composition Modality 65 comprising about 50% to about 99% of Compound (10), Petition 870250102374, dated 07 / 11 / 2025, p. 77 / 187 73 / 159 as measured by HPLC and / or GC analysis.

[0236] Composition Mode 67. The composition of Composition Mode 67 comprising about 89% to about 99% of Compound (10), as measured by HPLC and / or GC analysis.

[0237] Composition Modality 68. The composition of any of Composition Modalities 5-66 comprising about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98% or about 99% of Compound (10) as measured by HPLC and / or GC analysis.

[0238] Composition Modality 69. The composition of any of the Composition Modalities 5-68 comprising from about 0.000001% to about 10% of one or more molecules, as measured by HPLC and / or GC analysis.

[0239] Composition Mode 70. The composition of Composition Mode 69 comprising from about 0.000001% to about 5% of one or more molecules, as measured by HPLC and / or GC analysis.

[0240] Composition Mode 71. The composition of Composition Mode 69 comprising from about 0.0001% to about 10% of one or more molecules, as measured by HPLC and / or GC analysis.

[0241] Composition Mode 72. The composition of Composition Mode 71 comprising from about 0.0001% to about 5% of one or more molecules, as measured by HPLC and / or GC analysis.

[0242] Composition Mode 72. The composition of Composition Mode 72 comprising from about 0.001% to about 3% of one or more molecules, as measured by HPLC and / or GC analysis.

[0243] Composition Mode 73. The composition of any of the Composition Modes 5-68, wherein the weight ratio of any one or more molecules to Compound (10) is 0.000001 to 0.1.

[0244] Composition Modality 74. A composition comprising Compound (10); and

[0245] (i) from about 0.000001% to about 5% of Compound (2) based on Petition 870250102374, dated 07 / 11 / 2025, p. 78 / 187 74 / 159 HPLC analysis;

[0246] (ii) from about 0.000001% to about 5% of Compound (21) based on HPLC analysis;

[0247] (iii) from about 0.000001% to about 5% of Compound (25) based on HPLC analysis; and / or

[0248] (iv) from about 0.000001% to about 5% of Compound (37) based on HPLC analysis.

[0249] Composition Modality 75. The composition of Composition Modality 74 comprising from about 0.000001% to about 2% of Compound (2) based on HPLC analysis.

[0250] Composition Modality 76. The composition of Composition Modality 75 comprising from about 0.000001% to about 1% of Compound (2) based on HPLC analysis.

[0251] Composition Modality 77. The composition of Composition Modality 76 comprising from about 0.000001% to about 0.5% of Compound (2) based on HPLC analysis.

[0252] Composition Modality 78. The composition of Composition Modality 77 comprising from about 0.000001% to about 0.25% of Compound (2) based on HPLC analysis.

[0253] Composition Modality 79. The composition of Composition Modality 78 comprising from about 0.000001% to about 0.1% of Compound (2) based on HPLC analysis.

[0254] Composition Modality 80. The composition of Composition Modality 76 comprising about 0.001% to about 1% of Compound (2) based on HPLC analysis.

[0255] Composition Modality 81. The composition of Composition Modality 80 comprising about 0.01% to about 1% of Compound (2) based on HPLC analysis.

[0256] Composition Modality 82. The composition of Composition Modality 81 comprising about 0.1% to about 1% of Compound (2) based on HPLC analysis.

[0257] Composition Modality 83. The composition of any of the Petition 870250102374, dated 07 / 11 / 2025, page 79 / 187 75 / 159 Composition Modalities 74-82 comprising about 0.000001% to about 2% of Compound (21) based on HPLC analysis.

[0258] Composition Modality 84. The composition of Composition Modality 83 comprising from about 0.000001% to about 1% of Compound (21) based on HPLC analysis.

[0259] Composition Modality 85. The composition of Composition Modality 84 comprising from about 0.000001% to about 0.5% of Compound (21) based on HPLC analysis.

[0260] Composition Modality 86. The composition of Composition Modality 85 comprising from about 0.000001% to about 0.25% of Compound (21) based on HPLC analysis.

[0261] Composition Modality 87. The composition of Composition Modality 86 comprising from about 0.000001% to about 0.1% of Compound (21) based on HPLC analysis.

[0262] Composition Modality 88. The composition of Composition Modality 84 comprising about 0.001% to about 1% of Compound (21) based on HPLC analysis.

[0263] Composition Modality 89. The composition of Composition Modality 88 comprising about 0.01% to about 1% of Compound (21) based on HPLC analysis.

[0264] Composition Modality 90. The composition of Composition Modality 89 comprising about 0.1% to about 1% of Compound (21) based on HPLC analysis.

[0265] Composition Modality 91. The composition of any of the Composition Modalities 74-90 comprising from about 0.000001% to about 2% of Compound (25) based on HPLC analysis.

[0266] Composition Modality 92. The composition of Composition Modality 91 comprising from about 0.000001% to about 1% of Compound (25) based on HPLC analysis.

[0267] Composition Modality 93. The composition of Composition Modality 92 comprising from about 0.000001% to about 0.5% of Compound (25) based on HPLC analysis. Petition 870250102374, dated 07 / 11 / 2025, page 80 / 187 76 / 159

[0268] Composition Modality 94. The composition of Composition Modality 93 comprising from about 0.000001% to about 0.25% of Compound (25) based on HPLC analysis.

[0269] Composition Modality 95. The composition of Composition Modality 94 comprising from about 0.000001% to about 0.1% of Compound (25) based on HPLC analysis.

[0270] Composition Modality 96. The composition of Composition Modality 92 comprising about 0.001% to about 1% of Compound (25) based on HPLC analysis.

[0271] Composition Modality 97. The composition of Composition Modality 96 comprising about 0.01% to about 1% of Compound (25) based on HPLC analysis.

[0272] Composition Modality 98. The composition of Composition Modality 97 comprising about 0.1% to about 1% of Compound (25) based on HPLC analysis.

[0273] Composition Modality 99. The composition of any of the Composition Modalities 74-98 comprising from about 0.000001% to about 2% of Compound (37) based on HPLC analysis.

[0274] Composition Mode 100. The composition of Composition Mode 99 comprises from about 0.000001% to about 1% of Compound (37) based on HPLC analysis.

[0275] Composition Mode 101. The composition of Composition Mode 100 comprises from about 0.000001% to about 0.5% of Compound (37) based on HPLC analysis.

[0276] Composition Modality 102. The composition of Composition Modality 101 comprising from about 0.000001% to about 0.25% of Compound (37) based on HPLC analysis.

[0277] Composition Modality 103. The composition of Composition Modality 102 comprising from about 0.000001% to about 0.1% of Compound (37) based on HPLC analysis.

[0278] Composition Mode 104. The composition of Composition Mode 100 comprises from about 0.001% to about 1% of Compound (37) with Petition 870250102374, dated 07 / 11 / 2025, page 81 / 187 77 / 159 based on HPLC analysis.

[0279] Composition Modality 105. The composition of Composition Modality 104 comprising about 0.01% to about 1% of Compound (37) based on HPLC analysis.

[0280] Composition Modality 106. The composition of Composition Modality 105 comprising about 0.1% to about 1% of Compound (37) based on HPLC analysis.

[0281] Composition Modality 107. The composition of any of the Composition Modalities 74-106 comprising about 50% to about 99.9% of Compound (10) based on HPLC analysis.

[0282] Composition Modality 108. The composition of Composition Modality 107 comprising about 75% to about 99.9% of Compound (10) based on HPLC analysis.

[0283] Composition Modality 109. The composition of Composition Modality 108 comprising about 80% to about 99.9% of Compound (10) based on HPLC analysis.

[0284] Composition Mode 110. The composition of Composition Mode 109 comprises about 85% to about 99.9% of Compound (10) based on HPLC analysis.

[0285] Composition Modality 111. The composition of Composition Modality 110 comprising about 90% to about 99.9% of Compound (10) based on HPLC analysis.

[0286] Composition Mode 112. The composition of Composition Mode 111 comprising about 95% to about 99.9% of Compound (10) based on HPLC analysis.

[0287] The compositions in this Section II are collectively referred to as “Disclosure Compositions” and individually as “Disclosure Composition”. III. TIRE COMPOSITIONS FOR DISCLOSURE

[0288] In another embodiment, this disclosure provides compositions (collectively referred to as “Disclosure Tire Compositions” or individually as a “Disclosure Tire Composition”) comprising:

[0289] (i) a Disclosure Compound or Composition; and Petition 870250102374, dated 07 / 11 / 2025, p. 82 / 187 78 / 159

[0290] (ii) one or more elastomers; or

[0291] (iii) one or more charges; or

[0292] (iv) one or more rubber chemicals; or

[0293] (v) one or more plasticizers; or

[0294] (vi) one or more antidegradant seconds; or

[0295] (vii) a combination of one or more elastomers, one or more fillers, one or more rubber chemicals, one or more plasticizers and / or one or more second antidegradants.

[0296] In some embodiments, a Disclosure Tire Compound comprises about 0.1% w / w to about 99% w / w, for example, about 15% w / w to about 85% w / w of a Disclosure Compound or Composition. In some modalities, the composition comprises approximately 0.1% w / w, approximately 1% w / w, approximately 1% w / w, approximately 5% w / w, approximately 1% w / w, approximately 15% w / w, approximately 1% w / w, approximately 25% w / w, approximately 1% w / w, approximately 35% w / w, approximately 1% w / w, approximately 45% w / w, approximately 1% w / w, approximately 55% w / w, approximately 1% w / w, approximately 65% ​​w / w, approximately 1% w / w, approximately 75% w / w, approximately 1% w / w, approximately 85% w / w, approximately 1% w / w, approximately 95% w / w, approximately 5% w / w w / w about 15% in w / w, from about 5% in w / w about 25% in w / w, from about 5% in w / w about 35% in w / w, from about 5% in w / w about 45% in w / w, from about 5% in w / w about 55% in w / w,from about 5% w / w about 65% w / w, from about 5% w / w about 75% w / w, from about 5% w / w about 85% w / w, from about 5% w / w about 95% w / w, from about 15% w / w about 25% w / w, from about 15% w / w in w / w, from about 25% in w / w about 35% in w / w, about 25% in w / w about 45% in w / w, about 25% in w / w about 55% in w / w, about 25% in w / w about 65% in w / w, about 25% in w / w about 75% in w / w, 25% in p / pa approx. 85% in p / p, approximately 25% in p / pa, approximately 95% in p / p, approximately 35% in p / pa, approximately 45% in p / p, approximately 35% in, Petition 870250102374, dated 07 / 11 / 2025, p. 83 / 187 79 / 159 p / pa about 55% in w / w, about 35% in w / w about 65% in w / w about 55% w / w, about 45% w / w about 65% w / w, about 45% w / w about 75% w / w, about 45% w / w about 85% w / w, about 45% w / w about 95% w / w, about 55% w / w about 65% w / w, of ca. 55% w / w approximately 75% w / w, approximately 55% w / w approximately 85% w / w, approximately 55% w / w approximately 95% w / w, approximately 65% ​​w / w approximately 75% w / w, approximately 65% ​​w / w approximately 85% w / w, approximately 65% ​​w / w approximately 95% w / w, approximately 75% w / w approximately 85% w / w, approximately 75% w / w approximately 95% w / w, or approximately 85% w / w approximately 95% w / w of a Compound or Composition of the Disclosure.

[0297] In some embodiments, a Disclosure Tire Compound comprises approximately 50% by w / w of a Disclosure Compound or Compound. In some embodiments, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 10% w / w, approximately 15% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w or approximately 95% w / w of a Disclosure Compound or Composition.

[0298] In another embodiment, a Disclosure Tire Compound comprises a Disclosure Compound or Composition and one or more elastomers.

[0299] The term “elastomer,” as used herein, is a polymer with viscoelasticity (i.e., having viscosity and elasticity) that typically has low intermolecular forces, a low Young’s modulus, and high strain at failure. Elastomers can generally be crosslinked by heating in the presence of one or more crosslinking agents, a process called curing or vulcanization. Rubber is a type of elastomer. Non-limiting types of rubber include natural rubber (NR), synthetic rubber, and mixtures thereof. The term “natural rubber,” as used herein, refers to a natural elastomer that can be obtained from Hevea rubber trees. Non-limiting types of synthetic rubbers include rubbers Petition 870250102374, dated 07 / 11 / 2025, page 84 / 187 80 / 159 unsaturated rubbers, saturated rubbers, rubbers with fluoro and fluoroalkyl or fluoroalkoxy substituent groups in the polymer chain (FKM), silicone rubbers (Q), and mixtures thereof. Non-limiting examples of unsaturated rubbers include polyisoprene rubber (IR), butyl rubber (IIR), polybutadiene rubber (BR), styrene-isoprene-butadiene rubber (SIBR), styrene-butadiene rubber (SBR), nitrile-butadiene rubber (NBR), chloroprene rubber (CR), ethylene-propylene-diene rubber (EPDM), and mixtures thereof. These unsaturated rubbers undergo cyclization and crosslinking reactions that lead to hardening of the aged part. As oxidation occurs, these vulcanizates harden and eventually become brittle products. Partial oxidation of vulcanized materials leads to performance losses when used in applications such as vehicle tire sidewalls.Saturated rubbers are rubbers that do not contain C=C unsaturation and include, but are not limited to, acrylic rubber (ACM), chlorinated polyethylene (CM), chlorosulfonated polyethylene (CSM), polychloromethyloxirane (CO), ethylene-ethyl acrylate copolymer (EAM), epichlorohydrin rubber (ECO), ethylene propylene rubber (EPM), ethylene vinyl acetate copolymer (EVM), rubbers with fluoro and fluoroalkyl or fluoroalkoxy substituent groups in the polymer chain (FKM), silicone rubber (Q), and mixtures thereof.

[0300] In some embodiments, natural rubber comprises rubber derived from an alternative rubber plant. The term “natural rubber comprises rubber derived from an alternative rubber plant”, as used herein, refers to a natural elastomer that can be obtained from “non-Hevea” sources. In some embodiments, the alternative rubber plant is Parthenium argentatum (guayule) or Taraxacum kok-saghyz (Russian dandelion).

[0301] In some embodiments, one or more elastomers also comprise recycled rubber. The term “recycled rubber”, as used herein, refers to an elastomer that has been recovered from discarded materials, such as used tires.

[0302] In some embodiments, a Disclosure Tire Compound comprises from about 15% by weight to about 99% by weight of one or more elastomers. In some embodiments, a Disclosure Tire Compound comprises from about 15% by weight to about 85% by weight of one or more Petition 870250102374, dated 07 / 11 / 2025, p. 85 / 187 81 / 159 elastomers. In some forms, the composition comprises from about 1% by weight to about 5% by weight, from about 1% by weight to about 15% by weight, from about 1% by weight to about 25% by weight, from about 1% by weight to about 35% by weight, from about 1% by weight to about 45% by weight, from about 1% by weight to about 55% by weight, from about 1% by weight to about 65% by weight, from about 1% by weight to about 75% by weight, from about 1% by weight to about 85% by weight, from about 1% by weight to about 95% by weight, from about 5% by weight to about 15% by weight, from about 5% by weight to about 25% by weight, from about 5% by weight to about 35% w / w, about 5% w / w about 45% w / w, about 5% w / w about 55% w / w, about 5% w / w about 65% w / w, about 5% w / w about 75% w / w, about 5% w / w about 85% w / w, about from 5% w / w to around 95% w / w, from around 15% w / w to around 25% w / w,search 15% em p / pa search 35% em p / p, search 15% em p / pa search 45% em p / p, search 15% em p / pa search 55% em p / p, search 15% em p / pa search 65% em p / p, search 15% em p / pa search 75% em p / p, search 15% em p / pa search 95% em p / p search 25% em p / pa search 35% em p / p search 25% em p / pa search 45% em p / p search 25% em p / pa search 55% em p / p search 25% em p / pa search 65% em p / p search 25% em p / pa search 75% em p / p, looking for 25% em p / pa search 85% em p / p search 25% em p / pa search 95% em p / p search 35% em p / pa search 45% em p / p search 35% em p / pa search 55% em p / p search 35% em p / pa search 65% em p / p search 35% em p / pa search 75% in p / p, search 35% in p / pa search 85% in p / p, search 35% in p / pa search 95% in p / p, search 45% in p / pa search 55% in p / p, search 45% in p / pa search 65% in p / p,of about 45% w / w about 75% w / w, of about 45% w / w about 85% w / w %, of about 45% w / w about 95% w / w, of about 55% w / w about 65% w / w, of about 55% w / w about 75% w / w, of about 55% w / w about 85% w / w, about 55% w / w about 95% w / w, about 65% w / w about 75% w / w, about 65% w / w about 85% w / w, about 65% w / w about 95% w / w, about 75% w / w around 85% w / w, of around from 75% p / p to approximately 95% p / p, or approximately 85%, Petition 870250102374, dated 07 / 11 / 2025, p. 86 / 187 82 / 159 in p / p, approximately 95% in p / p of one or more elastomers.

[0303] In some embodiments, a Disclosure Tire Compound comprises approximately 50% by w / w of one or more elastomers. In some embodiments, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 10% w / w, approximately 15% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w or approximately 95% w / w of one or more elastomers.

[0304] The term “phr”, as used herein, refers to parts per hundred parts of rubber by weight. The parts by weight of the individual components are based on 100 parts by weight of the total mass of one or more elastomers present in the composition.

[0305] In some embodiments, a Disclosure Tire Compound comprises from about 1 phr to about 5 phr of a Disclosure Compound or Compound. In some embodiments, the composition comprises from about 0.01 phr to about 0.1 phr, from about 0.01 phr to about 0.5 phr, from about 0.01 phr to about 1 phr, from about 0.01 phr to about 2 phr, from about 0.01 phr to about 3 phr, from about 0.01 phr to about 4 phr, from about 0.01 phr to about 5 phr, from about 0.01 phr to about 7.5 phr, from about 0.01 phr to about 10 phr, from about 0.01 phr to about 20 phr, from about 0.1 phr to about 0.5 phr, from about 0.1 phr to about 1 phr, from about 0.1 phr to about 2 phr, from about 0.1 phr to about 3 phr, from about 0.1 phr to about 4 phr, from about 0.1 phr to about 5 phr, from about 0.1 phr to about 7.5 phr, from about 0.1 phr to about 10 phr, from about 0.1 phr to about 20 phr, from about 1 phr to about 2 phr,from about 1 phr to about 3 phr, from about 1 phr to about 4 phr, from about 1 phr to about 7.5 phr, from about 1 phr to about 10 phr, from about 1 phr to about 20 phr, from about 2 phr to about 3 phr, from about 2 phr to about 4 phr, from about 2 phr to about 5 phr, from about 2 phr to about 7.5 phr, from about 2 phr to about 10 phr, from about 2 phr to about 20 phr, from about 3 phr to about 4 phr, from about 3 phr to about 5 phr, from about 3 phr to about 7.5 phr, from about 3 phr to about 10 phr, from about 3 phr to about 20 phr, approximately 4, Petition 870250102374, dated 07 / 11 / 2025, page 87 / 187 83 / 159 phr to about 5 phr, from about 4 phr to about 7.5 phr, from about 4 phr to about 10 phr, from about 4 phr to about 20 phr, from about 5 phr to about 7.5 phr, from about 5 phr to about 10 phr, from about 5 phr to about 20 phr, from about 7.5 phr to about 10 phr, from about 7.5 phr to about 20 phr, or from about 10 phr to about 20 phr of a Disclosure Compound or Composition.

[0306] In some embodiments, a Disclosure Tire Compound comprises about 3 phr of a Disclosure Compound or Composition. In some embodiments, the composition comprises about 0.01 phr, about 0.1 phr, about 0.5 phr, about 1 phr, about 2 phr, about 3 phr, about 4 phr, about 5 phr, about 7.5 phr, about 10 phr or about 20 phr of a Disclosure Compound or Composition.

[0307] In some embodiments, a Disclosure Tire Compound comprises a Disclosure Compound or Compound and one or more fillers.

[0308] The term “filler,” as used herein, is a substance that reinforces an elastomeric composition or imparts to an elastomeric composition other properties, including, but not limited to, expanding the volume of the composition. Non-limiting examples of fillers include carbon black, silica, kaolin, calcium silicate, talc, carbon nanotubes (CNTs), high-carbon fibers (HCFs), graphite, graphene, aluminosilicates, starch and fibers, and combinations thereof.

[0309] In some embodiments, the filler is derived from natural sources. For example, silica can be derived from rice husks.

[0310] In some forms, a Disclosure Tire Compound comprises approximately 15% by weight to approximately 85% by weight of one or more loads. In some modalities, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 1% w / w, approximately 15% w / w, approximately 1% w / w, approximately 25% w / w, approximately 1% w / w, approximately 35% w / w, approximately 1% w / w, approximately 45% w / w, approximately 1% w / w, approximately 55% w / w, approximately 1% w / w, approximately 65% ​​w / w, approximately 1% w / w, approximately 75% w / w, approximately 1% w / w, approximately 85% w / w, approximately 95% w / w, approximately 5% w / w, approximately 15% w / w, approximately 5% w / w w / w about 25% w / w, about 5% w / w about 35% w / w, about 5% w / w about 45% w / w, about 5% w / w about Petition 870250102374, dated 07 / 11 / 2025, p. 88 / 187 84 / 159 55% em p / p, search 5% em p / pa search 65% em p / p, search 5% em p / pa search 75% em p / p, search 5% em p / pa search 85% em p / p, search 5% em p / pa search 95% em p / p, search 15% em p / pa search 25% em p / p, search from 15% em p / pa search 35% em p / p, search 15% em p / pa search 45% em p / p, search 15% em p / pa search 55% em p / p, search 15% em p / pa search 65% em p / p, search 15% em p / pa search 75% em p / p, search 15% em p / pa search of 95% em p / p, looking for 25% in p / pa looking for 35% in p / p, looking for 25% in p / pa looking for 45% in p / p, looking for 25% in p / pa looking for 55% in p / p, looking for 25% in p / pa looking for 65% in p / p, looking for 25% in p / pa looking for 75% in p / p, looking for 25% em p / pa search 85% em p / p, search 25% em p / pa search 95% em p / p, search 35% em p / pa search 45% em p / p, search 35% em p / pa search 55% em p / p, search 35% em p / pa search 65% em p / p,about 35% w / w about 75% w / w, about 35% w / w about 85% w / w, about 35% w / w about 95% w / w, about 45% w / w about 55% w / w, about 45% w / w about 65% w / w, about 45% w / w about 75% w / w, about 45% w / w about 85% w / w %, about 45% w / w about 95% w / w, about 55% w / w about 65% w / w, about 55% w / w about 75% w / w, about 55% w / w about 85% w / w, approx. from 55% p / pa to approximately 95% p / p, from approximately 65% ​​p / pa to approximately 75% p / p, from approximately 65% ​​p / pa to approximately 85% p / p, from approximately 65% ​​p / pa to approximately 95% p / p, from approximately 75% p / pa to approximately 85% p / p, from approximately 75% p / pa to approximately 95% p / p, or from approximately 85% p / pa to approximately 95% p / p of one or more loads.

[0311] In some forms, a Disclosure Tire Composition comprises approximately 50% by weight (w / w) of one or more loads. In some forms, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 10% w / w, approximately 15% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w or approximately 95% w / w of one or more fillers. Petition 870250102374, dated 07 / 11 / 2025, p. 89 / 187 85 / 159

[0312] In some embodiments, a Disclosure Tire Compound comprises from about 30 phr to about 500 phr of one or more loads. In some embodiments, the composition comprises from about 30 phr to about 50 phr, from about 30 phr to about 100 phr, from about 30 phr to about 150 phr, from about 30 phr to about 200 phr, from about 30 phr to about 250 phr, from about 30 phr to about 300 phr, from about 30 phr to about 350 phr, from about 30 phr to about 400 phr, from about 30 phr to about 450 phr, from about 30 phr to about 500 phr, from about 50 phr to about 100 phr, from about 50 phr to about 150 phr, from about 50 phr to about 200 phr, from about 50 phr to about 250 phr, from about 50 phr to about 300 phr, from about 50 phr to about 350 phr, from about 50 phr to about 400 phr, from about 50 phr to about 450 phr, from about 50 phr to about 500 phr, from about 100 phr to about 150phr,from about 100 phr to about 200 phr, from about 100 phr to about 250 phr, from about 100 phr to about 300 phr, from about 100 phr to about 350 phr, from about 100 phr to about 400 phr, from about 100 phr to about 450 phr, from about 100 phr to about 500 phr, from about 150 phr to about 200 phr, from about 150 phr to about 250 phr, from about 150 phr to about 300 phr, from about 150 phr to about 350 phr, from about 150 phr to about 400 phr, from about 150 phr to about 450 phr, from about 150 phr to about 500 phr, from about 200 phr to about 250 phr, from about 200 phr to about 300 phr, from about 200 phr to about 350 phr, from about 200 phr to about 400 phr, from about 200 phr to about 450 phr, from about 200 phr to about 500 phr, from about 250 phr to about 300 phr, from about 250 phr to about 350 phr, from about 250 phr to about 400 phr, from about 250 phr to about 450 phr, from about 250 phr to about 500 phr,from about 300 phr to about 350 phr, from about 300 phr to about 400 phr, from about 300 phr to about 450 phr, from about 300 phr to about 500 phr, from about 350 phr to about 400 phr, from about 350 phr to about 450 phr, from about 350 phr to about 500 phr, from about 400 phr to about 450 phr, from about 400 phr to about 500 phr, or from about 450 phr to about 500 phr of one or more loads.

[0313] In some embodiments, a Disclosure Tire Compound comprises approximately 300 phr of one or more loads. In some embodiments, the compound comprises approximately 30 phr, approximately 50 phr, approximately 100 phr, approximately Petition 870250102374, dated 07 / 11 / 2025, p. 90 / 187 86 / 159 of 150 phr, approximately 200 phr, approximately 250 phr, approximately 350 phr, approximately 400 phr, approximately 450 phr, or approximately 500 phr of one or more loads.

[0314] In some embodiments, a Disclosure Tire Composition comprises a Disclosure Compound or Composition and one or more rubber chemicals. The term “rubber chemicals,” as used herein, refers to a compound or substance used to facilitate the vulcanization of rubber. Rubber chemicals include, but are not limited to, vulcanizing agents, accelerators, activators, and pre-vulcanization inhibitors.

[0315] The term “vulcanization,” as used herein, refers to a process in which cross-links are formed between elastomers to effect changes in the material properties of the elastomers. In particular, vulcanization typically increases the stiffness and durability of elastomers. Vulcanization is carried out at room temperature or at elevated temperatures, depending on the nature of the elastomer(s), filler(s), and rubber chemical(s) used. The term “curing” is also used in the art to describe this process.

[0316] The term “vulcanizing agent,” as used herein, refers to any substance that permits crosslinking between elastomers. Vulcanizing agents may permit crosslinking between separate polymer chains of an elastomer by various mechanisms, including, but not limited to, the formation of covalent bonds between the vulcanizing agent and two or more separate polymer chains or the generation of radical species in separate polymer chains that may combine to form covalent bonds between the two polymer chains. Non-limiting examples of vulcanizing agents include sulfur, peroxides, vulcanized vegetable oil, forceps, and resins. Non-limiting examples of sulfur include octasulfur (S8), cyclododecasulfur (S12), and polymeric sulfur.Non-limiting examples of peroxides include benzoyl peroxide, dicumyl peroxide (DC), 2,5-dimethyl-2,5-di-(tert-butylperoxy)-3-hexyne (2,5 Tri), 2,5-dimethyl-2,5-di(tert-butylperoxy)hexane (DDPH), di-(2-tert-butylperoxyisopropyl)benzene (VC), butyl-4,4-di-(tert-butylperoxy)valerate (VAL), and 1,1-di(tert-butylperoxy)-3,3,5-trimethylcyclohexane (TMC). Non-limiting examples of resins include bonding resins. The term "bonding resin," as used herein, refers to a chemical, such as resorcinol formaldehyde resins and phenolic resins, that reacts with... Petition 870250102374, dated 07 / 11 / 2025, page 91 / 187 87 / 159 methylene donors (such as hexamethylenetetramine (HMTA) or hexamethoxymethylmelamine (HMMM)) to promote adhesion.

[0317] The term “accelerator,” as used herein, refers to any substance that increases the kinetics of vulcanization. In some embodiments, accelerators allow vulcanization to be carried out at lower temperatures and / or allow the vulcanizing agent, for example, sulfur, to be used more efficiently. Non-limiting examples of accelerators include guanidines, thiazoles, sulfenamides, thiurams, dithiocarbamates, xanthates, and thiophosphates. Non-limiting examples of guanidines include diphenylguanidine (DPG). Non-limiting examples of thiazoles include 2-mercaptobenzothiazole (MBT), zinc 2-mercaptobenzothiazole (ZMBT), mercaptobenzothiazole disulfide (MBTS), and N-tert-butyl-2-benzothiazole sulfenimide (TBSI).Non-limiting examples of sulfenamides include N-tert-butyl-2-benzothiazolesulfenamide (TBBS), N-cyclohexylbenzothiazole-2-sulfenamide (CBS), dicyclohexyl-2-benzothiazolesulfenamide (DCBS), N-oxydiethylene benzothiazole sulfenamide (OBTS), N-oxydiethylenethiocarbamyl-N'-oxydiethylene sulfenamide (OTOS), and thiocarbamyl sulfenamide. Non-limiting examples of thiurams include dithioperoxyanhydride dimethylcarbamothioic acid (thiram), dipentamethylene thiuram tetrasulfide (DPIT), tetrabenzyl thiuram disulfide (TBzTD), tetraethylthiuram disulfide (TETD), tetramethylthiuram disulfide (TMTD), and tetramethylthiuram monosulfide (TMTM). Non-limiting examples of dithiocarbamates include zinc dimethyldithiocarbamate (ZDMC), zinc diethyldithiocarbamate (ZDEC), zinc dibutyldithiocarbamate (ZDBC), nickel dibutyldithiocarbamate (NDBC), sodium dibenzyldithiocarbamate (SBEC), sodium diethyldithiocarbamate (SDEC), tellurium diethyldithiocarbamate (TDEC), and zinc dibenzyldithiocarbamate (ZEBC).

[0318] The term “activator,” as used herein, refers to any substance that activates a vulcanizing agent and enables it to cross-link elastomers as described above. Activators may act through various mechanisms, including, but not limited to, forming chemical complexes with accelerators or coordinating with sulfur (when sulfur is used as a vulcanizing agent). Non-limiting examples of activators include metal oxides, acids, and metal complexes. Non-limiting examples of metal oxides include zinc oxide, magnesium oxide, and lead oxide. Examples Petition 870250102374, dated 07 / 11 / 2025, page 92 / 187 88 / 159 Non-limiting examples of acids include stearic acid and lauric acid. Non-limiting examples of metal complexes include zinc ethylhexanoate.

[0319] The term “pre-vulcanization inhibitor”, as used herein, refers to compounds that retard the onset and / or rate of vulcanization. These compounds are also called “retarders”. Non-limiting examples of pre-vulcanization inhibitors include N-(cyclohexylthio)phthalimide (CTP), benzoic anhydride, salicylic anhydride, and phthalic anhydride.

[0320] In some embodiments, a Disclosure Tire Compound comprises from about 15% by w / w to about 85% by w / w of one or more rubber chemicals. In some modalities, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 1% w / w, approximately 15% w / w, approximately 1% w / w, approximately 25% w / w, approximately 1% w / w, approximately 35% w / w, approximately 1% w / w, approximately 45% w / w, approximately 1% w / w, approximately 55% w / w, approximately 1% w / w, approximately 65% ​​w / w, approximately 1% w / w, approximately 75% w / w, approximately 1% w / w, approximately 85% w / w, approximately 95% w / w, approximately 5% w / w, approximately 15% w / w, approximately 5% in w / w about 25% in w / w, in about 5% in w / w about 35% in w / w, in about 5% in w / w about 45% in w / w, in about 5% in w / w about 55% in w / w, in about 5% in w / w about 65% in w / w, in about 5% in w / w about 75% in p / p,search 5% em p / pa search 85% em p / p, search 5% em p / pa search 95% em p / p, search 15% em p / pa search 25% em p / p, search 15% em p / pa search 35% em p / p, search 15% em p / pa search 45% em p / p, search 15% em p / pa search 55% in p / p, search 15% in p / pa search 65% in p / p, search 15% in p / pa search 75% in p / p, search 15% in p / pa search 95% in p / p, search 25% in p / pa search 35% in p / p, search 25% in p / pa search 45% em p / p, looking for 25% em p / pa search 55% em p / p, search 25% em p / pa search 65% em p / p, search 25% em p / pa search 75% em p / p, search 25% em p / pa search 85% em p / p, search 25% em p / pa search 95% em p / p, search 35% em p / pa search 45% em p / p, search 35% em p / pa search 55% em p / p, search 35% em p / pa search 65% em p / p, search 35% em p / pa search 75% em p / p, search 35% em p / pa search 85% em p / p, search 35% em, Petition 870250102374, dated 07 / 11 / 2025, p. 93 / 187 89 / 159 p / pa approximately 95% p / p, approximately 45% p / p, approximately 55% p / p, approximately 45% p / pa, approximately 65% ​​p / p, approximately 45% p / pa, approximately 75% p / p, approximately 45% p / pa, approximately 85% p / p, approximately 45% p / pa, approximately 95% p / p, approximately 55% p / pa, approximately 65% ​​p / p, approximately 55% p / pa, approximately 75% p / p, approximately 55% p / pa, approximately 85% p / p, approximately 55% p / pa, approximately 95% p / p, approximately 65% ​​p / pa, approximately p / p, of one or more rubber chemicals.

[0321] In some embodiments, a Disclosure Tire Compound comprises approximately 15% by w / w of one or more rubber chemicals. In some embodiments, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 10% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 50% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w or approximately 95% w / w of one or more rubber chemicals.

[0322] In some embodiments, a Disclosure Tire Compound comprises from about 1 phr to about 20 phr of one or more rubber chemicals.In some embodiments, the composition comprises from about 0.1 phr to about 1 phr, from about 0.1 phr to about 5 phr, from about 0.1 phr to about 10 phr, from about 0.1 phr to about 15 phr, from about 0.1 phr to about 20 phr, from about 0.1 phr to about 25 phr, from about 0.1 phr to about 30 phr, from about 0.1 phr to about 35 phr, from about 0.1 phr to about 40 phr, from about 1 phr to about 5 phr, from about 1 phr to about 10 phr, from about 1 phr to about 15 phr, from about 1 phr to about 25 phr, from about 1 phr to about 30 phr, from about 1 phr to about 35 phr, from about 1 phr to about 40 phr, from about 5 phr to about 10 phr, from about 5 phr to about 15 phr, from about 5 phr to about 20 phr, from about 5 phr to about 25 phr, from about 5 phr to about 30 phr, from about from 5 phr to about 35 phr, from about 5 phr to about 40 phr, from about. Petition 870250102374, dated 07 / 11 / 2025, page 94 / 187 90 / 159 from 10 phr to about 15 phr, from about 10 phr to about 20 phr, from about 10 phr to about 25 phr, from about 10 phr to about 30 phr, from about 10 phr to about 35 phr, from about 10 phr to about 40 phr, from about 15 phr to about 20 phr, from about 15 phr to about 25 phr, from about 15 phr to about 30 phr, from about 15 phr to about 35 phr, from about 15 phr to about 40 phr, from about 20 phr to about 25 phr, from about 20 phr to about 30 phr, from about 20 phr to about 35 phr, from about 20 phr to about 40 phr, from about 25 phr to about 30 phr, from about 25 phr to about 35 phr, from about 25 phr to about 40 phr, from about 30 phr to about 35 phr, from about 30 phr to about 40 phr, or from about 35 phr to about 40 phr of one or more chemical products of borracha.

[0323] In some embodiments, a Disclosure Tire Compound comprises about 10 phr of one or more rubber chemicals. In some embodiments, the compound comprises about 0.1 phr, about 1 phr, about 5 phr, about 15 phr, about 20 phr, about 25 phr, about 30 phr, about 35 phr or about 40 phr of one or more rubber chemicals.

[0324] The term “plasticizer,” as used herein, refers to a processing aid used to reduce viscosity, increase plasticity, and / or extend the volume of a composition. Plasticizers facilitate the mixing and forming process of a composition comprising an elastomer before the composition is vulcanized. Non-limiting examples of plasticizers include mineral oils (paraffinic, aromatic, or naphthenic), organic esters, resins, waxes, ester plasticizers, and naturally derived oils such as soybean oil, vegetable oil, or orange oil.

[0325] In some embodiments, a Disclosure Tire Compound comprises approximately 15% by weight to approximately 85% by weight of one or more plasticizers. In some modalities, the composition comprises approximately 1% w / w to approximately 5% w / w, approximately 1% w / w to approximately 15% w / w, approximately 1% w / w to approximately 25% w / w, approximately 1% w / w to approximately 35% w / w, approximately 1% w / w to approximately 45% w / w, approximately 1% w / w to approximately 55% w / w, approximately 1% w / w to approximately 65% ​​w / w, approximately 1% w / w to approximately 75% w / w, approximately 1% w / w to approximately 85% w / w, approximately 1% w / w to approximately 95% w / w, approximately 5% w / w to approximately 15% Petition 870250102374, dated 07 / 11 / 2025, p. 95 / 187 91 / 159 em p / p, search 5% em p / pa search 25% em p / p, search 5% em p / pa search 35% em p / p, search 5% em p / pa search 45% em p / p, search 5% em p / pa search 55% em p / p, search 5% em p / pa search 65% em p / p, search 5% em p / pa search 75% em p / p, search 5% em p / pa search 85% em p / p, search 5% em p / pa search 95% em p / p, search 15% em p / pa search 25% em p / p, search 15% em p / pa search 35% em p / p, search 15% em p / pa search for 45% em p / p, looking for 15% in p / pa looking for 55% in p / p, looking for 15% in p / pa looking for 65% in p / p, looking for 15% in p / pa looking for 75% in p / p, looking for 15% in p / pa looking for 95% in p / p, looking for 25% in p / pa looking for 35% in p / p, looking for 25% em p / pa search 45% em p / p, search 25% em p / pa search 55% em p / p, search 25% em p / pa search 65% em p / p, search 25% em p / pa search 75% em p / p, search 25% em p / pa search 85% em p / p,search 25% em p / pa search 95% em p / p, search 35% em p / pa search 45% em p / p, search 35% em p / pa search 55% em p / p, search 35% em p / pa search 65% em p / p, search 35% em p / pa search 75% em p / p, search 35% em p / pa search 85% em p / p search 35% em p / pa search 95% em p / p search 45% em p / pa search 55% em p / p search 45% em p / pa search 65% em p / p search 45% em p / pa search 75% em p / p search 45% em p / pa search 85% em p / p %, search 45% em p / pa search 95% em p / p search 55% em p / pa search 65% em p / p search 55% em p / pa search 75% em p / p search 55% em p / pa search 85% em p / p search 55% em p / pa search 95% em p / p search 65% em p / pa search 75% em p / p, search 65% em p / pa search 85% em p / p, search 65% em p / pa search 95% em p / p, search 75% em p / pa search 85% em p / p, search 75% em p / pa search 95% em p / p,or approximately 85% by weight (w / w) or approximately 95% by weight (w / w) of one or more plasticizers.

[0326] In some embodiments, a Disclosure Tire Compound comprises approximately 15% by w / w of optionally one or more plasticizers. In some embodiments, the compound comprises approximately 1% by w / w, approximately 5% by w / w, approximately 10% by w / w, approximately 20% by w / w, approximately 25% by w / w, approximately 30% by w / w, approximately 35% by w / w, approximately 40% by w / w, approximately 45% by w / w, approximately 50% by w / w, approximately 55% by w / w, approximately 60% by w / w, approximately 65% ​​by w / w, Petition 870250102374, dated 07 / 11 / 2025, p. 96 / 187 92 / 159 approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w or approximately 95% w / w of one or more plasticizers.

[0327] In some embodiments, a Disclosure Tire Compound comprises from about 1 phr to about 20 phr of, optionally, one or more plasticizers. In some embodiments, the composition comprises from about 0.1 phr to about 1 phr, from about 0.1 phr to about 5 phr, from about 0.1 phr to about 10 phr, from about 0.1 phr to about 15 phr, from about 0.1 phr to about 20 phr, from about 0.1 phr to about 25 phr, from about 0.1 phr to about 30 phr, from about 0.1 phr to about 35 phr, from about 0.1 phr to about 40 phr, from about 1 phr to about 5 phr, from about 1 phr to about 10 phr, from about 1 phr to about 15 phr, from about 1 phr to about 25 phr, from about 1 phr to about 30 phr, from about 1 phr to about 35 phr, from about 1 phr to about 40 phr, from about 5 phr to about 10 phr, from about 5 phr to about 15 phr, from about 5 phr to about 20 phr, from about 5 phr to about 25 phr, from about 5 phr to about 30 phr,from about 5 phr to about 35 phr, from about 5 phr to about 40 phr, from about 10 phr to about 15 phr, from about 10 phr to about 20 phr, from about 10 phr to about 25 phr, from about 10 phr to about 30 phr, from about 10 phr to about 35 phr, from about 10 phr to about 40 phr, from about 15 phr to about 20 phr, from about 15 phr to about 25 phr, from about 15 phr to about 30 phr, from about 15 phr to about 35 phr, from about 15 phr to about 40 phr, from about 20 phr to about 25 phr, from about 20 phr to about from 30 phr, from about 20 phr to about 35 phr, from about 20 phr to about 40 phr, from about 25 phr to about 30 phr, from about 25 phr to about 35 phr, from about 25 phr to about 40 phr, from about 30 phr to about 35 phr, from about 30 phr to about 40 phr, or from about 35 phr to about 40 phr of one or more plasticizers.

[0328] In some embodiments, a Disclosure Tire Compound comprises about 10 phr of one or more plasticizers. In some embodiments, the compound comprises about 0.1 phr, about 1 phr, about 5 phr, about 15 phr, about 20 phr, about 25 phr, about 30 phr, about 35 phr or about 40 phr of one or more plasticizers.

[0329] In some forms, a Disclosure Tire Compound also includes a second or even additional antidegradant(s) that do not Petition 870250102374, dated 07 / 11 / 2025, p. 97 / 187 93 / 159 is a Disclosure Compound or Composition. In some embodiments, the additional antidegradant is an antioxidant, a heat stabilizer, a light stabilizer, or a fatigue crack stabilizer. In some embodiments, the second antidegradant is an antiozonant. Non-limiting examples of antidegradants include paraphenylenediamines (PPDs), trimethyldihydroquinolines (TMQs), phenolics or hindered phenolics, alkylated diphenylamines (DPAs), diphenylamine ketone condensates and natural antidegradants, quinones, hydroquinones, amines, hindered amines, paraffinic or microcrystalline waxes. Non-limiting examples of ppds include n1-(4-methylpentan-2-yl)-n4-phenylbenzene-1,4diamine (6PPD), n-(1,4-dimethylpentyl)-n'uid), 1-phenyl-n4-(propan-2-yl)benzene-1,4diamine (IPPD), n,n'-di-sec-butyl-p-phenylenediamine (44pd), n,n'-bis(1,3-dimethylbutyl)-pphenylenediamine (66PD), n,n'-bis(1,4-dimethylpentyl)-p-phenylenediamine (77PD) and n'dioctyl-p-phenylenediamine (88PD).Non-limiting examples of TMQs include 2,2,4-trimethyl-1,2-dihydroquinoline and oligomers or polymers thereof.

[0330] In some embodiments, a Disclosure Tire Compound comprises approximately 15% by w / w of approximately 85% by w / w of a second antidegradant. In some modalities, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 1% w / w, approximately 15% w / w, approximately 1% w / w, approximately 25% w / w, approximately 1% w / w, approximately 35% w / w, approximately 1% w / w, approximately 45% w / w, approximately 1% w / w, approximately 55% w / w, approximately 1% w / w, approximately 65% ​​w / w, approximately 1% w / w, approximately 75% w / w, approximately 1% w / w, approximately 85% w / w, approximately 95% w / w, approximately 5% w / w, approximately 15% w / w, approximately 5% w / w w / w about 25% in w / w, about 5% in w / w about 35% in w / w, about 5% in w / w about 45% in w / w, about 5% in w / w about 55% in w / w, about 5% in w / w about 65% in w / w, about 5% in w / w about 75% in p / p,of about 5% in w / w about 85% in w / w, of about 5% in w / w about 95% in w / w, of about 15% in w / w about 25% in w / w, of about 15% in w / w about 35% in w / w about 55% in w / w, about 15% in w / w about 65% in w / w, about 15% in w / w about 75% in w / w, about 15% in w / w about 95% in w / w, about 25% in, Petition 870250102374, dated 07 / 11 / 2025, p. 98 / 187 94 / 159 p / pa search 35% in p / p, search 25% in p / pa search 45% in p / p, search 25% in p / pa search 55% in p / p, search 25% in p / pa search 65% in p / p, search 25% in p / pa search 75% in p / p, search 25% in p / pa search 85% in p / p, search 25% in p / pa search 95% in p / p, search 35% in p / pa search 45% in p / p, search 35% in p / pa search 55% in p / p, search 35% in p / pa search 65% in p / p, search 35% in p / pa search 75% em p / p, looking for 35% em p / pa search 85% em p / p search 35% em p / pa search 95% em p / p search 45% em p / pa search 55% em p / p search 45% em p / pa search 65% em p / p search 45% em p / pa search 75% em p / p search 45% em p / pa search 85% in p / p %, search 45% in p / pa search 95% in p / p, search 55% in p / pa search 65% in p / p, search 55% in p / pa search 75% in p / p, search 55% in p / pa search 85% in p / p, search 55% in p / pa search 95% w / w,from about 65% w / w, approximately 75% w / w, from about 65% w / w, approximately 85% w / w, from about 65% w / w, approximately 95% w / w, from about 75% w / w, approximately 85% w / w, from about 75% w / w, approximately 95% w / w, or from about 85% w / w, approximately 95% w / w of a second antidegradant.

[0331] In some forms, a Disclosure Tire Compound comprises approximately 15% by w / w of a second antidegradant. In some embodiments, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 10% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 50% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w or approximately 95% w / w of a second antidegradant.

[0332] In some embodiments, a Disclosure Tire Composition comprises from about 1 to about 5 phr of a second antidegradant. In some embodiments, the composition comprises from about 0.001 phr to about 0.01 phr, from about 0.001 phr to about 0.1 phr, from about 0.001 phr to about 1 phr, from about 0.001 phr to about 5 phr, from about 0.001 phr to about 7.5 phr, from about 0.001 phr to about 10 phr, from about 0.01 phr to about 0.1 phr, from about 0.01 phr to about 1 phr, from about 0.01 phr to about 5 phr, from about Petition 870250102374, dated 07 / 11 / 2025, p. 99 / 187 95 / 159 from 0.01 phr to about 7.5 phr, from about 0.01 phr to about 10 phr, from about 0.1 phr to about 1 phr, from about 0.1 phr to about 5 phr, from about 0.1 phr to about 7.5 phr, from about 0.1 phr to about 10 phr, from about from 1 phr to about 7.5 phr, from about 1 phr to about 10 phr, from about 5 phr to about 7.5 phr, from about 5 phr to about 10 phr, or from about 7.5 phr to about 10 phr.

[0333] In some embodiments, a Disclosure Tire Compound comprises about 3 phr of a second antidegradant. In some embodiments, the compound comprises about 0.001 phr, about 0.01 phr, about 0.1 phr, about 1 phr, about 2 phr, about 4 phr, about 5 phr, about 7.5 phr or about 10 phr of a second antidegradant.

[0334] In some embodiments, the present disclosure provides a composition comprising a Disclosure Compound or Composition and one or more carriers. The term “carrier,” as used herein, refers to a solid that can adsorb a liquid while retaining the general properties of a solid at room temperature. In some embodiments, the carrier is an inert material. In some embodiments, the carrier has a high surface area. In some embodiments, the carrier comprises particles with diameters smaller than 500 microns.

[0335] In some forms, the composition comprises approximately 15% by weight / weight and approximately 85% by weight / weight of one or more carriers.In some modalities, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 1% w / w, approximately 15% w / w, approximately 1% w / w, approximately 25% w / w, approximately 1% w / w, approximately 35% w / w, approximately 1% w / w, approximately 45% w / w, approximately 1% w / w, approximately 55% w / w, approximately 1% w / w, approximately 65% ​​w / w, approximately 1% w / w, approximately 75% w / w, approximately 1% w / w, approximately 85% w / w, approximately 95% w / w, approximately 5% w / w, approximately 15% w / w, approximately 5% in w / w about 25% in w / w, in about 5% in w / w about 35% in w / w, in about 5% in w / w about 45% in w / w, in about 5% in w / w about 55% in w / w, in about 5% in w / w about 65% in w / w, in about 5% in w / w about 75% in w / w, from about 5% w / w to about 85% w / w, from about 5% w / w to about 95% w / w, from about 15% w / w to about 25% w / w, from about. Petition 870250102374, dated 07 / 11 / 2025, p. 100 / 187 96 / 159 15% em p / pa search 35% em p / p, search 15% em p / pa search 45% em p / p, search 15% em p / pa search 55% em p / p, search 15% em p / pa search 65% em p / p, search 15% em p / pa search 75% em p / p, search 15% em p / pa search 95% in p / p, search 25% in p / pa search 35% in p / p, search 25% in p / pa search 45% in p / p, search 25% in p / pa search 55% in p / p, search 25% in p / pa search 65% in p / p, search 25% in p / pa search 75% em p / p, looking for 25% em p / pa search 85% em p / p search 25% em p / pa search 95% em p / p search 35% em p / pa search 45% em p / p search 35% em p / pa search 55% em p / p search 35% em p / pa search 65% em p / p search 35% em p / pa search 75% in p / p, search 35% in p / pa search 85% in p / p, search 35% in p / pa search 95% in p / p, search 45% in p / pa search 55% in p / p, search 45% in p / pa search 65% in p / p, search 45% in p / pa search 75% in w / w,from about 45% p / pa, about 85% p / p, from about 45% p / pa, about 95% p / p, from about 55% p / pa, about 65% p / p, from about 55% p / pa, about 75% p / p, from about 55% p / pa, about 85% p / p, from about 55% p / pa, about 95% p / p, from about 65% p / pa, about 75% p / p, from about 65% p / pa, about 85% p / p, from about 65% p / pa, about 95% p / p, from about 75% p / pa, about 85% p / p, from about 75% p / pa, about 95% p / p, or from approximately 85% in p / p, approximately 95% in p / p from one or more carriers.

[0336] In some forms, the composition comprises approximately 15% by weight of one or more carriers. In some forms, the composition comprises approximately 1% w / w, approximately 5% w / w, approximately 10% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 50% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w, or approximately 95% w / w of one or more carriers.

[0337] In some forms, this publication provides a recited composition in Table 9. Petition 870250102374, dated 07 / 11 / 2025, p. 101 / 187 97 / 159 TABLE 9 Component 1 % w / w of Component 1 Type of composition Component 2 % w / w of Component 2 Compound or Composition of Disclosure 0.1-10 Tire or other rubber article (belt, hose, support, etc.) (vulcanized) Elastomer 5-95 Compound or Composition of Disclosure 0.01-10 Tire component or constructed component or other end-use component (tread, polymer blends, etc.) (unvulcanized) Elastomer 5-95 Compound or Composition of Disclosure 5-95 Masterbatch Elastomer 95-5 Compound or Composition of Disclosure 5-95 Premix Filler 95-5 Compound or Composition of Disclosure 5-95 Premix Rubber chemical 95-5 Compound or Composition of Disclosure 5-95 Premix Plasticizer 95-5 Compound or Composition of Disclosure 5-95 Premix Additional Antidegradant(s) 95-5

[0338] In some embodiments, the composition of vulcanized tire or other rubber article in Table 9 comprises about 0.1% w / w, about 0.2% w / w, about 0.3% w / w, about 0.4% w / w, about 0.5% w / w, about 0.6% w / w, about 0.7% w / w, about 0.8% w / w, about 0.9% w / w, about 1% w / w, about 2% w / w, about 3% w / w, about 4% w / w, Petition 870250102374, dated 07 / 11 / 2025, p. 102 / 187 98 / 159 approximately 5% w / w, approximately 6% w / w, approximately 7% w / w, approximately 8% w / w, approximately 9% w / w or approximately 10% w / w of a Disclosure Compound or Composition. In some embodiments, the vulcanized tire or other rubber article in Table 9 comprises about 5% by w / w, about 10% by w / w, about 15% by w / w, about 20% by w / w, about 25% by w / w, about 30% by w / w, about 35% by w / w, about 40% by w / w, about 45% by w / w, about 50% by w / w, about 55% by w / w, about 60% by w / w, about 65% by w / w, about 70% by w / w, about 75% by w / w, about 80% by w / w, about 85% by w / w, about 90% by w / w or about 95% by w / w of at least one elastomer.

[0339] In some embodiments, the composition of the unvulcanized tire component or constructed component or other end-use component of Table 9 comprises about 0.01% w / w, about 0.02% w / w, about 0.03% w / w, about 0.04% w / w, about 0.05% w / w, about 0.06% w / w, about 0.07% w / w, about 0.08% w / w, about 0.09% w / w, about 0.1% w / w, about 0.2% w / w, about 0.3% w / w, about 0.4% w / w, about 0.5% w / w, about 0.6% w / w, about 0.7% w / w, about 0.8% w / w p / p, approximately 0.9% p / p, approximately 1% p / p, approximately 2% p / p, approximately 3% p / p, approximately 4% p / p, approximately 5% p / p, approximately 6% p / p, approximately 7% p / p, approximately 8% p / p, approximately 9% p / p or approximately 10% p / p of a Disclosure Compound or Composition.In some embodiments, the unvulcanized tire component or constructed component or other end-use component composition of Table 9 comprises about 5% w / w, about 10% w / w, about 15% w / w, about 20% w / w, about 25% w / w, about 30% w / w, about 35% w / w, about 40% w / w, about 45% w / w, about 50% w / w, about 55% w / w, about 60% w / w, about 65% w / w, about 70% w / w, about 75% w / w, about 80% w / w, about 85% w / w, about 90% w / w or about 95% w / w of at least one elastomer.

[0340] This disclosure also provides processes for preparing a composition comprising a Compound or Composition of the Disclosure and one or more carriers, the process comprising mixing the compound and one or more carriers.

[0341] This disclosure also provides lubricant compositions that Petition 870250102374, dated 07 / 11 / 2025, p. 103 / 187 99 / 159 comprises a Disclosure Compound or Composition and a lubricant. Non-limiting examples of lubricants include mineral oil, high molecular weight petroleum distillates such as aromatic, naphthenic and paraffinic distillates, synthetic oils such as polyalpha-olefin (PAO), synthetic esters, polyalkylene glycols (PAG), phosphate esters, perfluoropolyether (PFPE), alkylated naphthalenes (AN), silicate esters, ionic fluids and multiply alkylated cyclopentanes (MAC), solid lubricants such as polytetrafluoroethylene (PTFE), graphite, hexagonal boron nitride, molybdenum disulfide, tungsten disulfide, aqueous lubricants such as hydrated brush polymers, and biolubricants such as triglyceride esters, high oleic canola oil, castor oil, palm oil, sunflower seed oil and rapeseed oil.

[0342] This disclosure also provides fuel compositions comprising a fuel and a Disclosure Compound or Composition. Non-limiting examples of fuel include gasoline, diesel, kerosene, liquefied petroleum gas, synthetic fuel and biodiesel.

[0343] This disclosure also provides fuel additive compositions comprising a fuel additive and a Disclosure Compound or Composition. Non-limiting examples of fuel additives include oxygenates such as alcohols and ethers, antioxidants, stabilizers, detergents, anti-knock agents, lead removers, fuel colorants, viscosity modifiers, and butyl rubber. In some embodiments, butyl rubber is in the form of polyisobutylene succinimide. In some embodiments, butyl rubber is added as a detergent to prevent fouling in diesel fuel injectors. IV. Vulcanized Elastomeric Articles

[0344] This disclosure also provides vulcanized elastomeric articles comprising a Compound or Composition of the Disclosure. The term “vulcanized elastomeric article” refers to an article that is made by forming a composition comprising an elastomer in a specific shape and by vulcanizing the composition to provide the article.

[0345] This disclosure also provides vulcanized elastomeric articles prepared using a Tire Composition from the Disclosure. Petition 870250102374, dated 07 / 11 / 2025, p. 104 / 187 100 / 159

[0346] In some embodiments, the vulcanized elastomeric article is a tire. In some embodiments, the tire is a passenger vehicle tire, a light truck tire, a heavy truck or bus tire, a motorcycle tire, an agricultural tire, an excavator tire, an aircraft tire, or a racing tire.

[0347] In some embodiments, the vulcanized elastomeric article is a component of a tire. In some embodiments, the component is a bead, a belt, a carcass ply, an inner lining, a sidewall, a tread bottom, or a tread.

[0348] In some embodiments, the vulcanized elastomeric article is a rubber spare, a sealing strip, an acoustic panel, an air spring, a bellows, a membrane, a tactile sensor, a protective pad, a hose, a conveyor belt or a floor.

[0349] In some embodiments, this disclosure provides a vehicle comprising a vulcanized elastomeric article comprising a Compound or Composition of the Disclosure. V. PROCESSES

[0350] This disclosure also provides processes for preparing a vulcanized elastomeric article, the process comprising: (a) forming a Disclosure Tire Composition into a formed shape; and (b) vulcanizing the formed shape to provide a vulcanized elastomeric article.

[0351] In some forms, vulcanization is carried out at an average temperature of about 140 °C to about 160 °C. In some forms, vulcanization is carried out at an average temperature of approximately 80°C to approximately 100°C, approximately 80°C to approximately 120°C, approximately 80°C to approximately 140°C, approximately 80°C to approximately 160°C, approximately 80°C to approximately 180°C, approximately 80°C to approximately 200°C, approximately 100°C to approximately 120°C, approximately 100°C to approximately 140°C, approximately 100°C to approximately 160°C, approximately 100°C to approximately 180°C, approximately 100°C to approximately 200°C, approximately 120°C to approximately 140°C, approximately 120°C °C to about 160 °C, from about 120 °C to about 180 °C, from about 120 °C to about 200 °C, from about 140 °C to about 180 °C, from Petition 870250102374, dated 07 / 11 / 2025, p. 105 / 187 101 / 159 from about 140 °C to about 200 °C, from about 160 °C to about 180 °C, from about 160 °C to about 200 °C, or from about 180 °C to about 200 °C.

[0352] In some embodiments, vulcanization is carried out at an average temperature of about 150 °C. In other embodiments, vulcanization is carried out at an average temperature of about 80 °C, about 100 °C, about 120 °C, about 140 °C, about 160 °C, about 180 °C or about 200 °C.

[0353] This disclosure also provides processes for tire retreading, the process comprising: (a) apply a Disclosure Tire Compound to a tire; (b) to place a pre-vulcanized tread around the tire; (c) place a curing envelope around the tire; and (d) vulcanize the tire.

[0354] In another embodiment, the present disclosure provides a process for preparing the composition comprising Compound (10), or a salt or solvate thereof.

[0355] In another embodiment, the present disclosure provides a process for preparing the composition comprising Compound (10), or a salt or solvate thereof, and Compound (2), Compound (4) and / or Compound (11), the process comprising reacting 4-aminodiphenylamine with acetone, 2,2-dimethoxypropane or mesityl oxide in the presence of a strong acid, for example, hydrochloric acid.

[0356] This disclosure provides the following specific process modalities.

[0357] Embodiment of the Process 1. A process for preparing the composition of any of the Embodiments of Composition 1-112, see above, the process comprising the reaction of a composition comprising 4-aminodiphenylamine with acetone, 2,2-dimethoxypropane, diacetone alcohol or mesityl oxide in the presence of a catalyst.

[0358] Process Mode 2. The process of Process Mode 1, in which the catalyst is a homogeneous catalyst.

[0359] Process Mode 3. The process of Process Mode 2, in which the homogeneous catalyst is a Lewis acid, a Bronsted acid, a base, a halogen, a halogen donor, or a combination thereof. Petition 870250102374, dated 07 / 11 / 2025, pp. 106 / 187 102 / 159

[0360] Process Modality 4. The process of Process Modality 2, in which the homogeneous catalyst is selected from the group consisting of iodine, pyridinium perbromide, bromine, bismuth(III) trifluoromethane sulfonate, zinc(II) trifluoromethane sulfonate, hydrobromic acid, magnesium(II) bromide, aluminum(III) chloride, p-toluene sulfonic acid monohydrate, N-bromosuccinimide, copper(II) bromide, copper(II) chloride, methane sulfonic acid, benzene sulfonic acid, boron trifluoride diethyl etherate, boron trifluoride dihydrate, hydrochloric acid, copper(II) trifluoromethane sulfonate, iron(III) chloride, magnesium(II) chloride, copper(I) iodide and zinc(II) chloride, or the salts or solvates thereof.

[0361] Process Mode 5. The process of Process Mode 4, in which the homogeneous catalyst is selected from the group consisting of pyridinium perbromide, magnesium(II) bromide, magnesium(II) bromide hexahydrate and aluminum(III) chloride.

[0362] Process Mode 6. The Process of Process Mode 1, in which the catalyst is a heterogeneous catalyst.

[0363] Process Mode 7. The process of Process Mode 6, in which the heterogeneous catalyst is an acid-treated resin, a solid-supported acid, a compound catalyst, a solid acid, or a base catalyst.

[0364] Process Mode 8. The process of Process Mode 7, wherein the acid-treated resin is a polyfluorinated sulfonic acid resin, a strongly acidic sulfonic acid exchange resin (Amberlyst 15), a macroporous strong acidic ion exchange resin, a strong acidic ion exchange resin, a solid acidic ion exchange resin (NRW150), a sieved strong acidic ion exchange resin or a strong acidic ion exchange resin (type A2 acid resin).

[0365] Process Embodiment 9. The process of Process Embodiment 7, in which the acid supported on a solid is a micro-mesomacroporous zeolite catalyst HY-MMM, a strong acidity molecular sieve H-MCM-22, an organic protonic acid supported by graphene oxide, an organic protonic acid supported by a zeolite, a small pore size zeolite, a heterogeneous acidic silica catalyst, tungstophosphoric acid (TPA) exchanged for Zn2+, Sn2+ and Petition 870250102374, dated 07 / 11 / 2025, page 107 / 187 103 / 159 Cu2+ supported on Y-Al2O3, activated earth tonsil (acid-treated bentonite clay), alumina, titania, zirconia, niobium, silica-alumina, sulfated zirconia, tungstate zirconia, para-toluenesulfonic acid (p-TSA) / ZnCl2, or WO3 / activated carbon / SO3H.

[0366] Process Mode 10. The process of Process Mode 7, in which the compound catalyst is a zirconium-doped titania oxide compound catalyst, solid superacid H2SO4-MoO3-TiO2 or ptoluenesulfonic acid / iodine.

[0367] Process Mode 11. The process of Process Mode 7, in which the solid acid is a heteropolyacid or a metal-organic structure.

[0368] Process Mode 12. The process of Process Mode 7, in which the base catalyst is ZrO2 / MgO.

[0369] Process Modality 13. The process of any of the Process Modalities 1-12 comprising the reaction of a composition comprising 4-aminodiphenylamine with acetone.

[0370] Process Modality 14. The process of any of the Process Modalities 1-12 comprising the reaction of a composition comprising 4-aminodiphenylamine with 2,2-dimethoxypropane.

[0371] Process Modality 15. The process of any of the Process Modalities 1-12 comprising the reaction of a composition comprising 4-aminodiphenylamine with diacetone alcohol.

[0372] Process Modality 16. The process of any of the Process Modalities 1-12 comprising the reaction of a composition comprising 4-aminodiphenylamine with mesityl oxide. VI. KITS

[0373] This disclosure also provides kits comprising the Disclosure Compound or Composition or a Disclosure Tire Composition packaged in a manner, for example, in a container, that facilitates the use of the compound or composition to practice the processes and / or methods of this disclosure. In some embodiments, the kit comprises a Disclosure Tire Composition and instructions for using the composition in a vulcanizable elastomeric composition. In some embodiments, the kit comprises a Disclosure Tire Composition and instructions for using the composition to prepare an article. Petition 870250102374, dated 07 / 11 / 2025, pp. 108 / 187 104 / 159 Vulcanized elastomeric. The composition may be packaged in any suitable container, such as a bottle or sealed container, with a label affixed to the container or included in the kit describing the composition and its proper use. VII. DEFINITIONS

[0374] The term “weight ratio”, as used herein, refers to the mass of one compound divided by the mass of another compound in a composition. For example, the weight ratio of Compound (2) to Compound (10) in a composition comprising 1 gram of Compound (2) and 1000 grams of Compound (10) is 0.001. The weight ratio of Compound (2) to Compound (10) in a composition comprising 10 grams of Compound (2) and 100 grams of Compound (10) is 0.1.

[0375] In some embodiments, a compound of the present disclosure comprises a mixture of E and Z stereoisomers, as illustrated for Compound (4) below: Compound (4) Compound (E-4) Compound (Z-4)

[0376] In some embodiments, a compound of the present disclosure comprises a mixture of E and Z stereoisomers, wherein the E:Z ratio is 500:1 to 1:500. In some embodiments, the E:Z ratio is 100:1 to 1:100. In some embodiments, the E:Z ratio is 10:1 to 1:10. In some embodiments, the E:Z ratio is 5:1 to 1:5. In some embodiments, the E:Z ratio is 3:1 to 1:3. In some embodiments, the E:Z ratio is 2:1 to 1:2. In some modalities, the E:Z ratio is approximately 10:1, approximately 9:1, approximately 8:1, approximately 7:1, approximately 6:1, approximately 5:1, approximately 4:1, approximately 3:1, or approximately 2:1. In some modalities, the E:Z ratio is approximately 1:10, approximately 1:9, approximately 1:8, approximately 1:7, approximately 1:6, approximately 1:5, approximately 1:4, approximately 1:3, or approximately 1:2. In some modalities, the E:Z ratio is approximately 1:1.

[0377] In some forms, a Disclosure Compound comprises Petition 870250102374, dated 07 / 11 / 2025, p. 109 / 187 105 / 159 only the E stereoisomer, i.e., there is no detectable amount of the Z stereoisomer as measured by HPLC.

[0378] In some embodiments, a Disclosure Compound comprises only the Z stereoisomer, i.e., there is no detectable amount of the E stereoisomer as measured by HPLC.

[0379] The term “about”, as used here, includes the recited number ± 10%. Therefore, “about 10” means 9 to 11.

[0380] The word “comprising” is used in a manner consistent with its open meaning, that is, to signify that a given product, composition or process may optionally have additional features or elements beyond those expressly described. It is understood that whenever embodiments are described using the language “comprising”, analogous embodiments described in terms of “consisting of” and / or “essentially consisting of” are also contemplated and fall within the scope of this disclosure.

[0381] Salts and solvates, for example, hydrates, of the Compounds of Disclosure may also be used in the methods disclosed herein.

[0382] This disclosure covers the preparation and use of salts of Disclosure Compounds. Salts of Disclosure Compounds may be prepared during the isolation and final purification of the compounds or separately by reacting the compound with an acid having a suitable cation. Salts of Disclosure Compounds may be acid addition salts formed with acceptable acids. Examples of acids that may be employed to form salts include inorganic acids such as nitric, boric, hydrochloric, hydrobromic, sulfuric, and phosphoric acids, and organic acids such as oxalic, maleic, succinic, and citric acids.Non-limiting examples of salts of disclosure compounds include, but are not limited to, hydrochloride, hydrobromide, iodide, sulfate, bisulfate, 2-hydroxyethanesulfonate, phosphate, hydrogen phosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerol phosphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, mesitylenesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, trichloroacetate, trifluoroacetate, phosphate, glutamate, salts. Petition 870250102374, dated 07 / 11 / 2025, page 110 / 187 106 / 159 of bicarbonate, paratoluenesulfonate, undecanoate, lactate, citrate, tartrate, gluconate, methanesulfonate, ethanedisulfonate, benzenesulfonate and paratoluenesulfonate. Furthermore, the available amino groups present in the Disclosure Compounds may be quaternized with methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dimethyl, diethyl, dibutyl and diamyl sulfates; decyl, lauryl, myristyl and steryl chlorides, bromides and iodides; and benzyl and phenethyl bromides. In light of the foregoing, any reference to the Disclosure Compounds appearing herein shall include the Disclosure Compounds as well as salts, hydrates or solvates thereof.

[0383] This disclosure covers the preparation and use of solvates of Compounds of the Disclosure. The term “solvate,” as used herein, is a combination, physical association, and / or solvation of a compound of the present disclosure with a solvent molecule, such as, for example, a dissolvate, monosolvate, or hemisolvate, where the ratio of solvent molecule to compound of the present disclosure is about 2:1, about 1:1, or about 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain cases, the solvate may be isolated, such as when one or more solvent molecules are incorporated into the crystalline structure of a crystalline solid. Therefore, “solvate” encompasses both solution-phase solvates and isolable solvates.The Disclosure Compounds may be present as solvated forms with a solvent, such as water, methanol, and ethanol, and the Disclosure is intended to include both solvated and non-solvated forms of the Disclosure Compounds.

[0384] One type of solvate is the hydrate. A “hydrate” refers to a specific subgroup of solvates where the solvent molecule is water. The preparation of solvates is known in the art. See, for example, M. Caira et al., J. Pharmaceut. Sci., 93(3):601-611 (2004), which describes the preparation of fluconazole solvates with ethyl acetate and with water. Similar preparations of solvates, hemisolvates, hydrates, and the like are described by van Tonder et al., AAPS Pharm. Sci. Tech., 5(1):Article 12 (2004), and AL Bingham et al., Chem. Commun. 603-604 (2001). A typical and non-limiting process for preparing a solvate would involve dissolving a Disclosure Compound or Composition in a desired solvent (organic, Petition 870250102374, dated 07 / 11 / 2025, p. 111 / 187 107 / 159 water or a mixture thereof) at temperatures above 20 °C to about 25 °C, then cooling the solution at a rate sufficient to form crystals and isolating the crystals by known methods, for example, filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a solvate crystal.

[0385] The use of the terms “a”, “an”, “the” and similar referents in the context of the disclosure description (especially in the context of the claims) should be interpreted as encompassing both the singular and the plural, unless otherwise indicated. The recitation of value ranges contained herein serves only as a shorthand method of individual reference to each separate value that falls within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were recited individually herein. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended to better illustrate the disclosure and is not a limitation on the scope of the disclosure, unless otherwise claimed. No language in the descriptive report should be interpreted as indicating any unclaimed element as essential to the practice of disclosure.

[0386] As used herein, the term “and / or” is to be considered as a specific disclosure of each of the two specified features or components, with or without the other. Thus, the term “and / or”, as used in a phrase such as “A and / or B” herein, is intended to include “A and B”, “A or B”, “A” (alone) and “B” (alone). Similarly, the term “and / or”, as used in a phrase such as “A, B and / or C”, is intended to encompass each of the following aspects: A, B and C; A, B or C; A or B; A or C; B or C; A and B; A and C; B and C; A (alone); B (alone); and C (alone).

[0387] The term “% w / w” as used herein refers to the mass of a component in a composition or mixture, for example, a composition comprising a Disclosure Compound and one or more elastomers; or a Disclosure Composition and one or more fillers; or a mixture comprising two or more elastomers, etc., divided by the combined mass of all components in the composition or mixture, times 100. For example, the % w / w of a Disclosure Compound in a composition comprising 1 kg of the compound, 1 kg of natural rubber and 2 kg of synthetic rubber is 25% w / w (1 kg / 4 kg = 0.25 x Petition 870250102374, dated 07 / 11 / 2025, p. 112 / 187 108 / 159 100 = 25% w / w). The w / w percentage of a Disclosure Compound in a composition comprising 1 kg of the compound and 1 kg of carbon black is 50% w / w (1 kg / 2 kg = 0.20 x 100 = 50% w / w). The w / w percentage of a Disclosure Compound in a composition comprising 1 kg of the compound, 1 kg of natural rubber, 2 kg of synthetic rubber and 1 kg of carbon black is 20% w / w (1 kg / 5 kg = 0.20 x 100 = 20% w / w). The w / w percentage of natural rubber in a mixture of one or more elastomers comprising 20 kg of natural rubber and 30 kg of synthetic rubber is 40% w / w (20 kg / 50 kg = 0.40 x 100 = 40% w / w).

[0388] As used herein, the term “masterbatch” refers to a composition comprising at least one elastomer and a Disclosure Compound or Composition. In some embodiments, the masterbatch comprises about 5% w / w about 95% w / w of at least one elastomer and about 5% w / w about 95% w / w of a Disclosure Compound or Composition. In some embodiments, the masterbatch comprises approximately 5% w / w, approximately 10% w / w, approximately 15% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 50% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w or approximately 95% w / w of a Disclosure Compound or Composition.In some embodiments, the masterbatch comprises approximately 5% w / w, approximately 10% w / w, approximately 15% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 50% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w, or approximately 95% w / w of at least one elastomer.

[0389] As used herein, the term “premix” refers to a composition comprising a Disclosure Compound or Composition and at least one additional component, for example, a filler, a rubber chemical, a plasticizer, an additional antidegradant, or a combination thereof. In some embodiments, the premix does not comprise an elastomer. In some embodiments, the premix comprises about 5% w / w about Petition 870250102374, dated 07 / 11 / 2025, p. 113 / 187109 / 159 of 95% by w / w of a Compound or Composition of Disclosure and about 5% by w / w of about 95% by w / w of at least one additional component, for example, a filler, a rubber chemical, a plasticizer, an additional antidegradant or a combination thereof. In some embodiments, the premix comprises about 5% w / w, about 10% w / w, about 15% w / w, about 20% w / w, about 25% w / w, about 30% w / w, about 35% w / w, about 40% w / w, about 45% w / w, about 50% w / w, about 55% w / w, about 60% w / w, about 65% w / w, about 70% w / w, about 75% w / w, about 80% w / w, about 85% w / w, about 90% w / w or about 95% w / w of a Disclosure Compound.In some embodiments, the premix comprises approximately 5% w / w, approximately 10% w / w, approximately 15% w / w, approximately 20% w / w, approximately 25% w / w, approximately 30% w / w, approximately 35% w / w, approximately 40% w / w, approximately 45% w / w, approximately 50% w / w, approximately 55% w / w, approximately 60% w / w, approximately 65% ​​w / w, approximately 70% w / w, approximately 75% w / w, approximately 80% w / w, approximately 85% w / w, approximately 90% w / w or approximately 95% w / w of at least one additional component, for example, a filler, a rubber chemical, a plasticizer, an additional anti-degradant, or a combination thereof.

[0390] The term “one or more”, as used herein, is intended to mean that at least one component in a relevant category of components, for example, one or more elastomers, is present and, in some embodiments, more than one component is present. In some embodiments, one or more means 1 to 50. In some embodiments, one or more means 1 to 40. In some embodiments, one or more means 1 to 30. In some embodiments, one or more means 1 to 20. In some embodiments, one or more means 1 to 10. In some embodiments, one or more means 1 to 5. In some embodiments, one or more means 1 to 3. In some embodiments, one or more means 1 or 2. In some embodiments, one or more means 1. VIII. PARTICULAR MODALITIES

[0391] This disclosure provides the following particular embodiments. The composite structures are given in Table 1.

[0392] Modality 1. Compound (9), or a salt or solvate thereof. Petition 870250102374, dated 07 / 11 / 2025, p. 114 / 187 110 / 159

[0393] Modality 2. Compound (10), or a salt or solvate thereof.

[0394] Embodiment 3. A composition comprising the compound of Embodiments 1 or 2 and Compound (1), wherein the composition comprises from about 0.0001% to about 10% of Compound (1), as measured by HPLC analysis, for example, about 0.001% to about 10%, about 0.01% to about 10%, about 0.1% to about 10%, about 0.0001% to about 5%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.0001% to about 1%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to 0.5% of Compound (1).

[0395] Embodiment 4. A composition comprising the compound of Embodiments 1 or 2 and Compound (2), wherein the composition comprises from about 0.0001% to about 10% of Compound (2), as measured by HPLC analysis, for example, about 0.001% to about 10%, about 0.01% to about 10%, about 0.1% to about 10%, about 0.0001% to about 5%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.0001% to about 1%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to 0.5% of Compound (2).

[0396] Embodiment 5. A composition comprising the compound of Embodiments 1 or 2 and Compound (3), wherein the composition comprises from about 0.001% to about 10% of Compound (3), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (3).

[0397] Embodiment 6. A composition comprising the compound of Embodiments 1 or 2 and Compound (4), wherein the composition comprises from about 0.001% to about 10% of Compound (4), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, Petition 870250102374, dated 07 / 11 / 2025, p. 115 / 187 111 / 159 about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to about 0.5% of Compound (4).

[0398] Embodiment 7. A composition comprising the compound of Embodiments 1 or 2 and Compound (5), wherein the composition comprises from about 0.001% to about 10% of Compound (5), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (5).

[0399] Embodiment 8. A composition comprising the compound of Embodiments 1 or 2 and Compound (6), wherein the composition comprises from about 0.001% to about 10% of Compound (6), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (6).

[0400] Embodiment 9. A composition comprising the compound of Embodiments 1 or 2 and Compound (7), wherein the composition comprises from about 0.001% to about 10% of Compound (7), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (7).

[0401] Embodiment 10. A composition comprising the compound of Embodiments 1 or 2 and Compound (8), wherein the composition comprises from about 0.001% to about 10% of Compound (8), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, Petition 870250102374, dated 07 / 11 / 2025, pp. 116 / 187 112 / 159 about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to about 0.5% of Compound (8).

[0402] Embodiment 11. A composition comprising the compound of Embodiments 1 or 2 and Compound (11A), wherein the composition comprises from about 0.001% to about 10% of Compound (11A), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (11A).

[0403] Embodiment 12. A composition comprising the compound of Embodiments 1 or 2 and Compound (12), wherein the composition comprises from about 0.001% to about 10% of Compound (12), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (12).

[0404] Embodiment 13. A composition comprising the compound of Embodiments 1 or 2 and Compound (13), wherein the composition comprises from about 0.001% to about 10% of Compound (13), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (13).

[0405] Embodiment 14. A composition comprising the compound of Embodiments 1 or 2 and Compound (14), wherein the composition comprises from about 0.001% to about 10% of Compound (14), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about Petition 870250102374, dated 07 / 11 / 2025, pp. 117 / 187 113 / 159 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to about 0.5% of Compound (14).

[0406] Embodiment 15. A composition comprising the compound of Embodiments 1 or 2 and Compound (15), wherein the composition comprises from about 0.001% to about 10% of Compound (15), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (15).

[0407] Embodiment 16. A composition comprising the compound of Embodiments 1 or 2 and Compound (16), wherein the composition comprises from about 0.001% to about 10% of Compound (16), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (16).

[0408] Embodiment 17. A composition comprising the compound of Embodiments 1 or 2 and Compound (17), wherein the composition comprises from about 0.001% to about 10% of Compound (17), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (17).

[0409] Embodiment 18. A composition comprising the compound of Embodiments 1 or 2 and Compound (18), wherein the composition comprises from about 0.001% to about 10% of Compound (18), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about Petition 870250102374, dated 07 / 11 / 2025, pp. 118 / 187 114 / 159 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to about 0.5% of Compound (18).

[0410] Embodiment 19. A composition comprising the compound of Embodiments 1 or 2 and Compound (19), wherein the composition comprises from about 0.001% to about 10% of Compound (19), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (19).

[0411] Embodiment 20. A composition comprising the compound of Embodiments 1 or 2 and Compound (20A), wherein the composition comprises from about 0.001% to about 20% of Compound (20A), as measured by HPLC analysis, for example, from about 0.01% to about 20%, from about 0.1% to about 20%, from about 0.001% to about 15%, from about 0.01% to about 15%, from about 0.1% to about 15%, from about 0.001% to about 10%, from about 0.01% to about 10%, from about 0.01% to about 15%, from about 0.5% to about 15% or from about 1% to 15% of Compound (20).

[0412] Modality 21. A composition comprising Compound (10); and: (i) Compound (2), wherein the composition comprises from about 0.0001% to about 10% of Compound (2), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (2); and / or (ii) Compound (4), wherein the composition comprises from about 0.001% to about 10% of Compound (4), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, about 0.001% Petition 870250102374, dated 07 / 11 / 2025, p. 119 / 187 115 / 159 to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to 0.5% of Composto (4); e / ou. (iii) Compound (11A) or Compound (11B), wherein the composition comprises from about 0.001% to about 10% of Compound (11A) or Compound (11B), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (11A) or Compound (11B);and / or (iv) Compound (20A) or Compound (20B), wherein the composition comprises from about 0.001% to about 10% of Compound (20A) or Compound (20B), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (20A) or Compound (20B);

[0413] Modality 22. Compound (3).

[0414] Modality 23. Compound (4).

[0415] Modality 24. A composition comprising the compound of Modalities 22 or 23.

[0416] Modality 25. A composition comprising the composition of any of the Modalities 3-21, 24, 118-125, 127, 129, 130, 133 or 134, or the composite of Modalities 22, 23, 126, 128, 131 or 132; and: (i) one or more elastomers; or (ii) one or more fillers; or (iii) one or more rubber chemicals; or (iv) one or more plasticizers; or (v) one or more secondary antidegradants; or (vi) a combination of one or more elastomers, one or more fillers, one or more rubber chemicals, one or more plasticizers and / or one or more secondary antidegradants.

[0417] Modality 26. The composition of claim 25, in which the Petition 870250102374, dated 07 / 11 / 2025, pp. 120 / 187 116 / 159 composition comprises one or more elastomers.

[0418] Embodiment 27. The composition of claim 26, wherein the composition comprises about 15% by w / w about 85% by w / w of the composition of (i) and about 15% by w / w about 85% by w / w of one or more elastomers.

[0419] Modality 28. The composition of any of the Modalities 2527, in which one or more elastomers comprise natural rubber (NR).

[0420] Modality 29. The composition of Modality 28, wherein one or more elastomers comprise from about 5% by w / w to about 80% by w / w of natural rubber (NR).

[0421] Modality 30. The composition of Modality 28 or 29, in which the natural rubber comprises rubber derived from an alternative rubber plant.

[0422] Modality 31. The composition of Modality 30, in which the alternative rubber plant is Parthenium argentatum (guayule) or Taraxacum kok-saghyz (Russian dandelion).

[0423] Modality 32. The composition of any of the Modalities 2631, in which one or more elastomers comprise synthetic rubber.

[0424] Modality 33. The composition of Modality 32, wherein the synthetic rubber comprises an unsaturated rubber, a saturated rubber, a rubber with fluoro and fluoroalkyl or fluoroalkoxy substituent groups in the polymer chain (FKM), a silicone rubber (Q) or a mixture thereof.

[0425] Modality 34. The composition of Modality 33, wherein the unsaturated rubber comprises polyisoprene rubber (IR), butyl rubber (IIR), polybutadiene rubber (BR), styrene butadiene rubber (SBR), nitrile butadiene rubber (NBR), chloroprene rubber (CR), ethylene propylene diene rubber (EPDM) or a mixture thereof.

[0426] Modality 35. The composition of Modality 34, in which the unsaturated rubber comprises styrene-butadiene rubber (SBR).

[0427] Modality 36. The composition of Modality 35, wherein one or more elastomers comprise from about 5% by w / w to about 80% by w / w of styrene-butadiene rubber (SBR). Petition 870250102374, dated 07 / 11 / 2025, pp. 121 / 187 117 / 159

[0428] Modality 37. The composition of any of the Modalities 3436, in which the unsaturated rubber comprises polybutadiene rubber (BR).

[0429] Modality 38. The composition of Modality 37, wherein one or more elastomers comprise from about 5% by w / w to about 80% by w / w of polybutadiene rubber (BR).

[0430] Modality 39. The composition of any of the Modalities 3438, in which the unsaturated rubber comprises butyl rubber (IIR).

[0431] Modality 40. The composition of Modality 39, wherein one or more elastomers comprise from about 1% by w / w to about 30% by w / w of butyl rubber (IIR).

[0432] Modality 41. The composition of any of the Modalities 3340, wherein the saturated rubber comprises acrylic rubber (ACM), chlorinated polyethylene (CM), chlorosulfonated polyethylene (CSM), polychloromethyloxirane (CO), ethylene-ethyl acrylate copolymer (EAM), epichlorohydrin rubber (ECO), ethylene propylene rubber (EPM), ethylene vinyl acetate copolymer (EVM) or a mixture thereof.

[0433] Modality 42. The composition of the Modalities is any of the Modalities 35-41, in which one or more elastomers further comprise recycled rubber.

[0434] Modality 43. The composition of any of the Modalities 3542, wherein the composition comprises from about 0.1 phr to about 10 phr of the composition of (i).

[0435] Modality 44. The composition of Modality 43, wherein the composition comprises from about 0.5 phr to about 5 phr of the composition of (i).

[0436] Modality 45. The composition of Modality 44, wherein the composition comprises from about 1 phr to about 5 phr of the composition of (i).

[0437] Modality 46. The composition of any of the Modalities 2545, in which the composition comprises one or more loads.

[0438] Modality 47. The composition of Modality 46, wherein the composition comprises approximately 15% p / pa approximately 85% p / p of the composition of (i) and approximately 15% p / pa approximately 85% p / p of one or more loads. Petition 870250102374, dated 07 / 11 / 2025, p. 122 / 187 118 / 159

[0439] Modality 48. The composition of Modalities 46 or 47, where the composition comprises from approximately 30 phr to approximately 500 phr of one or more loads.

[0440] Modality 49. The composition of any of the Modalities 4648, wherein one or more fillers comprise carbon black, silica, kaolin, calcium silicate, talc, carbon nanotubes (CNTs), carbon fibers (HCFs), graphite, graphene, aluminosilicates, starch, fibers or a combination thereof.

[0441] Modality 50. The composition of Modality 49, where one or more fillers comprise silica.

[0442] Modality 51. The composition of Modality 50, in which the silica is derived from rice husks.

[0443] Modality 52. ​​The composition of any of the Modalities 4651, in which one or more charges comprise carbon black.

[0444] Modality 53. The composition of any of the Modalities 2552, wherein the composition comprises one or more rubber chemicals.

[0445] Modality 54. The composition of Modality 53, wherein the composition comprises about 15% by w / w about 85% by w / w of the composition of (i) and about 15% by w / w about 85% by w / w of one or more rubber chemicals.

[0446] Modality 55. The composition of Modalities 53 or 54, where the composition comprises from about 0.1 phr to about 30 phr of one or more rubber chemicals.

[0447] Modality 56. The composition of Modality 55, where the composition comprises from about 1 phr to about 20 phr of one or more rubber chemicals.

[0448] Modality 57. The composition of any of the Modalities 5356, wherein one or more rubber chemicals comprise one or more vulcanizing agents, one or more accelerators, one or more activators, one or more pre-vulcanization inhibitors or a combination thereof.

[0449] Modality 58. The composition of Modality 57, in which one or more rubber chemicals comprise one or more vulcanizing agents.

[0450] Modality 59. The composition of Modality 58, in which one or more Petition 870250102374, dated 07 / 11 / 2025, pp. 123 / 187 119 / 159 Vulcanizing agents comprise sulfur, peroxide, resin or a combination thereof.

[0451] Modality 60. The composition of Modality 59, in which the sulfur is octasulfur (S8), cyclododecasulfur (S12), polymeric sulfur or a combination thereof.

[0452] Embodiment 61. The composition of Embodiment 59, wherein the peroxide is benzoyl peroxide, dicumyl peroxide (DC), 2,5-dimethyl-2,5-di-(tert-butylperoxy)3-hexyne (2,5 Tri), 2,5-dimethyl-2,5-di(tert-butylperoxy)hexane (DDPH), di-(2-tert-butylperoxyisopropyl)benzene (VC), butyl-4,4-di-(tert-butylperoxy)valerate (VAL), 1,1-di(tert-butylperoxy)-3,3,5-trimethylcyclohexane (TMC) or a combination thereof.

[0453] Modality 62. The composition of Modality 59, in which the resin is a bonding resin.

[0454] Modality 63. The composition of Modalities 57-62, in which one or more rubber chemicals comprise one or more accelerators.

[0455] Modality 64. The composition of Modality 63, wherein one or more accelerators comprise a guanidine, a thiazole, a sulfenamide, a thiuram, a dithiocarbamate, a xanthate, a thiophosphate or a combination thereof.

[0456] Modality 65. The composition of Modality 64, in which guanidine is diphenylguanidine (DPG).

[0457] Modality 66. The composition of Modality 64, wherein the thiazole comprises 2-mercaptobenzothiazole (MBT), zinc 2-mercaptobenzothiazole (ZMBT), mercaptobenzothiazole disulfide (MBTS), N-tert-butyl-2-benzothiazole sulfenimide (TBSI) or a combination thereof.

[0458] Modality 67. The composition of Modality 64, wherein the sulfenamide comprises N-tert-butyl-2-benzothiazolesulfenamide (TBBS), N-cyclohexylbenzothiazole-2-sulfenamide (CBS), dicyclohexyl-2-benzothiazolesulfenamide (DCBS), N-oxydiethylene benzothiazole sulfenamide (OBTS), N-oxydiethylenethiocarbamyl-N'-oxydiethylene sulfenamide (OTOS), thiocarbamyl sulfenamide or a combination thereof.

[0459] Modality 68. The composition of Modality 64, wherein thiuram is dimethylcarbamothioic acid dithioperoxyanhydride (thiram), dipentamethylene thiuram tetrasulfide (DPIT), tetrabenzyl thiuram disulfide (TBzTD), tetraethylthiuram disulfide Petition 870250102374, dated 07 / 11 / 2025, pp. 124 / 187 120 / 159 (TETD), tetramethylthiuram disulfide (TMTD), tetramethylthiuram monosulfide (TMTM), or a combination thereof.

[0460] Modality 69. The composition of Modality 64, wherein the dithiocarbamate comprises zinc dimethyldithiocarbamate (ZDMC), zinc diethyldithiocarbamate (ZDEC), zinc dibutyldithiocarbamate (ZDBC), nickel dibutyldithiocarbamate (NDBC), sodium dibenzyldithiocarbamate (SBEC), sodium diethyldithiocarbamate (SDEC), tellurium diethyldithiocarbamate (TDEC), zinc dibenzyldithiocarbamate (ZEBC) or a combination thereof.

[0461] Modality 70. The composition of any of the Modalities 5769, in which one or more rubber chemicals comprise one or more activators.

[0462] Modality 71. The composition of Modality 70, wherein one or more activators comprise a metal oxide, an acid, a metal complex, or a combination thereof.

[0463] Modality 72. The composition of Modality 71, wherein the metal oxide comprises zinc oxide, magnesium oxide, lead oxide or a combination thereof.

[0464] Modality 73. The composition of Modality 72, wherein the acid comprises stearic acid, lauric acid or a combination thereof.

[0465] Modality 74. The composition of Modality 72, in which the metal complex comprises zinc ethylhexanoate.

[0466] Modality 75. The composition of any of the Modalities 5774, in which one or more rubber chemicals comprise one or more pre-vulcanization inhibitors.

[0467] Modality 76. The composition of Modality 75, wherein one or more pre-vulcanization inhibitors comprise N-(cyclohexylthio)phthalimide (CTP), benzoic anhydride, salicylic anhydride, phthalic anhydride or a combination thereof.

[0468] Modality 77. The composition of any of the Modalities 2576, wherein the composition comprises one or more plasticizers.

[0469] Modality 78. The composition of Modality 77, in which the composition comprises approximately 15% p / p and approximately 85% p / p of Petition 870250102374, dated 07 / 11 / 2025, p. 125 / 187 121 / 159 composition of (i) and about 15% by w / w about 85% by w / w of one or more plasticizers.

[0470] Modality 79. The composition of Modalities 77 or 78, where the composition comprises from about 0.1 phr to about 30 phr of one or more plasticizers.

[0471] Modality 80. The composition of Modality 79, where the composition comprises from about 1 phr to about 20 phr of one or more plasticizers.

[0472] Modality 81. The composition of any of the Modalities 7780, wherein one or more plasticizers comprise a mineral oil, an organic ester, a resin, a wax, an ester plasticizer, a naturally derived oil or a combination thereof.

[0473] Modality 82. The composition of Modality 81, in which the mineral oil is naphthenic oil, paraffinic oil or aromatic oil.

[0474] Modality 83. The composition of Modality 81, in which the naturally derived oil is soybean oil, vegetable oil or orange oil.

[0475] Modality 84. The composition of any of the Modalities 2583, in which the composition also includes a second antidegradant.

[0476] Modality 85. The composition of Modality 84, wherein the composition comprises about 15% by w / w about 85% by w / w of the composition of (i) and about 15% by w / w about 85% by w / w of one or more second antidegradants.

[0477] Modality 86. The composition of Modality 84 or 85, in which one or more second antidegradants are present in an amount of about 0.001 phr to about 10 phr.

[0478] Modality 87. The composition of Modality 86, in which one or more second antidegradants are present in an amount of about 0.1 phr to about 5 phr.

[0479] Modality 88. The composition of Modality 87, in which one or more second antidegradants are present in an amount of about 0.5 phr to about 5 phr.

[0480] Modality 89. The composition of Modality 88, in which one or more Petition 870250102374, dated 07 / 11 / 2025, pp. 126 / 187 Antidegradants are present in an amount of about 1 phr to about 5 phr per second.

[0481] Modality 90. The composition of any of the Modalities 8489, in which one or more second antidegradants are an antioxidant.

[0482] Modality 91. The composition of any of the Modalities 8489, in which one or more second antidegradants are antiozonants.

[0483] Embodiment 92. The composition of any of the Embodiments 8491, wherein one or more second antidegradants are a paraphenylenediamine (PPD), a trimethyldihydroquinoline (TMQ), a phenolic, an alkylated diphenylamine (DPA) or a diphenylamine ketone condensate.

[0484] Modality 93. the composition of modality 92, in which the ppd is n1(4-methylpentan-2-yl)-n4-phenylbenzene-1,4-diamine (6PPD), n-(1,4-dimethylpentyl)-n'-phenylp-phenylenediamine (7PPD), n1-phenyl-n4-(propan-2-yl)benzene-1,4-diamine (IPPD), n,n'di-sec-butyl-p-phenylenediamine (44PD), n,n'-bis(1,3-dimethylbutyl)-p-phenylenediamine (66PD), n,n-bis(1,4-dimethylpentyl)-p-phenylenediamine (77PD) or nn-dioctyl-pphenylenediamine (88PD).

[0485] Modality 94. the composition of modality 93, in which the PPD is 6PPD.

[0486] Embodiment 95. the composition of embodiment 92, wherein TMQ is 2,2,4-trimethyl-1,2-dihydroquinoline or an oligomer or polymer thereof.

[0487] Category 96. A vulcanized elastomeric article comprising the composition of any of the Categories 2595.

[0488] Embodiment 97. A vulcanized elastomeric article prepared using the composition of any of Embodiments 25-95.

[0489] Modality 98. The vulcanized elastomeric article of Modalities 96 or 97, where the vulcanized elastomeric article is a tire.

[0490] Modality 99. The vulcanized elastomeric article of Modality 98, wherein the tire is a passenger vehicle tire, a light truck tire, a heavy truck or bus tire, a motorcycle tire, an agricultural tire, an excavator tire, an aircraft tire or a racing tire.

[0491] Modality 100. The vulcanized elastomeric article of Modalities 96 or 97, where the vulcanized elastomeric article is a component of a tire. Petition 870250102374, dated 07 / 11 / 2025, pp. 127 / 187 123 / 159

[0492] Modality 101. Vulcanized elastomeric article of Modality 100, wherein the component is a bead, a belt, a carcass ply, an inner lining, a sidewall, a tread bottom or a tread.

[0493] Modality 102. The vulcanized elastomeric article of Modalities 96 or 97, wherein the vulcanized elastomeric article is a rubber oversole, a sealing strip, an acoustic panel, an air spring, a bellows, a membrane, a tactile sensor, a protective pad, a hose, a conveyor belt or a floor.

[0494] Modality 103. A process for preparing a vulcanized elastomeric article, the process comprising: (a) forming the composition of any of the 25-95 embodiments into a formed shape; and (b) vulcanizing the formed shape to provide a vulcanized elastomeric article.

[0495] Modality 104. The process of Modality 103, in which vulcanization is carried out at an average temperature of about 120 °C to about 180 °C.

[0496] Modality 105. The process of Modality 104, in which vulcanization is carried out at an average temperature of about 140 °C to about 160 °C.

[0497] Modality 106. The process of any of the Modalities 103105, in which the vulcanized elastomeric article is a tire.

[0498] Modality 107. The process of Modality 106, wherein the tire is a passenger vehicle tire, a light truck tire, a heavy truck or bus tire, a motorcycle tire, an agricultural tire, an excavator tire, an airplane tire or a racing tire.

[0499] Modality 108. The process of any of the Modalities 103107, in which the vulcanized elastomeric article is a component of a tire.

[0500] Modality 109. The process of Modality 108, in which the component is a bead, a belt, a carcass ply, an inner lining, a sidewall, a tread bottom or a tread. Petition 870250102374, dated 07 / 11 / 2025, pp. 128 / 187 124 / 159 tires.

[0501] Modality 110. The process of any of the 103105 modalities, wherein the vulcanized elastomeric article is a rubber oversole, a sealing strip, an acoustic panel, an air spring, a bellows, a membrane, a tactile sensor, a protective pad, a hose, a conveyor belt or a floor.

[0502] Modality 111. A lubricating composition comprising a lubricant and the composition of any of the Modalities 25-95.

[0503] Modality 112. A fuel composition comprising a fuel and the composition of any of Modalities 25-95.

[0504] Modality 113. A fuel additive composition comprising a fuel additive and the composition of any of the Modalities 25-95.

[0505] Modality 114. A process for retreading tires, the process comprising: (a) apply the composition of any of the 25-95 Modalities to a tire; (b) to place a pre-vulcanized tread around the tire; (c) place a curing envelope around the tire; and (d) vulcanize the tire. Modality 115. A kit comprising the composition of any of the Modalities 25-95 and instructions for using the composition in a vulcanizable elastomeric composition.

[0506] Modality 116. A kit comprising the composition of any of the Modalities 25-95 and instructions for using the composition to prepare a vulcanized elastomeric article.

[0507] Embodiment 117. A process for preparing the composition of any of the Embodiments 3-21, the process comprising the reaction of 4-aminodiphenylamine with acetone, 2,2-dimethoxypropane or mesityl oxide in the presence of a strong acid, for example, hydrochloric acid.

[0508] Modality 118. A composition comprising the compound of Modalities 1 or 2 and Compound (21), wherein the composition comprises from about 0.0001% to about 10% of Compound (21), as measured by HPLC analysis, Petition 870250102374, dated 07 / 11 / 2025, pp. 129 / 187 125 / 159 for example, about 0.001% to about 10%, 0.01% to about 10%, about 0.1% to about 10%, about 0.0001% to about 5%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.0001% to about 1%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.1% to about 1%, about 0.5% to about 10% or about 1% to about 10% of Compound (21).

[0509] Modality 119. A composition comprising Compound (10); and: (i) Compound (2), wherein the composition comprises from about 0.0001% to about 10% of Compound (2), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (2); and / or (ii) Compound (4), wherein the composition comprises from about 0.001% to about 10% of Compound (4), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (4);and / or (iii) Compound (11A) or Compound (11B), wherein the composition comprises from about 0.001% to about 10% of Compound (11A) or Compound (11B), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (11A) or Compound (11B); and / or (iv) Compound (20A) or Compound (20B), wherein the composition comprises from about 0.001% to about 10% of Compound (20A) or Compound (20B), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about; Petition 870250102374, dated 07 / 11 / 2025, pp. 130 / 187 126 / 159 5%, about 0.1% to about 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to 0.5% of Compound (20A) or Compound (20B); and / or (v) Compound (21), wherein the composition comprises from about 0.0001% to about 10% of Compound (21), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (21).

[0510] Modality 120. A composition comprising Compound (10) and Compound (2), wherein the composition comprises from about 0.0001% to about 10% of Compound (2), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (2).

[0511] Modality 121. A composition comprising Compound (10) and Compound (21), wherein the composition comprises from about 0.0001% to about 10% of Compound (21), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (21).

[0512] Modality 122. A composition comprising Compound (10); and: (i) Compound (2), wherein the composition comprises from about 0.0001% to about 10% of Compound (2), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, about Petition 870250102374, dated 07 / 11 / 2025, pp. 131 / 187 127 / 159 from 0.1% to about 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5% or about 0.1% to about 0.5% of Compound (2); and (ii) Compound (21), wherein the composition comprises from about 0.0001% to about 10% of Compound (21), as measured by HPLC analysis, for example, from about 0.01% to about 10%, from about 0.01% to about 10%, from about 0.1% to about 10%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.05% to about 0.5% or from about 0.1% to 0.5% of Compound (21).

[0513] Modality 123. A composition comprising Compound (10) and Compound (2), wherein the composition comprises about 85% to about 99.5% of Compound (10), as measured by HPLC analysis, for example, about 90% to about 99.5%, or about 95% to about 99% of Compound (10), and about 0.0001% to about 10% of Compound (2), as measured by HPLC analysis, for example, about 0.01% to about 10%, about 0.01% to about 10%, about 0.1% to about 10%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5%, or about 0.1% to 0.5% of Compound (2), and about 85% to about 99.5% of Compound (10), for example, about 90% to about 99.5%, or about 95% to about 99% of Compound (10).

[0514] Modality 124. A composition comprising Compound (10) and Compound (21), wherein the composition comprises about 85% to about 99.5% of Compound (10), as measured by HPLC analysis, for example, about 90% to about 99.5%, or about 95% to about 99% of Compound (10), and about 0.0001% to about 10% of Compound (21), as measured by HPLC analysis, for example, about 0.01% to about 10%, about 0.01% to about 10%, about 0.1% to about 10%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5%, or about 0.1% to about 0.5% of Compound (21). Petition 870250102374, dated 07 / 11 / 2025, p. 132 / 187 128 / 159

[0515] Modality 125. A composition comprising Compound (10), Compound (2) and Compound (21), wherein the composition comprises about 85% to about 99.5% of Compound (10), as measured by HPLC analysis, for example, about 90% to about 99.5%, or about 95% to about 99% of Compound (10), about 0.0001% to about 10% of Compound (2), as measured by HPLC analysis, for example, about 0.01% to about 10%, about 0.01% to about 10%, about 0.1% to about 10%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5%, or about 0.1% to about 0.5% of Compound (2), and about 0.0001% to about 10% of Compound (21) as measured by HPLC analysis, e.g., about 0.01% to about 10%, about 0.01% to about 10%, about 0.1% to about 10%, about 0.001% to about 5%, about 0,01% to about 5%, about 0.1% to about 5%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.05% to about 0.5%, or about 0.1% to 0.5% of Compound (21).

[0516] Modality 126. Compound (21).

[0517] Modality 127. A composition comprising the compound of Modality 126.

[0518] Modality 128. Compound (22).

[0519] Modality 129 A composition comprising the compound of Modality 128.

[0520] Embodiment 130. A composition comprising the compound of Embodiments 1 or 2 and Compound (22), wherein the composition comprises from about 0.0001% to about 10% of Compound (22), as measured by HPLC analysis, for example, from about 0.001% to about 10%, 0.01% to about 10%, from about 0.1% to about 10%, from about 0.0001% to about 5%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.0001% to about 1%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.1% to about 1%, about 0.5% to about 10% or about 1% to 10% of Compound (22).

[0521] Modality 131. Compound (23). Petition 870250102374, dated 07 / 11 / 2025, pp. 133 / 187 129 / 159

[0522] Modality 132. Compound (24).

[0523] Embodiment 133. A composition comprising the compound of Embodiments 1 or 2 and Compound (23), wherein the composition comprises from about 0.0001% to about 10% of Compound (23), as measured by HPLC analysis, for example, from about 0.001% to about 10%, 0.01% to about 10%, from about 0.1% to about 10%, from about 0.0001% to about 5%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.0001% to about 1%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.1% to about 1%, about 0.5% to about 10% or about 1% to 10% of Compound (23).

[0524] Embodiment 134. A composition comprising the compound of Embodiments 1 or 2 and Compound (24), wherein the composition comprises from about 0.0001% to about 10% of Compound (24), as measured by HPLC analysis, for example, from about 0.001% to about 10%, 0.01% to about 10%, from about 0.1% to about 10%, from about 0.0001% to about 5%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.0001% to about 1%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.1% to about 1%, about 0.5% to about 10% or about 1% to 10% of Compound (24).

[0525] Embodiment 135. A composition comprising the compound of Embodiments 1 or 2 and Compound (25), wherein the composition comprises from about 0.0001% to about 10% of Compound (25), as measured by HPLC analysis, for example, from about 0.001% to about 10%, 0.01% to about 10%, from about 0.1% to about 10%, from about 0.0001% to about 5%, from about 0.001% to about 5%, from about 0.01% to about 5%, from about 0.1% to about 5%, from about 0.0001% to about 1%, from about 0.001% to about 1%, from about 0.01% to about 1%, from about 0.1% to about 1%, about 0.5% to about 10% or about 1% to 10% of Compound (25).

[0526] Embodiment 136. A composition comprising the compound of Embodiments 1 or 2 and Compound (37), wherein the composition comprises from about 0.0001% to about 10% of Compound (37), as measured by HPLC analysis, for example, from about 0.001% to about 10%, 0.01% to about 10%, about 0.1% Petition 870250102374, dated 07 / 11 / 2025, pp. 134 / 187 130 / 159 to about 10%, about 0.0001% to about 5%, about 0.001% to about 5%, about 0.01% to about 5%, about 0.1% to about 5%, about 0.0001% to about 1%, about 0.001% to about 1%, about 0.01% to about 1%, about 0.1% to about 1%, about 0.5% to about 10% or about 1% to about 10% of Compound (37).

[0527] This disclosure provides the following particular embodiments. The composite structures are given in Table 1.

[0528] Modality No. 1. A compound of Formula (I): (I) or a salt or solvate thereof, where = represents a single or double bond.

[0529] Modality 2. The compound of Modality No. 1, where the compound of Formula (I) is Compound (1).

[0530] Modality No. 3. The compound of Modality No. 1, where the compound of Formula (I) is Compound (2).

[0531] Modality No. 4. A composition comprising the compound of any of Modalities Nos. 1-3, or a salt or solvate thereof.

[0532] Modality No. 5. A compound of Formula (II): or a salt or solvate thereof, where = represents a single or double bond.

[0533] Modality No. 6. The compound of Modality No. 5, where the compound of Formula (II) is Compound (3).

[0534] Modality No. 7. The compound of Modality No. 5, where the compound of Formula (II) is Compound (4). Petition 870250102374, dated 07 / 11 / 2025, pp. 135 / 187 131 / 159

[0535] Modality No. 8. A composition comprising the compound of any of the Modalities Nos. 5-7, or a salt or solvate thereof.

[0536] Modality No. 9. A compound of Formula (III): (III), or a salt or solvate thereof, where = represents a single or double bond.

[0537] Modality No. 10. The compound of Modality No. 9, in which the compound of Formula (III) is Compound (5).

[0538] Modality No. 11. The compound of Modality No. 9, where the compound of Formula (III) is Compound (6).

[0539] Modality No. 12. A composition comprising the compound of any of the Modalities Nos. 9-11, or a salt or solvate thereof.

[0540] Modality No. 13. A compound that is Compound (21), or a salt or solvate thereof.

[0541] Modality No. 14. A composition comprising the compound of Modality No. 13, or a salt or solvate thereof.

[0542] Modality No. 15. A compound that is Compound (23), or a salt or solvate thereof.

[0543] Modality No. 16. A composition comprising the compound of Modality No. 15, or a salt or solvate thereof.

[0544] Modality No. 17. A compound that is Compound (24), or a salt or solvate thereof.

[0545] Modality No. 18. A composition comprising the compound of Modality No. 17, or a salt or solvate thereof.

[0546] Modality No. 19. A composition comprising a compound of Formula (IV): Petition 870250102374, dated 07 / 11 / 2025, pp. 136 / 187 132 / 159 1. or a 2. (a) one 4. or a 5. (b) one salt or solvate thereof, and: compound of Formula (I): 3. (IV), (I), salt or solvate thereof; or: compound of Formula (II): 6. (II), 7. or a salt or solvate thereof; or 8. (c) a compound of Formula (III): 9. (III), 10. or a salt or solvate thereof; or 11. (d) Compound (7), or a salt or solvate thereof; or 12. (e) Compound (8), or a salt or solvate thereof; or 13. (f) Compound (11A) or Compound (11B), or a salt or solvate thereof; or 14. (g) Compound (20A) or Compound (20B), or a salt or solvate thereof; or Petition 870250102374, dated 07 / 11 / 2025, pp. 137 / 187 133 / 159 15. (h) Compound 21, or a salt or solvate thereof; or 16. (i) Compound (22), or a salt or solvate thereof; or 17. (j) Compound (23), or a salt or solvate thereof; or 18. (k) Compound (24), or a salt or solvate thereof; or 19. (l) a combination of Formula (I), or a salt or solvate thereof; Formula (II), or a salt or solvate thereof; Formula (III), or a salt or solvate thereof; Compound (7), or a salt or solvate thereof; Compound (8), or a salt or solvate thereof; Compound (11A) or Compound (11B), or a salt or solvate thereof; Compound (20A) or Compound (20B), or a salt or solvate thereof; and / or Compound (21), or a salt or solvate thereof; Compound (22), or a salt or solvate thereof; Compound (23), or a salt or solvate thereof; and / or Compound (24), or a salt or solvate thereof; 20. where = represents a single or double bond.

[0547] Modality No. 20. The composition of Modality No. 19 comprising a compound of Formula (IV), or a salt or solvate thereof, and a compound of Formula (I), or a salt or solvate thereof.

[0548] Embodiment No. 21. The composition of Embodiments Nos. 19 or 20, comprising from about 0.1 to about 10% of Formula (I), as measured by high-performance liquid chromatography (HPLC) analysis.

[0549] Modality No. 22. The composition of Modalities Nos. 19 or 20, where the weight ratio of Formula (I) to Formula (IV) is from 0.001 to 0.1.

[0550] Modality No. 23. The composition of any of the Modalities Nos. 19-33 comprising a compound of Formula (IV), or a salt or solvate thereof, and a compound of Formula (II), or a salt or solvate thereof.

[0551] Modality No. 24. The composition of any of the Modalities No. 19-23, comprising about 0.1 to about 10% of Formula (II), as measured by HPLC analysis.

[0552] Modality No. 25. The composition of any of the Modalities No. 19-23, where the weight ratio of Formula (II) to Formula (IV) is 0.001 to 0.1.

[0553] Modality No. 26. The composition of any of the Modalities Nos. 19-25 comprising a compound of Formula (IV), or a salt or solvate of Petition 870250102374, dated 07 / 11 / 2025, pp. 138 / 187 134 / 159 itself, and a compound of Formula (III), or a salt or solvate thereof.

[0554] Modality No. 27. The composition of any of Modalities No. 19-26, comprising about 0.1 to about 10% of Formula (III), as measured by HPLC analysis.

[0555] Modality No. 28. The composition of any of the Modalities No. 19-26, where the weight ratio of Formula (IIII) to Formula (IV) is 0.001 to 0.1.

[0556] Embodiment No. 29. The composition of any of Embodiments Nos. 19-28 comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (7), or a salt or solvate thereof.

[0557] Modality No. 30. The composition of any of the Modalities No. 19-29, comprising from about 0.1 to about 10% of Compound (7), as measured by HPLC analysis.

[0558] Modality No. 31. The composition of any of the Modalities No. 19-29, where the weight ratio of Compound (7) to Formula (IV) is 0.001 to 0.1.

[0559] Modality No. 32. The composition of any of the Modalities Nos. 19-31, comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (11), or a salt or solvate thereof.

[0560] Modality # 33. The composition of any of the Modalities # 19-32, comprising from about 0.001 to about 10% of Compound (8), as measured by HPLC analysis.

[0561] Modality No. 34. The composition of any of the Modalities No. 19-32, where the weight ratio of Compound (8) to Formula (IV) is 0.001 to 0.1.

[0562] Modality No. 35. The composition of any of the Modalities No. 19-34, comprising from about 0.001 to about 10% of Compound (11A) or Compound (11B), as measured by HPLC analysis.

[0563] Modality No. 36. The composition of any of the Modalities No. 19-34, where the weight ratio of Compound (11A) or Compound (11B) to Formula (IV) is 0.001 to 0.1.

[0564] Modality No. 37. The composition of any of the Modalities No. Petition 870250102374, dated 07 / 11 / 2025, pp. 139 / 187 135 / 159 19-36, comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (21), or a salt or solvate thereof.

[0565] Modality # 38. The composition of any of the Modalities # 19-37, comprising about 0.1 to about 10% of Compound (21), as measured by HPLC analysis.

[0566] Modality No. 39. The composition of any of the Modalities No. 19-37, where the weight ratio of Compound (21) to Formula (IV) is 0.001 to 0.1.

[0567] Modality No. 40. The composition of any of the Modalities Nos. 19-39, comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (23), or a salt or solvate thereof.

[0568] Modality No. 41. The composition of any of the Modalities No. 19-40, comprising from about 0.1 to about 10% of Compound (23), as measured by HPLC analysis.

[0569] Modality No. 42. The composition of any of the Modalities No. 19-40, where the weight ratio of Compound (23) to Formula (IV) is 0.001 to 0.1.

[0570] Modality No. 43. The composition of any of the Modalities Nos. 19-42, comprising a compound of Formula (IV), or a salt or solvate thereof, and Compound (24), or a salt or solvate thereof.

[0571] Modality No. 44. The composition of any of the Modalities No. 19-43, comprising from about 0.01 to about 10% of Compound (23), as measured by HPLC analysis.

[0572] Modality No. 45. The composition of any of the Modalities No. 19-43, where the weight ratio of Compound (23) to Formula (IV) is 0.0001 to 0.1.

[0573] Modality No. 46. The composition of any of the Modalities No. 19-45, in which the compound of Formula (IV) is Compound (9).

[0574] Modality No. 47. The composition of any of the Modalities No. 19-47, in which the compound of Formula (IV) is Compound (10).

[0575] Modality No. 48. A composition comprising Compound (10); and Petition 870250102374, dated 07 / 11 / 2025, pp. 140 / 187 136 / 159 (i) about 0.001% to about 10% of Compound (2), as measured by HPLC analysis; and / or (ii) about 0.001% to about 10% of Compound (4), as measured by HPLC analysis, and / or (iii) about 0.001% to about 10% of Compound (11A) or Compound (11B) as measured by HPLC analysis, and / or (iv) about 0.001% to about 20% of Compound (20A) or Compound (20B), as measured by HPLC analysis, and / or (v) about 0.001% to about 10% of Compound (21), as measured by HPLC analysis, and / or (vi) about 0.0001% to about 3% of Compound (23), as measured by HPLC analysis, and / or (vii) about 0.0001% to about 3% of Compound (24), as measured by HPLC analysis.

[0576] Modality No. 49. The composition of Modality No. 48 comprising Compound (10) and about 0.001% to about 10% of Compound (2), as measured by HPLC analysis.

[0577] Modality No. 50. The composition of Modalities No. 48 or 49 comprising Compound (10) and from about 0.01% to about 1% of Compound (2), as measured by HPLC analysis.

[0578] Modality No. 51. The composition of Modalities No. 8 or 49 comprising Compound (10) and from about 0.03% to about 3% of Compound (2), as measured by HPLC analysis.

[0579] Modality No. 52. The composition of Modality 8 comprising Compound (10) and about 0.001% to about 10% of Compound (21) as measured by HPLC analysis.

[0580] Modality No. 53. The composition of any of the Modalities No. 48-52 comprising Compound (10) and from about 0.01% to about 1% of Compound (21), as measured by HPLC analysis.

[0581] Modality No. 54. The composition of any of the Modalities No. 48-52 comprising Compound (10) and from about 0.03% to about 3% of Compound (21), as measured by HPLC analysis. Petition 870250102374, dated 07 / 11 / 2025, pp. 141 / 187 137 / 159

[0582] Modality No. 55. The composition of any of the Modalities No. 48-52 comprising from about 0.02% to about 2% of Compound (11A) or Compound (11B), as measured by HPLC analysis.

[0583] Modality No. 56. The composition of any of the Modalities No. 48-52 comprising from about 1% to about 20% of Compound (20A) or Compound (20B), as measured by HPLC analysis.

[0584] Modality No. 57. The composition of any of the Modalities No. 48-56 comprising about 90% to about 99% of Compound (10), as measured by HPLC analysis.

[0585] Modality No. 58. The composition of any of the Modalities No. 4, 8, 12, 14, 16, 18-57 which also includes: (i) one or more elastomers; or (ii) one or more fillers; or (iii) one or more rubber chemicals; or (iv) one or more plasticizers; or (v) one or more secondary antidegradants; or (vi) a combination of one or more elastomers, one or more fillers, one or more rubber chemicals, one or more plasticizers and / or one or more secondary antidegradants.

[0586] Modality No. 59. A vulcanized elastomeric article comprising the composition of Modality No. 58.

[0587] Modality No. 60. A vehicle comprising the vulcanized elastomeric article of Modality No. 59.

[0588] Modality No. 61. A kit comprising the composition of Modality No. 58 and instructions for using the composition to prepare a vulcanized elastomeric article.

[0589] Embodiment No. 62. A process for preparing the composition of any of Embodiments Nos. 4, 8, 14, 16, 18-45, the process comprising reacting a composition comprising 4-aminodiphenylamine with acetone, 2,2-dimethoxypropane or mesityl oxide in the presence of a strong acid.

[0590] Modality No. 63. A composition comprising the composite of Modalities No. 2, 3, 6, 7, 10, 11, 13, 15 and 17 and: Petition 870250102374, dated 07 / 11 / 2025, pp. 142 / 187 138 / 159 (i) one or more elastomers; or (ii) one or more fillers; or (iii) one or more rubber chemicals; or (iv) one or more plasticizers; or (v) one or more secondary antidegradants; or (vi) a combination of one or more elastomers, one or more fillers, one or more rubber chemicals, one or more plasticizers and / or one or more secondary antidegradants.

[0591] Modality No. 64. A vulcanized elastomeric article comprising the composition of Modality No. 63.

[0592] Modality No. 65. A vehicle comprising the vulcanized elastomeric article of Modality No. 64.

[0593] Modality No. 66. A kit comprising the composition of Modality No. 65 and instructions for using the composition to prepare a vulcanized elastomeric article. EXAMPLES EXAMPLE 1 Reaction of 4-Aminodiphenylamine with acetone

[0594] 184.0 g of 4-aminodiphenylamine (1.0 mol; 99.2% purity) and 8.3 mL of concentrated hydrochloric acid (0.1 mol, 37%, δ = 1.18) catalyst were loaded into a 500 mL kettle-type reactor equipped with a mechanical stirrer, temperature control, addition funnel, nitrogen inlet, and condenser with receiver. It was heated to 95 °C under nitrogen with stirring. 440 mL of acetone (6.0 mol, technical grade, δ = 0.784) was fed from the addition funnel into the reactor, which was stirred for 4.5 hours at 95 °C under nitrogen. 265 mL of acetone collected in the receiver was transferred to the addition funnel, and the reactor was fed for 1.5 hours at 95 °C with stirring under nitrogen. The reaction mass was neutralized with 60 mL of 15% aqueous sodium carbonate. It was cooled to room temperature. The contents of the reactor were transferred to a separatory funnel containing 200 mL of toluene and 50 mL of water in 2 portions. Layers were separated and the aqueous layer was discarded. Toluene was removed by rotary evaporation.212 g of 37% of 6-anilino-2,2,4-trimethyl-1,2-dihydroquinoline, i.e., Compound (10), and 54% of starting material were recovered. Petition 870250102374, dated 07 / 11 / 2025, pp. 143 / 187 139 / 159 Unreacted 4-aminodiphenylamine (“4-ADPA”) was determined by HPLC percentage area. 4ADPA was separated from Compound (10) by preparing a crude solution of approximately 20 g of the reaction mixture in 30 mL of chloroform, loading onto a sintered glass filter (13.3 cm diameter, 2000 mL size) prepared with 350-400 g of silica gel 60, eluting with an additional 3-4 L of chloroform, collecting the clean filtrates (point-checked for the effectiveness of 4-ADPA separation by thin-layer chromatography) in 500 mL portions, and removing volatiles by rotary evaporation. Analysis of the final material purified by silica column filtering showed 95.3% Compound (10) and other unexpected molecules, i.e., byproducts, as measured by HPLC. See Figure 1, Table 1 and Table 2. It has not yet been determined whether the HPLC peak at 8.7 min is Composite (11A), Composite (11B), Composite (20A) or Composite (20B). TABLE 2 Retention time (minutes) Composite % of HPLC Area Mass-to-load ratio 5.6; 6.0 E / Z-(4) 0.36; 0.39 263 7.1 (10) 95.3 265 8.1 (2) 0.10 265 8.3 (13) 0.05 489 8.4 (14), (25) 0.16 445,279 8.7 (11A), (11B), (20A) or (20B) 0.25 305 9.1 (15) 0.15 445 10.0 (12) 0.16 529 METHOD 1. HPLC ANALYSIS

[0595] Chromatograms were obtained using an Agilent 1260 Infinity II series HPLC system equipped with a Poroshell 120 column (EC-C18 4.6 x 50 mm, 2.7 μm) maintained at 25 °C with an injection volume of 5 μL. A diode array detector was used to measure the UV absorption of the effluent at various wavelengths in the range of 200 to 450 nm (2 nm step). The wavelength of 260 nm was used for determination of the percentage of each component by peak area. The analytes can be reliably detected at or above 0.5 ppm. Petition 870250102374, dated 07 / 11 / 2025, pages 144 / 187 140 / 159 The molecular weights of each peak observed in the chromatograms were identified by MS coupled to the LC-UV system using a single mass-selective quadrupole detector with atmospheric pressure chemical ionization in positive mode. The source parameters were defined as follows: the gas and vaporizer temperatures were 300 °C and 200 °C, respectively, the gas flow rate was 5.0 L / min, and the nebulizer pressure was 15 PSI. The mobile phase (flow rate of 1 mL / min) consisted of 5 mmol / L aqueous ammonium formate (Solvent A) and acetonitrile (Solvent B) using the following gradient shown in Table 3. TABLE 3 Time (min) Solvent A (%) Solvent B (%) 0.00 70 30 0.50 70 30 9.00 5 95 16.00 5 95 18.00 70 30 20.00 70 30 METHOD 2: HPLC-UV / MS

[0596] Chromatograms were obtained using an Agilent 1260 Infinity II series HPLC system equipped with an Agilent Poroshell 120 column (EC-C18 4.6 x 100 mm, 2.7 μm, PN:695975-902) maintained at 25 °C with an injection volume of 5 μL. A diode array detector was used to measure the UV absorption of the effluent at various wavelengths in the range of 200 to 450 nm (2 nm step). The wavelength of 290 nm (bw = 20) can be used for detection of each component percentage by peak area. The molecular weights of each peak observed in the chromatograms were identified by MS coupled to the LCUV system using an Agilent InfinityLab LC / MSD G6125C single quadrupole mass-selective detector in APCI+ mode with a fragmentation voltage of 100 V. The compounds were detected as the protonated form of the parent ion [M + 1]+.The source parameters were defined as follows: gas and vaporizer temperatures were 300 °C and 200 °C, respectively; gas flow rate was 5.0 L / min; and nebulizer pressure was 15 PSI. For selected ion monitoring (SIM) detection, the mass spectrometer was adjusted to monitor the intensity of the selected compound response at m / z = [M+1]+. For detection. Petition 870250102374, dated 07 / 11 / 2025, pages 145 / 187 141 / 159 For the SIM of compounds (2), (21), (23) and (25), the mass spectrometer was set to m / z = 265, 225 and 279 amu, respectively. The mobile phase (flow rate of 1 mL / min) consisted of 75 mM aqueous formic acid and 5 mM aqueous buffer solution of ammonium formate (Solvent D) and acetonitrile (Solvent B) using the following gradient shown in Table 4. TABLE 4 Time (min) Solvent B (%) Solvent D (%) 0.00 20 80 1.00 20 80 29.00 95 5 38.00 95 5 40.00 20 80 42.00 20 80

[0597] To minimize interference from high concentrations of Compound (10), when using SIM, a diverter valve was used to divert the eluent from the MS detector to the residue during the elution time of Compound (10) during acquisition.

[0598] To determine the experimental limit of detection (LOD) or lower limit of the working calibration range, two stock solutions of Compound (21) were prepared with concentrations of 470 ppm (μg / ml) and 958 ppm (μg / ml). A 10:1 serial dilution was applied to each stock solution until concentrations of 4.70 parts per billion (ppb) and 0.958 ppb were reached, respectively. Standards with concentrations between 4.70 ppm and 0.958 ppb (eight standards in total) were injected using Method 2, and a linear calibration with displacement (origin ignored) was used to evaluate the calibration range. The lower limit of the working range was determined by the lowest concentration standard with a relative residual percentage within + / - 20%. For Molecule (21), the LOD was determined to be 9.58 parts per billion, with a residual of -19.3%. METHOD 3: GC-MS

[0599] Chromatograms were obtained using a Thermo Fisher Trace 1310 gas chromatograph with an ISQ7000 single quadrupole mass spectrometer for detection. One microliter of sample solution was injected with an AI 1310 autosampler into a split inlet with a split flow rate of 15 ml / min and a purge flow rate of 5 ml / min, maintaining an inlet temperature of 250 Petition 870250102374, dated 07 / 11 / 2025, pages 146 / 187 142 / 159 °C. Helium was used as the carrier gas at a constant flow rate of 1 ml / min, with an Agilent VF-5ms capillary column (15 m x 0.25 mm x 1 μm) used for the stationary phase. The initial oven temperature of 35 °C was maintained for one minute before increasing at 15 °C / min to 240 °C. The oven was maintained at 240 °C for 3 minutes, followed by an increase of 8 °C / min to 300 °C, where it was held isothermally for 20 minutes, resulting in a total method time of 45.2 minutes. The temperatures of the mass spectrometer transfer line and the ion source were both 300 °C. Electron impact (EI) ionization mode was used to collect total ion chromatograms from 40 to 550 amu (dwell time of 0.1 s) for general identification, while target mass ranges with the same ionization mode and parameters were used for quantitative analysis of specific analytes of interest.The target mass ranges depended on the analyte and were selected from the most abundant ion in the spectra generated from the above conditions. The selected ion ranges were 208–210 amu for Compound (21), 262–265 amu for Compounds (23) and (25), and 248–250 amu for Compound (2). The methods were calibrated with purified external standards diluted to various levels, typically between 50 ppb and 5000 ppb, although the ranges may vary depending on the analyte concentration observed. Chromeleon CDS was used for spectra and quantitative analysis.

[0600] To estimate the experimental limit of detection (LOD) or lower limit of the working calibration range, two stock solutions of Compound (25) were prepared with concentrations of 554 ppm (μg / ml) and 1184 ppm (μg / ml). A 10:1 serial dilution was applied to each stock solution until concentrations of 5.54 parts per billion (ppb) and 1.18 ppb were achieved, respectively. Standards with concentrations between 5.54 ppm and 1.18 ppb (eight standards in total) were injected using Method 3, and a linear calibration with displacement (origin ignored) was used to evaluate the calibration range. The lower limit of the working range was estimated by the lowest concentration standard with a relative residual percentage within + / - 20%. For Molecule (25), the LOD was determined to be 55.4 parts per billion, with a residual of -5.75%. EXAMPLE 2 Reaction of 4-Aminodiphenylamine with mesityl oxide Petition 870250102374, dated 07 / 11 / 2025, pages 147 / 187 143 / 159

[0601] 5.54 g of 4-aminodiphenylamine (30 mmol; 99.2% purity) and 0.5 mL of concentrated hydrochloric acid (6 mmol, 37%, δ = 1.18) catalyst were loaded into a 50 mL reactor equipped with a magnetic stirrer, temperature control, addition funnel, nitrogen inlet, and reflux condenser with receiver. The reactor was heated to 100 °C under nitrogen with stirring. 23 mL of mesityl oxide (180 mmol, 90% technical grade, Sigma, δ = 0.858) was added for 2 hours at 100 °C under nitrogen with stirring. The reactor was then maintained for a further 2.5 hours under the same conditions, monitoring the reaction until completion by HPLC analysis (Method 1). The reactor was neutralized with 4 mL of 15% aqueous sodium carbonate. The contents of the reactor were cooled to room temperature. They were transferred to a separatory funnel containing 50 mL of chloroform and 20 mL of water in two portions. The layers were separated, and the aqueous layer was discarded. Chloroform and some mesityl oxide were removed by rotary evaporation.9.7 g of 59.1% of Compound (10) were recovered, along with approximately 10% of total unreacted starting materials (9% mesityl oxide and 1% 4-aminodiphenylamine) and other unexpected molecules, i.e., byproducts, measured by percentage area by HPLC. See EXAMPLE 1 for details of the HPLC analysis, Table 1 and Table 5. It has not yet been determined whether the HPLC peak at 7.3 min is Compound (11A), Compound (11B), Compound (20A), or Compound (20B). TABLE 5 Retention time (minutes) Composite % of HPLC Area Mass-to-load ratio 5.6; 6.0 E / Z-(4) 0.25; 0.19 263 6.9 (17) 1.8 363 7.1 (10) 59.1 265 7.3 (11A), (11B), (20A) or (20B) 9.9 305 8.5 (18) 2.3 345 8.6 (19) 2.6 345 EXAMPLE 3 REACTION OF 4-AMINODIPHENYLAMINE WITH ACETONE AND OXIDE OF MESTILA Petition 870250102374, dated 07 / 11 / 2025, pp. 148 / 187 144 / 159

[0602] To a stirred solution of 4-aminodiphenylamine (1.50 g, 8.14 mmol) in 3:2 v:v acetone:mesityl oxide (5 mL) at room temperature, zinc triflate (0.296 g, 0.814 mmol) was added. The stirred mixture was heated to 80 °C and held for 22 h. The mixture was then allowed to stand and cooled for 10 minutes at room temperature. The solution was then decanted, pouring it into a clean flask. The remaining sediment was washed with 20 mL of acetone in two portions, which were combined with the solution in the flask. The resulting solution was then evaporated under reduced pressure to give 3.08 g of material containing Compound (10) and other unexpected molecules, i.e., byproducts, including Compounds (2), (21), (23), (25), and (37). Figures 2-5 and 23. EXAMPLE 4 Reaction of 4-Aminodiphenylamine with acetone

[0603] A solution of 4-aminodiphenylamine (750.0 g, 2.7 mol) in acetone (1800 mL) was added to zinc triflate (148 g, 0.27 mol) under a nitrogen atmosphere at room temperature. The resulting mixture was heated to 60-65 °C and held for 20 h. After completion of the reaction by TLC, it was cooled to room temperature and filtered through a celite bed. The celite bed was washed with ethyl acetate, the filtrate was collected and evaporated under reduced pressure. This procedure was repeated 4 times, and the crude materials were combined. The combined crude material was purified by column chromatography using silica gel (mesh 100-200) eluting with 5-10% ethyl acetate in hexane to give 1534.0 g of purified Compound (10) as a light yellow solid. Analysis of the final material by Method 1 showed 98.5% of Compound (10) and other unexpected molecules, i.e., byproducts. Figures 6 and 7. EXAMPLE 5 Reaction of 2-Aminodiphenylamine with acetone

[0604] 5.53 g of 2-aminodiphenylamine (30 mmol, Sigma) and 0.25 mL of concentrated hydrochloric acid (3 mmol, 37%, δ = 1.18) catalyst were loaded into a 50 mL reactor equipped with a magnetic stirrer, temperature control, addition funnel, nitrogen inlet, and reflux condenser with receiver. It was heated to 95 °C under nitrogen with stirring. It was fed with 13.5 mL of acetone (180 mmol, ACS grade, δ = 0.784) for 1.5 hours at 95 °C under nitrogen and stirring. It was maintained Petition 870250102374, dated 07 / 11 / 2025, pp. 149 / 187 145 / 159 for an additional 1.5 hours under the same conditions. Neutralized with 2 mL of 15% aqueous sodium carbonate. Cooled to room temperature. Transferred the reactor contents to a separatory funnel containing 50 mL of toluene and 20 mL of water in 2 portions. Separated layers and water discarded. Toluene removed by rotary evaporation. 5.6 g of material containing 4.5% 8-anilino-2,2,4-trimethyl-1,2-dihydroquinoline (Compound (2)), 65.6% unreacted 2-aminodiphenylamine (“2-ADPA”) starting material and other molecules, i.e., byproducts, measured by percentage of area by HPLC, were recovered. See EXAMPLE 1 for details of the HPLC analysis and Table 6. TABLE 6 Retention time (minutes) Composite % of HPLC Area Mass load ratio 4.5 2-ADPA 65.6 185 5.2 (21) 13.8 225 6.1 (7) 13.2 225 8.1 (2) 4.5 265 EXAMPLE 6 Reaction of 2-aminodiphenylamine with mesityl oxide

[0605] 4.28 g of 2-aminodiphenylamine (23.2 mmol, Sigma) and 0.2 mL of concentrated hydrochloric acid (2.4 mmol, 37%, δ = 1.18) catalyst were loaded into a 50 mL reactor equipped with a magnetic stirrer, temperature control, addition funnel, nitrogen inlet, and reflux condenser with receiver. The mixture was heated to 95 °C under nitrogen with stirring. 11 mL of mesityl oxide (91.4 mmol, 95%, TCI, δ = 0.858) was added for 1 hour at 95 °C under nitrogen with stirring. The mixture was then maintained for another 1.5 hours under the same conditions. The mixture was neutralized with 1.5 mL of 15% aqueous sodium carbonate. It was allowed to cool to room temperature. Analysis of the gross reaction mass showed 4.6% of Compound (2), 65.1% of the total unreacted starting materials (42.3% mesityl oxide and 22.8% 2-ADPA) and other byproducts measured by percentage of area by HPLC. See EXAMPLE 1 for details of the HPLC analysis and Table 7.It has not yet been determined whether the HPLC peak at 8.4 min is Composite (11A), Composite (11B), Composite (20A) or Composite (20B). Petition 870250102374, dated 07 / 11 / 2025, pp. 150 / 187 146 / 159 TABLE 7 Retention time (minutes) Compound % of HPLC Area Mass load ratio 1.5 Mesityl oxide 42.3 4.5 2-ADPA 22.8 185 5.2 (21) 6.2 225 6.2 (7) 5.1 225 8.1 (2) 4.6 265 8.4 (11A), (11B), (20A) or (20B) 6.4 305 EXAMPLE 7 SYNTHESIS OF COMPOUND (4) (2,2,4-TRIMETHYL-N-PHENYLQUINOLINE-6(2H)IMINE) IMaOCí (aqueous) Acetonitrile (4)

[0606] A 250 mL round-bottom flask fitted with a stir bar was loaded with 2,2,4-trimethyl-N-phenyl-1,2-dihydroquinolin-6-amine (5.5 g; 20.8 mmol) and then covered with N2. Acetonitrile (60 mL) was added and the mixture was stirred (the substrate dissolved in minutes). 10-15% aqueous NaOCl (16 mL; 25,938.9 mmol hypochlorite anion) was added in portions over 6-7 min. A dense liquid separated immediately. The biphasic system was stirred without external cooling or heating. A gradual and moderate exothermic reaction occurred, peaking at about 25 min. After 30 min of reaction, the TLC on silica gel using 20% ​​AcOEt in hexanes as eluent showed complete consumption of the substrate (Rf = 0.45), as well as the formation of two new points (Rf = 0.2 and 0.4). After approximately 50 minutes of reaction, 1.69 mol / L aqueous Na2SOs (15 mL; 25.35 mmol sulfite anion) was added to quench the excess hypochlorite anion (an exothermic reaction was observed).The two-phase system was diluted with ethyl acetate (60 mL) in a separatory funnel. The aqueous phase was discarded. The organic phase was washed with water. Petition 870250102374, dated 07 / 11 / 2025, pp. 151 / 187 147 / 159 deionized (60 mL), with dilute aqueous NaCl (60 mL), with saturated aqueous NaCl (60 mL), dried over anhydrous MgSCM, filtered and then removed from volatiles under reduced pressure (rotary evaporator; water bath = 50 °C). Subsequent drying in the rotary evaporator (50 °C; approx. 10 mbars) to constant weight yielded a dark viscous liquid (4.7 g; 86% yield relative to 2,2,4-trimethyl-N-phenyl-1,2-dihydroquinoline-6-amine). The structure was authenticated by NMR spectroscopy as well as LC-MS m / z [M+1]+= 263. The purity of Compound (4) was 99.03% (combined areas of the 2 stereoisomers) measured by LC-UV 260 nm. The proton NMR (DMSO-de) spectrum and the HPLC chromatogram are shown in Figure 8 and Figure 9, respectively. EXAMPLE 8 SYNTHESIS OF COMPOUND (2) (2,2,4-TRIMETHYL-N-PHENYL-1,2DIHYDROQUINOLINE-8-AMINE) AND COMPOUND (21) (11,11-DIMETHYL-10,11DIHYDRO-5H-DIBENZO[B,E][1,41DIAZEPINE)

[0607] In a 100 mL round-bottom flask fitted with a stirring bar and a reflux condenser, Compound (32) (10.48 g; 56.9 mmol) and acetone (17.0 mL; 232 mmol) were loaded. The mixture was stirred under N2 protection (2-ADPA dissolved easily). Zinc triflate (2.15 g; 5.91 mmol) was added in portions and the reaction mixture was gradually heated with an oil bath (set temperature = 70 °C). Once the temperature was reached, it was maintained for 24 hours. After cooling to room temperature (overnight), the viscous residue was diluted with a mixture of toluene (2 mL) and acetone (3 mL). The resulting free-flowing dark liquid (containing traces of insoluble materials) was loaded onto a 41 mm internal diameter column prepared with silica gel 60 and 10% AcOEt in hexanes. The height of the wet silica gel in the column was 25-26 cm. The walls of the flask and column were rinsed with toluene (1 mL).The column was eluted with 10% AcOEt in hexanes. Each portion that came out was analyzed by TLC on silica gel. Fraction 1, containing 0 material with an Rf of 0.5 (10% AcOEt in...), Petition 870250102374, dated 07 / 11 / 2025, pages 152 / 187 A fraction of 148 / 159 hexanes was collected. The column was eluted with 30% AcOEt in hexanes. Fraction 2, containing the material with an Rf of 0.2 (10% AcOEt in hexanes), was collected. Each fraction was independently separated from the volatiles under reduced pressure (rotary evaporator; water bath = 55 °C). Subsequent drying in the rotary evaporator (60 °C; 5-15 mbars) to constant weight yielded the two products.

[0608] Fraction 1: Compound (2); isolated yield = 0.37 g; light brown oil, which solidified upon standing at room temperature overnight. The structure was authenticated by NMR spectroscopy as well as LC-MS m / z [M+1]+ = 265. Purity was 95.2% area, measured by LC-UV 260 nm. The carbon 13 (DMSO-d6) APT NMR spectrum and HPLC chromatogram are shown in Figure 10 and Figure 11, respectively.

[0609] Fraction 2: isolated yield = 9.2 g; light orange solid. This impure material containing approximately 9% residual 2-ADPA (LC-UV 260 nm) was dissolved in AcOEt (14 mL) using a warm water bath. To the resulting solution, under stirring and protection with N2, hexanes (25 mL) were added. The mixture was stirred until a solid separated. A mixture of AcOEt - hexanes (7 mL and 11 mL, respectively) was added to loosen the solid. The solid was collected by vacuum filtration on a 0.2 micron disposable polyethylene frit and washed with a mixture of AcOEt - hexanes (4 mL and 7 mL, respectively). The wet beige solid was dried under vacuum at 50 °C for a few hours and then at room temperature overnight. Yield = 2.5 g; gas, an almost white solid. The structure was authenticated by NMR spectroscopy as well as LC-MS m / z [M+1]+= 225. The purity of Compound (21) was 98.9% area, measured by LC-UV 260 nm.The carbon-13 (DMSO-d6) APT NMR spectrum and the HPLC chromatogram are plotted in Figure 12 and Figure 13, respectively. EXAMPLE 9 SYNTHESIS OF THE COMPOUND (23) (1,2,2,4-TETRAMETHYL-N-PHENYL-1,2DIIDRQQU!NOLIN-6-AMINE) AND THE COMPOUND (241(Ni1J212J4-RENTAMETHYL-NFENYL-1.2-DIHYDROQUINOLIN-6-AMINE) Petition 870250102374, dated 07 / 11 / 2025, pp. 153 / 187 149 / 159 □ MF KjCOj Temp, environment Compound (23) Compound (24)

[0610] In a 250 mL round-bottom flask fitted with a stirring bar, Compound (10) (5.0 g; 18.9 mmol) was loaded. The flask was placed under N2 protection and dry DMF (27 mL) was added. Stirring was started. Once Compound (10) was completely dissolved, anhydrous potassium carbonate (3.317 g; 24.0 mmol) was added. The flask was cooled with a cold tap water bath, and lodomethane (1.5 mL; 24.0 mmol) was added over 1–2 minutes. No perceptible exothermic reactions occurred. The cooling bath was removed. The reaction mixture was stirred without external cooling or heating for 21.5 hours. Deionized water (27 mL) was added and the mixture was stirred for 30 minutes. AcOEt (100 mL) and deionized water (20 mL) were added and the mixture was stirred until the gummy material dissolved. The resulting two-phase system was transferred to a separatory funnel and the organic layer was collected.The aqueous layer was extracted with AcOEt (70 mL). The combined organic layers were washed with 1 mol / L aqueous NaOH (3 x 50 mL) and aqueous NaCl, dried over MgSO4, filtered, and then removed from volatiles under reduced pressure (rotary evaporator; water bath = 50 °C). Further drying on the rotary evaporator (60 °C; < 10 mbars; 1 hour) yielded the crude material (brown oil; 4.1 g). The crude material was dissolved in 5% AcOEt in hexanes (7 mL). The resulting solution was loaded onto a 41 mm internal diameter column prepared with silica gel 60 and 5% AcOEt in hexanes. The height of the wet silica gel in the column was 25-26 cm. The column was eluted with 5% AcOEt in hexanes. Each portion that exited was analyzed by TLC on silica gel. Fraction 1, containing material with an Rf of 0.4 (5% AcOEt in hexanes), was collected. The column was eluted with 20% AcOEt in hexanes. Fraction 2, containing material with an Rf of 0.15 (5% AcOEt in hexanes), was collected.Each fraction was independently separated from volatiles under reduced pressure (rotary evaporator; water bath = 50 °C). Subsequent drying in the rotary evaporator (60 °C; 9-10 mbars) to constant weight yielded the final products.

[0611] Fraction 1: Compound (24); isolated yield = 0.8 g; yellow oil Petition 870250102374, dated 07 / 11 / 2025, pages 154 / 187 150 / 159 clear. The structure was authenticated by NMR spectroscopy as well as LC-MS m / z [M+1]+= 293. The purity was 99.0% area, measured by LC-UV 260 nm. The carbon-13 APT (DMSO-de) NMR spectrum and the HPLC chromatogram are shown in Figure 14 and Figure 15, respectively.

[0612] Fraction 2: Compound (23); isolated yield = 3.2 g; light yellow oil. The structure was authenticated by NMR spectroscopy as well as LC-MS m / z [M+1]+= 279. Purity was 95.5% area, measured by LC-UV 260 nm. The carbon 13 APT (DMSO-de) NMR spectrum and HPLC chromatogram are shown in Figure 16 and Figure 17, respectively. EXAMPLE 10 SYNTHESIS OF COMPOUND (7) (2,2-DIMETHYL-1-PHENYL-2,3-DIHYDRO-1 HBENZO[D]IMIDAZOLE) Compound (32) PURE MgBr26H2O 70 degrees C Compound (7)

[0613] In a 2-DR flask fitted with a stir bar, Compound (32) (1.632 g; 8.86 mmol), magnesium bromide hexahydrate (270 mg; 0.924 mmol), and acetone (3 mL; 40.9 mmol) were loaded. The flask was purged with N2 for a few seconds, stoppered, and then heated to 70 °C (heating block) for 17 hours. After cooling to room temperature, part of the post-reaction mixture was loaded directly onto a 2.54 cm (1 inch) internal diameter column prepared with neutral alumina (grade I) and 10% AcOEt in hexanes. The height of the wet alumina in the column was 11–12 cm. The column was eluted with 10% AcOEt in hexanes. Each resulting fraction was analyzed by TLC of neutral alumina (20% AcOEt in hexanes). The fractions containing the point at Rf = 0.6 were collected, combined, and removed from the volatiles under reduced pressure (rotary evaporator; water bath = 45 °C). Subsequent drying in the rotary evaporator (45 °C) until weight Petition 870250102374, dated 07 / 11 / 2025, pp. 155 / 187 151 / 159 constant produced a light brown oil (0.2 g), which solidified as a beige solid when left at room temperature overnight. The structure was authenticated by NMR spectroscopy as well as LC-MS m / z [M+1]+= 225. The purity of Compound (7) was 84.2% area, measured by LC-UV 260 nm (the chromatogram also shows 12.5% ​​area of ​​compound (32)). The carbon 13 (CD2CI2) APT NMR spectrum and HPLC chromatogram are plotted in Figure 18 and Figure 19, respectively. EXAMPLE 11 SYNTHESIS OF COMPOUND (25) (N,2,2,4-TETRAMETHYL-N-PHENYL-1,2DIHYDROQUINOLIN-6-AMINE) Toluene Pd2(dba)3 X-phos Sodium tert-butoxide 105 degrees C Compound (25)

[0614] In a 250 mL round-bottom flask fitted with a stir bar and a reflux condenser, the substrate 6-bromo-2,2,4-trimethyl-1,2-dihydroquinoline (1.415 g; 5.61 mmol), anhydrous toluene (20.5 mL) and N-methylaniline (0.63 mL; 5.81 mmol) were loaded. The mixture was stirred under a N2 mantle. After complete dissolution of the substrate (a few minutes), dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphane (0.1159 g; 0.243 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.1238 g; 0.135 mmol) and sodium tert-butoxide (0.6087 g; 6.33 mmol) were sequentially added to the flask. N2 was bubbled into the mixture for about one minute, and then the reaction mixture was heated (oil bath temperature adjusted to 105 °C) under a layer of N2 for 3.5 hours. After cooling to room temperature (overnight), the post-reaction mixture was filtered by suction over Celite S. The filter cake was washed with toluene.The combined filtrates were stripped of volatiles under reduced pressure (rotary evaporator; water bath = 70°C). The resulting brown oil was diluted with hexanes (4 mL) and the solution was loaded onto a 2.54 cm (1 inch) internal diameter column prepared with silica gel 60 and 5% AcOEt in hexanes. The height of the wet silica gel in the column was approximately 18 cm. The column was eluted with 5% AcOEt in hexanes. Each resulting fraction was analyzed by gel TLC. Petition 870250102374, dated 07 / 11 / 2025, pages 156 / 187 152 / 159 silica (5% AcOEt in hexanes). The fractions containing the point at Rf = 0.2 were combined and removed from volatiles under reduced pressure (rotary evaporator; water bath = 50°C). Drying under vacuum at 50°C for a few hours and then at room temperature overnight yielded 1.212 g of a very viscous light brown oil. The structure was authenticated by NMR spectroscopy as well as LC-MS m / z [M+1]+= 279. The purity of Compound (25) was 98.6% area, measured by LC-UV 260 nm. The proton and carbon 13 APT (DMSO-de) NMR spectra, as well as the HPLC chromatogram, are shown in Figure 20, Figure 21, and Figure 22, respectively. EXAMPLE 12 SYNTHESIS OF COMPOUND (8) (1-PHENYL-1 H-BENZO[D1IMIDAZOLE) Compound (8)

[0615] To a stirred solution of formic acid (425 mL) was added 2-amino-diphenylamine (85.0 g, 0.46 mol) at room temperature. The reaction was heated to 100 °C and maintained for 16 h. After completion of the reaction (monitored by TLC), the reaction mass was cooled to room temperature and dissolved in DCM (500 mL), washed with water (2 x 200 mL) and then saturated NaHCO3 solution. Separated organic layer evaporated under reduced pressure at 45 °C to give 75.0 g crude compound Compound (8).

[0616] Purification: The crude compound obtained was purified by column chromatography using silica gel (60-120 mesh) as the stationary phase, eluting with 5% ethyl acetate in hexane, collecting the pure fractions and evaporating under reduced pressure to provide the desired 55.0 g of Compound (8) as a brown semisolid.

[0617] 1H NMR (400 MHz, DMSO-de): δ 8.57 (s, 1H), 7.80 (dd, J=4.8 Hz, 1H), 7.79-760 (m, 1H), 7.51 (t, J=7.2 Hz, 1H), 7.49-7.29 (m, 1H). 13C NMR (100 MHz, DMSO-de): δ 147.39, 143.71, 136.46, 133.56, 130.50, 128.13, 124.08, 123.91, 122.92, 120.48, 111.08, 40.63, 40.42, 40.00, 39.80, 39.59, 39.38. Petition 870250102374, dated 07 / 11 / 2025, pp. 157 / 187 153 / 159 EXAMPLE 13 SYNTHESIS OF COMPOUND (34) (N-(2-(PHENYLAMINO)PHENYL)FORMAMIDE) Compound (34)

[0618] To a stirred solution of 2-amino-diphenylamine (2.5 g, 13.58 mmol) in THF (25 mL, 10 vol), N-formylsaccharin (2.8 g, 13.58 mmol) was added at room temperature, where it was stirred for 15-20 min. After completion of the reaction (monitored by TLC), it was quenched with saturated solution of NaHCO3 (12 mL) and extracted with DCM (30 mL). The organic layer was separated, dried over sodium sulfate, filtered and evaporated under vacuum to give 3.4 g of the crude compound (34). The crude product obtained was purified by silica-gel column chromatography (100 to 200 mesh) eluting with 15 to 20% ethyl acetate in hexane and pure fractions were collected and the solvent was evaporated under reduced pressure to give the pure Compound (34) (observed as Rotamers by 1H NMR) as a whitish solid. Yield 1.5 g.

[0619] 1H NMR (400 MHz, DMSO-d6 at 90°C): δ 9.21 (s, 1H), 8.32 (s, 1H), 7.73 (brs, 1H), 7.22-7.15 (m, 3H), 7.10-7.06 (m, 2H), 7.01-6.97 (m, 1H), 6.84-6.82 (m, 2H), 6.80-6.76 (m, 1H). 13C NMR (100 MHz, DMSO-d6): δ 163.87, 160.73, 145.31, 144.41, 135.74, 134.54, 130.88, 129.60, 129.53, 126.25, 125.45, 123.55, 123.22, 122.63, 122.20, 120.52, 119.96, 119.50, 116.79, 116.21. EXAMPLE 14 SYNTHESIS OF COMPOUND (37) (2-METHYL-1-PHENYL-1 H-BENZO[D]IMIDAZOLE) Compound (37) Petition 870250102374, dated 07 / 11 / 2025, pp. 158 / 187 154 / 159

[0620] To a stirred solution of acetic acid (500 mL) was added 2-amino-diphenylamine (100.0 g, 0.54 mol) at room temperature. Heated to 90 °C and held for 16 h. After completion of the reaction (monitored by TLC), the reaction mass was cooled to room temperature and dissolved in DCM (500 mL), washed with water (2 x 200 mL) and then saturated NaHCO3 solution. Separated organic layer evaporated under reduced pressure at 45 °C to give 110.0 g of crude compound, Compound (37).

[0621] Purification: The crude compound obtained was purified by column chromatography using silica gel (60-120 mesh) as the stationary phase, eluting with 5% ethyl acetate in hexane, collecting the pure fractions and evaporating under reduced pressure to provide the desired 60.0 g of Compound (37) as a light pink solid.

[0622] 1H NMR (400 MHz, DMSO-d6): δ 7.66 (t, J=7.2 Hz, 3H), 7.64-7.53 (m, 3H), 7.24-7.15 (m, 2H), 7.10 (d, J=7.2 Hz, 1H), 2.43 (s, 3H). 13C NMR (100 MHz, DMSO-d6): δ 151.74, 142.90, 136.07, 130.43, 129.12, 127.34, 122.75, 122.39, 118.97, 110.21,40.67, 40.63, 40.46, 40.42, 40.25, 40.21,40.00, 39.79, 39.58, 14.57. EXAMPLE 15 SYNTHESIS OF COMPOUND (38) (N1-METHYL-N1-PHENYLBENZENE-1,4DIAMINE) Intermediate 1 Compound (38)

[0623] To a stirred and degassed solution of toluene (2000 mL) was added Pdzdbas (23.2 g, 0.025 mol), X-Phos (6 g, 0.012 mol), at room temperature and degassed for 15 min., then the reaction contents were heated to 60 °C. Next, p-chloronitrobenzene (100.0 g, 0.63 mol) and N-methylaniline (75 g, 0.69 mol) were added, followed by NaOtBu (91.5 g, 0.95 mol). The resulting reaction mixture was heated to 90 °C and stirred for 16 h. The completion of the reaction, monitored by TLC, was cooled to room temperature and filtered through a celite pad and washed with ethyl acetate (300 mL). The combined filtrate was washed with water, Petition 870250102374, dated 07 / 11 / 2025, pp. 159 / 187 155 / 159 dried over Na2SO4 and evaporated under reduced pressure to give crude Intermediate 1 (75.0 g).

[0624] Purification: The crude product obtained was purified by column chromatography using silica gel (100-200 mesh) as the stationary phase, eluting with 5-10% ethyl acetate in hexane. The pure fractions were collected and the solvent evaporated under vacuum to provide the desired 60.0 g of Intermediate 1 as a brown solid.

[0625] 1H NMR (400 MHz, DMSO-d6): δ 7.54 (s, 1H), 7.10 (td, J= 8.4, 1.6 Hz, 2H), 6.82 (dd, J= 8.8, 1.2 Hz, 2H), 6.63-6.56 (m, 3H), 6.49 (dd, J= 8.0, 2.0 Hz, 1H), 4.38 (s, 2H), 3.72 (s, 3H). STAGE 2:

[0626] To a stirred solution of Intermediate 1 (60 g, 0.26 mol) in methanol (300 mL) was added Raney-Ni (15 g, 25% w / w) at room temperature. Hydrogen pressure (10 kg) was then applied and maintained for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a celite pad, washed with methanol (150 mL), and the solvent was evaporated to give 55.0 g of Compound 38 as a crude product.

[0627] Purification: The crude product obtained was purified by column chromatography using silica gel (100-200 mesh) as the stationary phase, eluting with 15% ethyl acetate in hexane. The pure fractions were collected and the solvent was evaporated under vacuum to provide the desired 44.0 g of Compound (38) as a brown solid.

[0628] 1H NMR (400 MHz, DMSO-d6): δ 7.11-7.06 (m, 2 H), 6.85-6.81 (m, 2H), 6.63-6.56 (m, 5H), 5.03 (s, 2H), 3.11 (s, 3H). 13C NMR (100 MHz, DMSO-d6): δ 150.49, 146.71, 137.65, 129.12, 127.52, 117.02, 115.27, 114.06. EXAMPLE 16 SYNTHESIS OF COMPOUND (39) (N1-METHYL-N4-PHENYLBENZENE-1,4DIAMINE) Petition 870250102374, dated 07 / 11 / 2025, pp. 160 / 187 156 / 159 Compound ¢39)

[0629] To a stirred and degassed solution of toluene (1000 mL) was added Pd2dbas (18.6 g, 0.02 mol), X-Phos (4.8 g, 0.01 mol), at room temperature and degassed for 15 mi...

Claims

CLAIMS 1. Compound, CHARACTERIZED in that it is selected from the group consisting of Compound (2), Compound (21) and Compound (25): (2), (25), or a salt or solvate thereof.

2. Compound according to claim 1, CHARACTERIZED in that it is Compound (2).

3. Compound according to claim 1, CHARACTERIZED in that it is Compound (21).

4. Compound according to claim 1, CHARACTERIZED in that it is Compound (25).

5. Composition, CHARACTERIZED in that it comprises: (i) Compound (10): (10), or a salt or solvate thereof; and (ii) one or more molecules, or a salt or solvate thereof, wherein the one or more molecules are selected from the group consisting of: Petition 870250080897, dated 09 / 09 / 2025, p. 9 / 29 2 / 17 (1), (3), (9), (5), (7), (2), (4), (6), (8), (11A), Petition 870250080897, dated 09 / 09 / 2025, p. 10 / 29 3 / 17 (11B), (12), (13), (14), (15), (16), (17), (18), (19), (20A), Petition 870250080897, dated 09 / 09 / 2025, p.11 / 29 4 / 17 (20B) Η οΑαί Η αχα ^-Ο nA 7 Η ^=7 (22) Ν (23),(24), Q , (25) 26, VV 27A, 27Β οΤΧ ​​2 (29), / (30)' Petition 870250080897, of 09 / 09 / 2025, p. 870250080897, dated 09 / 09 / 2025, page 14 / 29 7 / 17 or a combination thereof.

6. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (1) as a molecule.

7. Composition according to claims 5 or 6, CHARACTERIZED in that the composition comprises Compound (2) as a molecule.

8. Composition according to any one of claims 5 to 7, CHARACTERIZED in that the composition comprises Compound (3) as a molecule.

9. Composition according to any one of claims 5 to 8, CHARACTERIZED in that the composition comprises Compound (4) as a molecule. 10.Composition, according to any one of claims 5 to 9, CHARACTERIZED in that the composition comprises Compound (5) as a molecule.

11. Composition, according to any one of claims 5 to 10, CHARACTERIZED in that the composition comprises Compound (6) as a molecule.

12. Composition, according to any one of claims 5 to 11, CHARACTERIZED in that the composition comprises Compound (7) as a molecule.

13. Composition, according to any one of claims 5 to 12, CHARACTERIZED in that the composition comprises Compound (8) as a molecule.

14. Composition, according to any one of claims 5 to 13, CHARACTERIZED in that the composition comprises Compound (9) as a molecule.

15. Composition, according to any of claims 5 to 14, Petition 870250080897, dated 09 / 09 / 2025, page.15 / 29 8 / 17 CHARACTERIZED in that the composition comprises Compound (11A) as a molecule.

16. Composition according to any one of claims 5 to 15, CHARACTERIZED in that the composition comprises Compound (11B) as a molecule.

17. Composition according to any one of claims 5 to 16, CHARACTERIZED in that the composition comprises Compound (12) as a molecule.

18. Composition according to any one of claims 5 to 17, CHARACTERIZED in that the composition comprises Compound (13) as a molecule.

19. Composition according to any one of claims 5 to 18, CHARACTERIZED in that the composition comprises Compound (14) as a molecule.

20. Composition, according to any one of claims 5 to 19, CHARACTERIZED in that the composition comprises Compound (15) as a molecule. 21.Composition, according to any one of claims 5 to 20, CHARACTERIZED in that the composition comprises Compound (16) as a molecule.

22. Composition, according to any one of claims 5 to 21, CHARACTERIZED in that the composition comprises Compound (17) as a molecule.

23. Composition, according to any one of claims 5 to 22, CHARACTERIZED in that the composition comprises Compound (18) as a molecule.

24. Composition, according to any one of claims 5 to 23, Petition 870250080897, dated 09 / 09 / 2025, page 16 / 29 9 / 17 CHARACTERIZED in that the composition comprises Compound (19) as a molecule.

25. Composition, according to any one of claims 5 to 24, CHARACTERIZED in that the composition comprises Compound (20A) as a molecule. 26.Composition, according to any one of claims 5 to 25, CHARACTERIZED in that the composition comprises Compound (20B) as a molecule.

27. Composition, according to any one of claims 5 to 26, CHARACTERIZED in that the composition comprises Compound (21) as a molecule.

28. Composition, according to any one of claims 5 to 27, CHARACTERIZED in that the composition comprises Compound (22) as a molecule.

29. Composition, according to any one of claims 5 to 28, CHARACTERIZED in that the composition comprises Compound (23) as a molecule.

30. Composition, according to any one of claims 5 to 29, CHARACTERIZED in that the composition comprises Compound (24) as a molecule.

31. Composition, according to any one of claims 5 to 30, CHARACTERIZED in that the composition comprises Compound (25) as a molecule. 32.Composition, according to any one of claims 5 to 31, CHARACTERIZED in that the composition comprises Compound (26) as a molecule.

33. Composition, according to any one of claims 5 to 32, Petition 870250080897, dated 09 / 09 / 2025, page 17 / 29 10 / 17 CHARACTERIZED in that the composition comprises Compound (27A) as a molecule.

34. Composition, according to any one of claims 5 to 33, CHARACTERIZED in that the composition comprises Compound (27B) as a molecule.

35. Composition, according to any one of claims 5 to 34, CHARACTERIZED in that the composition comprises Compound (28) as a molecule.

36. Composition, according to any one of claims 5 to 35, CHARACTERIZED in that the composition comprises Compound (29) as a molecule. 37.Composition, according to any one of claims 5 to 36, CHARACTERIZED in that the composition comprises Compound (30) as a molecule.

38. Composition, according to any one of claims 5 to 37, CHARACTERIZED in that the composition comprises Compound (31) as a molecule.

39. Composition, according to any one of claims 5 to 38, CHARACTERIZED in that the composition comprises Compound (32) as a molecule.

40. Composition, according to any one of claims 5 to 39, CHARACTERIZED in that the composition comprises Compound (33) as a molecule.

41. Composition, according to any one of claims 5 to 40, CHARACTERIZED in that the composition comprises Compound (34) as a molecule.

42. Composition, according to any of claims 5 to 41, Petition 870250080897, dated 09 / 09 / 2025, page.18 / 29 11 / 17 CHARACTERIZED in that the composition comprises Compound (35) as a molecule.

43. Composition according to any one of claims 5 to 42, CHARACTERIZED in that the composition comprises Compound (36) as a molecule.

44. Composition according to any one of claims 5 to 43, CHARACTERIZED in that the composition comprises Compound (37) as a molecule.

45. Composition according to any one of claims 5 to 44, CHARACTERIZED in that the composition comprises Compound (38) as a molecule.

46. Composition according to any one of claims 5 to 45, CHARACTERIZED in that the composition comprises Compound (39) as a molecule.

47. Composition, according to any one of claims 5 to 46, CHARACTERIZED in that the composition comprises Compound (40) as a molecule. 48.Composition, according to any one of claims 5 to 47, CHARACTERIZED in that the composition comprises Compound (41) as a molecule.

49. Composition, according to any one of claims 5 to 48, CHARACTERIZED in that the composition comprises Compound (42) as a molecule.

50. Composition, according to any one of claims 5 to 49, CHARACTERIZED in that the composition comprises Compound (43) as a molecule.

51. Composition, according to any one of claims 5 to 50, Petition 870250080897, dated 09 / 09 / 2025, page 19 / 29 12 / 17 CHARACTERIZED in that the composition comprises Compound (44) as a molecule.

52. Composition, according to any one of claims 5 to 51, CHARACTERIZED in that the composition comprises Compound (45) as a molecule. 53.Composition, according to any one of claims 5 to 52, CHARACTERIZED in that the composition comprises Compound (46) as a molecule.

54. Composition, according to any one of claims 5 to 53, CHARACTERIZED in that the composition comprises Compound (47) as a molecule.

55. Composition, according to any one of claims 5 to 54, CHARACTERIZED in that the composition comprises Compound (48) as a molecule.

56. Composition, according to any one of claims 5 to 55, CHARACTERIZED in that the composition comprises Compound (49) as a molecule.

57. Composition, according to any one of claims 5 to 56, CHARACTERIZED in that the composition comprises Compound (50) as a molecule.

58. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (2) and Compound (21) as molecules. 59.Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (2) and Compound (25) as molecules.

60. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (2) and Compound (37) as molecules.

61. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (21) and Compound (25) as molecules.

62. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (21) and Compound (37) as molecules.

63. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (25) and Compound (37) as molecules.

64. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (2), Compound (21) and Compound (25) as molecules. 65.Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (2), Compound (21) and Compound (37) as molecules.

66. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (2), Compound (25) and Compound (37) as molecules.

67. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (21), Compound (25) and Compound (37) as molecules.

68. Composition according to claim 5, CHARACTERIZED in that the composition comprises Compound (2), Compound (21), Compound (25) and Compound (37) as molecules.

69. Composition, according to any of claims 5 to 68, Petition 870250080897, dated 09 / 09 / 2025, page 21 / 29 14 / 17 CHARACTERIZED in that it comprises about 50% to about 99% of Compound (10) as measured by HPLC and / or GC analysis. 70.Composition according to claim 69, CHARACTERIZED in that it comprises about 89% to about 99% of Compound (10), as measured by HPLC and / or GC analysis.

71. Composition according to any one of claims 5 to 70, CHARACTERIZED in that it comprises about 0.000001% to about 10% of one or more molecules, as measured by HPLC and / or GC analysis.

72. Composition according to claim 71, CHARACTERIZED in that it comprises about 0.0001% to about 5% of one or more molecules, as measured by HPLC and / or GC analysis.

73. Composition according to claim 72, CHARACTERIZED in that it comprises about 0.001% to about 3% of one or more molecules, as measured by HPLC and / or GC analysis.

74. Composition, according to any one of claims 5 to 70, CHARACTERIZED in that the weight ratio of one or more molecules to Compound (10) is from 0.000001 to 0.

1. 75.Composition, CHARACTERIZED in that it comprises the compound as defined in any one of claims 2 to 4 and (i) one or more elastomers; or (ii) one or more fillers; or (iii) one or more rubber chemicals; or (iv) one or more plasticizers; or (v) one or more second antidegradants; or (vi) a combination of one or more elastomers, one or more fillers, one or more rubber chemicals, one or more plasticizers and / or one or more second antidegradants. Petition 870250080897, dated 09 / 09 / 2025, page 22 / 29 15 / 17 76.Composition, CHARACTERIZED in that it comprises the composition as defined in any one of claims 5 to 74 and (i) one or more elastomers; or (ii) one or more fillers; or (iii) one or more rubber chemicals; or (iv) one or more plasticizers; or (v) one or more second antidegradants; or (vi) a combination of one or more elastomers, one or more fillers, one or more rubber chemicals, one or more plasticizers and / or one or more second antidegradants.

77. Vulcanized elastomeric article, CHARACTERIZED in that it comprises the composition as defined in claims 75 or 76.

78. Vehicle, CHARACTERIZED in that it comprises the vulcanized elastomeric article as defined in claim 77.

79. Kit, CHARACTERIZED in that it comprises the composition as defined in claims 77 or 78, and instructions for using the composition to prepare a vulcanized elastomeric article. 80.Process for preparing the composition as defined in any one of claims 5 to 74, the process CHARACTERIZED in that it comprises reacting a composition comprising 4-aminodiphenylamine with acetone, 2,2-dimethoxypropane, diacetone alcohol or mesityl oxide in the presence of a catalyst.

81. Process according to claim 80, CHARACTERIZED in that the catalyst is a homogeneous catalyst.

82. Process according to claim 81, CHARACTERIZED in that the homogeneous catalyst is a Lewis acid, a Bronsted acid, a base, a halogen, a halogen donor or a combination thereof. Petition 870250080897, dated 09 / 09 / 2025, pp. 23 / 29 16 / 17 83.Process according to claim 81, CHARACTERIZED in that the homogeneous catalyst is selected from the group consisting of iodine, pyridinium perbromide, bromine, bismuth(III) trifluoromethane sulfonate, zinc(II) trifluoromethane sulfonate, hydrobromic acid, magnesium(II) bromide, aluminum(III) chloride, p-toluene sulfonic acid monohydrate, N-bromosuccinimide, copper(II) bromide, copper(II) chloride, methane sulfonic acid, benzene sulfonic acid, boron trifluoride diethyl etherate, boron trifluoride dihydrate, hydrochloric acid, copper(II) trifluoromethane sulfonate, iron(III) chloride, magnesium(II) chloride, copper(I) iodide and zinc(II) chloride, or their salts or solvates.

84. Process according to claim 83, CHARACTERIZED in that the homogeneous catalyst is selected from the group consisting of pyridinium perbromide, magnesium(II) bromide, magnesium(II) bromide hexahydrate and aluminum(III) chloride. 85.Process according to claim 80, CHARACTERIZED in that the catalyst is a heterogeneous catalyst.

86. Process according to claim 85, CHARACTERIZED in that the heterogeneous catalyst is an acid-treated resin, a solid-supported acid, a compound catalyst, a solid acid, or a basic catalyst.

87. Process according to claim 86, CHARACTERIZED in that the acid-treated resin is a polyfluorinated sulfonic acid resin, a strongly acidic sulfonic acid exchange resin (Amberlyst 15), a macroporous strong acidic ion exchange resin, a strong acidic ion exchange resin, a solid acidic ion exchange resin (NRW150), a sieved strong acidic ion exchange resin, or a strong acidic ion exchange resin (type A2 acid resin). 88.Process, according to claim 86, CHARACTERIZED in that the acid supported on a solid is a micro-meso-macroporous zeolite catalyst. Petition 870250080897, dated 09 / 09 / 2025, page 86. 24 / 29 17 / 17 HY-MMM, a strongly acidic molecular sieve H-MCM-22, a graphene oxide-supported organic protonic acid, a zeolite-supported organic protonic acid, a small pore size zeolite, a heterogeneous acidic silica catalyst, tungstophosphoric acid (TPA) exchanged for Zn2+, Sn2+ and Cu2+ supported on y-AbOs, Tonsil activated earth (acid-treated bentonite clay), alumina, titania, zirconia, niobium, silica-alumina, sulfated zirconia, zirconia tungstate, paratoluenesulfonic acid (p-TSA) / ZnCl2, or WO3 / activated carbon / SO3H. 89.Process according to claim 86, characterized in that the compound catalyst is a zirconium-doped titanium oxide compound catalyst, solid superacid H2sO4-MoO3-TiO2 or p-toluenesulfonic acid / iodine.

90. Process according to claim 86, characterized in that the solid acid is a heteropolyacid or a metal-organic framework.

91. Process according to claim 86, characterized in that the basic catalyst is ZrO2 / MgO.

Images